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    Cell-matrix interactions are important in maintaining cartilage homeostasis. 
Hyaluronan binding to its principal receptor CD44 is essential for such 
interactions. Hyaluronan-CD44 interactions are required for the retention of 
proteoglycan in the pericellular matrix, the most active region of matrix assembly 
and turnover.  In previous work, SMAD1, the downstream transcriptional 
modulator of the canonical bone morphogenetic protein 7 (BMP7) signaling 
pathway, was found to interact with the cytoplasmic domain of CD44. Therefore, 
in this study the response to BMP7 stimulation was studied with murine 
chondrocytes isolated from CD44-/- and BALB/c mice to determine the role of 
CD44 as well as CD44-hyaluronan interactions in the BMP7 signaling pathway. 
The two part hypothesis is that chondrocytes from CD44-/- mice will be less 
responsive to BMP7 compared to wild type chondrocytes and that hyaluronan 
will have no effect on BMP7 signaling in CD44-/- mouse chondrocytes, but will 
promote BMP7 signaling in wild type chondrocytes. The results demonstrated 
that both CD44-/- murine chondrocytes and wild type chondrocytes transfected 
with CD44 siRNA were less responsive to BMP7 compared to wild type murine 
 chondrocytes. CD44-/- murine chondrocytes transfected with pCD44 showed a 
BMP7 sensitivity similar to wild type chondrocytes. There were no dose 
response differences observed between wild type and CD44-/- murine 
chondrocytes found upon EGF stimulation, thus the hyaluronan-CD44 
interaction appears selectively involved in the BMP7 signaling pathway. In both 
CD44-/- and wild type murine chondrocytes, hyaluronidase treatment decreased 
cellular responses to BMP7. However, with hyaluronan regrowth, SMAD1 
phosphorylation upon BMP7 stimulation was restored. Treatment of 
chondrocytes with 4-methylumbelliferone in order to reduce synthesis of 
endogenous hyaluronan, also indicated that hyaluronan promoted the BMP7 
signaling pathway.  Taken together, these investigations into the mechanisms 
underlying BMP7 signaling in chondrocytes reveal that while hyaluronan is vital 
for optimal BMP7 signaling in chondrocytes, the functional significance of CD44 
is more subtle and is dose dependent. 
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CHAPTER 1. INTRODUCTION 
 
1. Cartilage 
 
1.1 Structure and Composition of Cartilage 
 
Traditionally, a histological description of connective tissue included cells, fibers, and a 
ground substance (Dudek, 2010). However, more recently, a histological description of 
connective tissue includes cells and extracellular matrix, which combines both the fibers 
and ground substance (Schenk, R.K. et al., 1986). Cartilage is a special type of 
connective tissue that consists of cells (chondrogenic, chondroblasts, and 
chondrocytes), fibers (Type I collagen, Type II collagen, and elastic fibers), and a 
ground substance (proteoglycans, glycoproteins, and water). Cartilage has no blood 
supply and therefore receives its nutrients from perichondrial capillaries or joint synovial 
fluid by diffusion through the ground substance. In addition, cartilage has no nerve 
supply. Finally, there are three main types of cartilage: fibrocartilage, hyaline cartilage, 
and elastic cartilage (Dudek, 2010). 
 
Cells 
 
Chondrogenic cells reside in the perichondrium where they undergo mitosis and 
differentiate into chondroblasts. Chondroblasts eventually surround themselves with 
extracellular matrix and are then called chondrocytes. Chondrocytes cluster in lacunae 
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forming isogenous groups with a surrounding territorial matrix. Chondrocytes comprise 
only 5% of the total cartilage volume (Schenk et al., 1986) and therefore, like other 
connective tissues, the major component of cartilage is the extracellular matrix.  
 
Fibers 
 
The fibers found in cartilage include: Type I collagen, Type II collagen, and elastic 
fibers. Type I collagen fibers are present in fibrocartilage. Type II collagen fibers are 
present in hyaline cartilage and elastic cartilage. The nascent Type II collagen fibril (a 
heteropolymer) consists of Type IX collagen linked to the surface and Type XI collagen 
forming the filamentous template of the fibril (Eyre et al., 2006). Elastic fibers are 
present in elastic cartilage along with Type II collagen fibers. 
 
Ground Substance 
 
Proteoglycans consist of a core protein, both chondroitin sulfate and keratan sulfate to 
which are covalently linked to many side chains of highly-negatively charged 
glycosaminoglycans. The hallmark proteoglycan within the ground substance is called 
aggrecan, a large aggregating proteoglycan that forms a major structural component of 
cartilage. Hundreds of aggrecan monomers non-covalently bind to hyaluronan stabilized 
via the link protein, thereby forming huge proteoglycan aggregates (Christner et al., 
1977; Hascall, 1977). In addition to aggrecan, the ground substance contains other 
proteoglycans essential for its normal function such as: decorin, biglycan, fibromodulin, 
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and lumican (Roughley, 2006). In general, proteoglycans promote hydration since water 
binds to the negative charge of the glycosaminoglycans.   
 
Glycosaminoglycans are unbranched polysaccharides made of repeating units of 
disaccharides (that is, one uronic acid and one amino sugar). Glycosaminoglycans are 
highly-negatively charged under physiological conditions, due to the presence of sulfate 
and uronic acid groups. The highly sulfated glycosaminoglycans present in the ground 
substance of cartilage are chondroitin-4-sulfate, chondroitin-6-sulfate, and keratan 
sulfate.  Hyaluronan is a non-sulfated glycosaminoglycan, present in nearly all tissues 
but forms the central filament of the proteoglycan aggregate. 
 
The glycoproteins present in the ground substance are chondronectin, and 
chondrocalcin (a calcium-binding protein), and cartilage oligomeric protein (COMP; a 
member of the thrombospondin family) (Hedbom et al., 1992). 
 
1.2 Structure, Composition, and Function of Articular Cartilage 
 
Articular cartilage is hyaline cartilage located at the articular surface of bones. The 
articular cartilage slides during motion and transmits the applied loads across the 
articular surface. Articular cartilage shows an increased water and proteoglycan content 
(compared to fibrocartilage or bone) so that articular cartilage is fluid-filled and wear-
resistant. This reduces the friction between articular surfaces. 
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The arrangement of various components within articular cartilage (Fig 1) assures 
maximal adaptation for biomechanical functions. In this regard, aggrecan creates a high 
osmotic pressure that draws water into the ground substance of articular cartilage, 
places Type II collagen under tension, and thereby generates a compressive resilience 
(Hardingham et al., 1986). Therefore, the biomechanical properties of articular cartilage 
depend on two main factors. One is that a high concentration of aggrecan that draws 
water into the articular cartilage by osmosis thereby producing a swelling pressure on 
the collagen network and. The other is that a network of collagen fibrils (mainly Types II, 
VI, IX, and XI) that determines the overall form and tensile properties of the articular 
cartilage. The retention of aggrecan by hyaluronan plays a key role in producing a 
resilient load-bearing surface at the articular surface of bone (Hardingham et al., 1992). 
 
The cartilage extracellular matrix can be divided into three compartments called the 
pericellular matrix, territorial matrix, and interterritorial matrix (Hauselmann et al., 1991).  
The pericellular matrix lies in direct contact with chondrocytes and is characterized by 
no cross-banded fibrillar collagen and an abundance of proteoglycans and hyaluronan. 
The Particle Exclusion Assay (or Coat Assay) is an assay that visualizes the pericellular 
matrix. In general, this assay allows for the visualization of an expanded pericellular 
matrix retained by living chondrocytes in culture due to the exclusion of particles from 
the pericellular matrix. In particular, the Coat Assay uses paraformaldehyde-fixed horse 
red blood cells as standard-sized particles, which are added to chondrocytes after 
culture media removal. The red blood cells settle down on the culture plastic surface 
and are excluded from the pericellular matrix due to its high water content.  
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Figure 1. Histology and the structure of healthy human articular cartilage. Safranin 
O and fast green staining of healthy human articular cartilage showed intense staining 
of matrix proteoglycans in red (Panel A). The cartoon (Panel B) illustrates the basic 
composition of healthy articular cartilage: chondrocyte and extracellular matrix. In the 
extracellular matrix, there is type II collagen, the major collagen in articular cartilage. 
The aggrecan monomers form aggregates via interaction with hyaluronan and the 
aggrecan aggregates are tethered to chondrocytes via the interaction of hyaluronan and 
CD44, the principle receptor of hyaluronan. Hyaluronan is synthased by hyaluronan 
synthase located on the plasma membrane.  
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Phase-contrast microscopy reveals a clear, translucent halo (called the “coat”) around 
the chondrocytes. Pre-treatment of chondrocytes with Streptomyces hyaluronidase (an 
enzyme that has high substrate specificity for hyaluronan) followed by the Coat Assay 
eliminates the clear, translucent halo or “coat” around the chondrocytes thus 
demonstrating that hyaluronan provides the scaffold for the pericellular matrix 
(Knudson, 1993). The territorial matrix lies adjacent to the pericellular matrix and is 
characterized by a fine network of fibrillar collagen and a high mechanical resistance 
during homogenization (Heinegard and Axelsson, 1977). The collagen fibrils within the 
territorial matrix make contact with chondrocytes via fine cytoplasmic processes. The 
interterritorial matrix lies adjacent to the territorial matrix and is the largest domain in 
most cartilages. The interterritorial matrix is characterized by cross-banded fibrillar 
collagen running in parallel and establishing arcades (Hauselmann et al., 1991). 
 
1.3 Chondrocytes 
 
In the embryo, chondrogenesis occurs in a condensed mesenchyme regulated by Sox9, 
a transcription factor also important in maintaining chondrocyte phenotype (Tew and 
Hardingham, 2006). During chondrogenesis, embryonic mesenchymal cells undergo a 
distinct change in shape going from a spindle shape to a round shape due to retraction 
of mesenchymal cell processes. Subsequently, the newly differentiated chondrocytes 
begin to produce cartilage extracellular matrix. In addition to its role in chondrogenesis, 
Sox9 also controls the transcription of a number of cartilage extracellular matrix genes 
which include:  COL2A1, COL9A1, COL11A2, aggrecan and cartilage link protein 
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(CRTL1) genes (Tew and Hardingham, 2006). In the adult, limited chondrogenesis may 
occur due to the presence of chondrogenic cells within the perichondrium. These 
chondrogenic stem-like cells may undergo mitosis followed by the pattern of 
differentiation into chondroblasts and finally chondrocytes.  
 
In articular cartilage, chondrocytes vary in shape and arrangement depending on the 
depth within the cartilage. Near the surface, chondrocytes appear flat and scattered. In 
deeper layers, chondrocytes appear round and arranged in columns. Although the 
chondrocytes exhibit varied morphology from the articular surface through to the 
calcified cartilage zone, chondrocytes interact with the extracellular matrix via 
transmembrane matrix receptors to sense any changes in the extracellular matrix. In 
this way, chondrocyte-extracellular matrix interactions maintain cartilage homeostasis 
through the whole cartilage depth (Knudson, 2003). Important components in these 
chondrocyte-extracellular matrix interactions include CD44 and hyaluronan/aggrecan. 
CD44 is a single-pass transmembrane matrix receptor that binds hyaluronan and plays 
a primary role in the assembly and maintenance of the pericellular matrix. Hyaluronan is 
the scaffold of the pericellular matrix. In addition, aggrecan (the hallmark proteoglycan) 
binds to hyaluronan through its G1 domain to form aggrecan aggregates, which 
promote hydration. The chondrocyte-extracellular matrix interactions involving CD44 
and hyaluronan/aggrecan transduce signals in-and out of the chondrocytes thereby 
initiating corresponding responses between the chondrocyte and extracellular matrix.  
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Primary chondrocytes directly isolated from cartilage are round and tend towards de-
differentiation when cultured in vitro at low density (Benya and Shaffer, 1982; Homicz et 
al., 2002; Loty et al., 2000). With de-differentiation, a number of changes occur which 
include: a) a change from round to a flat, fibroblast-like cell, b) a decrease in the 
expression level of chondrocyte marker genes (e.g., aggrecan and Type II collagen), c) 
an increase in the expression level of a fibroblast marker gene (e.g., Type I collagen), 
and d) a loss of the pericellular matrix as visualized by the Coat Assay. In order to 
prevent de-differentiation, chondrocytes are cultured either at high density or in alginate 
beads so that primary chondrocyte characteristics persever. Using alginate bead 
culture, a number of changes occur which include: a) a change from flat, fibroblast-like 
cell to a round chondrocyte, b) an increase in the expression level of chondrocyte 
marker genes (e.g., aggrecan and Type II collagen), c) a decrease in the expression 
level of a fibroblast marker gene (e.g., Type I collagen), and d) a restoration of the 
pericellular matrix as visualized by the Coat Assay (Nishida et al., 2000a; Nishida et al., 
2000b; Nishida et al., 2000c; Nishida et al., 2000d).   
 
1.4 Osteoarthritis 
 
Osteoarthritis (OA) is a chronic, degenerative synovial joint disease that involves the 
dysregulation of the cartilage extracellular matrix exacerbated by the limited capacity for 
cartilage repair. OA causes degeneration predominately in the hand, knee, hip, and 
spine synovial joints. The societal impact of OA becomes apparent when it is realized 
that a majority of individuals over 65 are affected with OA, about 27 million Americans 
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were diagnosed with OA in 2005 (Lawrence et al., 2008), and one in two people will 
develop OA during their lifetime. In addition, OA saddles society with huge economic 
costs due not only to medical care but also lost and under-productive working days. 
 
The changes in normal cartilage architecture that occur in early stage OA include an 
initial loss of proteoglycans from the extracellular matrix, a subsequent disruption of the 
collagen fibrillar network, and finally a chondro-osseous transition with cell loss 
(Hunziker, 2000). These early changes eventually lead to a progressive loss of cartilage 
that results in remodeling of the entire synovial joint with synovial inflammation and local 
cartilage and bone formation (Lories and Luyten, 2005). During this degenerative 
process, the surviving resident chondrocytes augment their metabolic activity. However, 
the augmentation fails to overcome the degenerative processes (Hunziker, 2000). 
 
Cartilage homeostasis is normally maintained by a balance between anabolic and 
catabolic factors. Anabolic factors promote cartilage homeostasis and repair. Catabolic 
factors promote cartilage degeneration. The various anabolic and catabolic factors play 
a role in this delicate balance. Anabolic factors include Transforming Growth Factor- 
Beta (TGF-β), Bone Morphogenetic Proteins (BMPs), Insulin-like Growth Factors 
(IGFs), and Fibroblast Growth Factors (FGFs). These anabolic factors specifically 
promote type II collagen and proteoglycan synthesis which counteract catabolic effects. 
Catabolic factors include Matrix Metalloproteinases (MMPs), Aggrecanases, Interleukin-
1 (IL-1), interleukin-6 (IL-6), nitric oxide (NO). The MMPs and Aggrecanases degrade 
the cartilage extracellular matrix. The overexpression of NO due to the expression 
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inducible NO synthase (iNOS) contributes to chondrocyte apoptosis and other altered 
signaling (Hashimoto et al., 2008). 
 
The current treatments for OA include non-drug therapy, drug therapy, and various 
surgical procedures. Regretfully, no fundamental therapy aimed at repairing the 
underlying molecular problems exists to date. Non-drug therapies for OA include patient 
education, weight and diet control, physical therapy, and exercise. Drug therapies for 
OA include paracetamol, nonsteroidal anti-inflammatory drugs (NSAIDs), 
corticosteroids, and intra-articular hyaluronan injection. Paracetamol is recommended 
as an initial therapy for OA, due to its excellent safety and low cost compared to 
NSAIDs. NSAIDs are good for OA symptom relief in large joints, but with severe 
gastrointestinal side effects in some patients. Intra-articular corticosteroids injection is 
commonly used for knee OA patients who have active inflammation. Intra-articular 
hyaluronan injection shows better pain relief with longer time duration of action in knee 
OA patients. Surgical procedures for OA include microfracture, osteochondral autograft, 
allograft reconstruction, joint replacement, autologous chondrocyte implantation, and 
tissue engineering (Hashimoto et al., 2008).   
 
Future therapies directed at the underlying molecular problems in OA will require 
continued progress in elucidating genetic and proteomic factors involved in cartilage 
homeostasis. Genetic approaches could identify candidate genes involved in OA. In 
addition, proteomic profiling could identify alternated gene expression status in different 
stages of cartilage degeneration or repair. The combined genetic and proteomic 
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information would then provide a personal profile for each OA patient related to their 
specific stage of cartilage degeneration. As a result, a personal diagnosis and targeted 
treatment plan could potentially be generated (Rodeo et al., 2010). 
 
2. Hyaluronan 
 
2.1 Structure, Synthesis, Degradation, and Receptors 
 
In 1934, Professor Karl Meyer described a novel glycosaminoglycan isolated from the 
vitreous of bovine eyes containing an uronic acid and an amino sugar, but no 
sulfoesters, and proposed the name "hyaluronic acid", from hyaloid (vitreous) + uronic 
acid (Meyer and Palmer, 1934). We now know that hyaluronan is an anionic, 
nonsulfated glycosaminoglycan composed of repeating disaccharide (β1,4 D-glucuronic 
acid and β1,3 N-acetyl-D-glucosamine) sequences. In human synovial fluid, the average 
molecular weight is 3-4 million Daltons (Saari et al., 1993).  
 
Hyaluronan is synthesized by hyaluronan synthase (HAS) located in the cell membrane 
such that the elongating hyaluronan polymer translocates directly into the extracellular 
matrix. The multiple membrane domains of HAS catalyze monosaccharide addition to 
hyaluronan. In addition, cell membrane lipids closely associated with HAS may form 
pores for direct translocation of the hydrophilic elongating hyaluronan polymer across 
the cell membrane into the extracellular matrix (Weigel et al., 1997). Alternatively, the 
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hydrophilic elongating hyaluronan polymer may translocate across the cell membrane 
into the extracellular matrix via the ABC-transporter (Schulz et al., 2007).  
 
In vertebrates, three hyaluronan synthases have been identified: HAS1, HAS2 and 
HAS3. These isoforms are located on different chromosomes (Spicer et al., 1997).  The 
HAS isoforms differ in the length of the hyaluronan polymer produced, and the ease 
with which the hyaluronan polymer is released into the extracellular matrix (Itano et al., 
2002; Itano et al., 1999; Stern et al., 2006). In addition, normal human articular 
chondrocytes contain only the HAS-2 and HAS-3 isoforms wherein the HAS-2 isoform is 
the principle enzyme responsible for hyaluronan synthesis (Nishida et al., 2000a; 
Nishida et al., 2000b; Nishida et al., 1999).  
 
4-methylumbelliferone (4-MU) specifically inhibits HAS activity at the post-transcriptional 
level and results in a significant decrease in both hyaluronan synthesis and extracellular 
matrix formation. The mechanism of 4-MU inhibition involves the addition of glucuronide 
to 4-MU by endogenous UDP-glucuronyl transferase (UGT) that transfers GlcUA to 4-
MU from UDP-GlcUA. This results in a depletion of UDP-glucuronic acid, which is an 
essential substrate for hyaluronan synthesis. The inhibition of HAS activity is directly 
related to the glucuronidation mediated by UGT (Kakizaki et al., 2004). 
 
Hyaluronan is degraded by hyaluronidases located within lysosomes. Little evidence 
exists to support the presence of an extracellular and neutral pH-active hyaluronidase in 
cartilage. However, endocytosis of radiolabeled hyaluronan by chondrocytes and 
  13 
analysis of the intracellular pool showed two size classes of label. One is a class size >1 
x 106 Da, and the other is a class size consisting of small, extensively degraded 
hyaluronan products. In addition, the generation of these small, extensively degraded 
products was inhibited by chloroquine (a lysosomotropic agent). Thus, except for 
possible free-radical mechanisms of extracellular hyaluronan degradation, hyaluronan 
degradation probably occurs intracellularly within lysosomes via a low pH-active 
hyaluronidase (Hua et al., 1993).     
 
In humans, six hyaluronidase genes have been identified:  HYAL, HYAL2, HYAL3, and 
PH-20/SPAM1 (Csoka et al., 2001). Normal human articular chondrocytes primarily 
express HYAL2 (Chow and Knudson, 2005). Streptomyces hyaluronidase is the most 
important experimental hyaluronidase, which specifically degrades hyaluronan (Harrison 
et al., 1986). 
 
To date, three main hyaluronan receptors have been identified: CD44, Receptor for 
Hyaluronan-Mediated Motility (RHAMM), and Intracellular Adhesion Molecule (ICAM-1) 
(Aruffo et al., 1990; Gustafson et al., 1995; Hardwick et al., 1992). CD44 is a single-
pass transmembrane receptor that binds hyaluronan and plays a primary role in the 
assembly and maintenance of the pericellular matrix by chondrocytes (Knudson et al., 
1996). In addition, a particular pool of CD44 assists in the endocytosis of hyaluronan 
destined for degradation in lysosomes. This pool of CD44 associates with cholesterol-
rich microdomains of the cell membrane called lipid rafts. This association between 
CD44 and lipid rafts requires dual acylation of CD44 at Cys286 and Cys295.  Blocking the 
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association between CD44 and lipid rafts prevents hyaluronan internalization and CD44 
turnover, but not the interaction of CD44 with hyaluronan (Thankamony and Knudson, 
2006).  
 
2.2 Physiological Functions 
 
Hyaluronan plays an important role in cell proliferation, migration, tumor progression, 
tissue repair (Averbeck et al., 2007), innate immunity (Jiang et al., 2011), and brain 
development (Margolis and Margolis, 1989). As in other tissues, cartilage cell–matrix 
interactions mediated by transmembrane receptors maintain cartilage homeostasis. 
Chondrocytes sense and respond to changes in the extracellular matrix in part via 
hyaluronan–CD44 interactions.  
 
Hyaluronan is an important component of the extracellular matrix in articular cartilage. 
Aggrecan binds to hyaluronan via the N-terminal globular domain to form aggrecan 
aggregates. Since hyaluronan is synthesized by HAS2 in the cell membrane, aggrecan 
encounters hyaluronan only after hyaluronan translocates to the extracellular matrix. 
Thus, aggrecan aggregation occurs through an extracellular mechanism.   
 
The retention of aggrecan aggregates within the pericellular matrix of chondrocytes 
depends on the interaction between hyaluronan and CD44 (Knudson et al., 1996). 
Embryonic chick tibia chondrocytes were isolated such that a large proportion of their 
cell-associated matrix remained intact and tightly- associated with the chondrocyte cell 
  15 
membrane. Following treatment of these isolated chondrocytes with hyaluronan 
hexasaccharides, the cell-associated matrix was competitively displaced and lost from 
the chondrocytes (Maleski and Knudson, 1996). The pericellular matrix can be 
displaced by the addition of hyaluronan hexasaccharides or a dilute solution of 
Streptomyces hyaluronidase (Knudson, 1993). Upon removal of either of these 
reagents, chondrocytes re-synthesize and re-assemble the pericellular matrix. However, 
re-assembly can be prevented by incubation of the recovering chondrocytes with: anti-
CD44 antibody, dilute hyaluronidase, or hyaluronan hexasaccharides (but not 
chondroitin sulfate hexasaccharides or hyaluronan disaccharides). Disruption of the 
chondrocyte pericellular matrix results in a diminished chondrocyte response to BMP-7 
(Peterson et al., 2004). However, treatment with exogenous hyaluronan or increased 
expression of HAS2 restores the chondrocyte response to BMP-7 (Andhare et al., 
2009). These results support the model that the hyaluronan/pericellular matrix is 
attached to the chondrocyte cell membrane via the interaction between hyaluronan and 
CD44 (the principal hyaluronan receptor).  
 
The retention of hyaluronan to the cell membrane is not solely due to the interaction 
with CD44 or other receptors. In a variety of cell types, including chondrocytes, 
hyaluronan is retained at the cell membrane through interactions with other non-
receptor proteins, such as, hyaluronan synthase (Evanko et al., 2007; Knudson and 
Toole, 1988). The definition of non-receptor bound hyaluronan means that it cannot be 
displaced by exogenous hyaluronan. Using exogenous, unlabeled hyaluronan to 
displace of radiolabeled cell surface hyaluronan, Knudson and Toole measured 
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hyaluronan-binding site of mesoderm cell cultures from various developmental stages. 
They found that very little hyaluronan was displaced from mesodermal cells from 
younger stage embryos (stages 19, 20 and 21). However, greater than 50% of cell 
surface hyaluronan was displaced from later stage mesodermal cells (stage 22, 24, 26 
and 38). These results indicated that at younger stage embryos, hyaluronan was 
retained at the cell membrane primarily through interaction with non-receptors. 
However, at later stage, hyaluronan was retained at the cell membrane primarily 
through interaction with receptors (Evanko et al., 2007; Knudson and Toole, 1988). 
 
3. CD44 
 
3.1 Structure and Distribution 
 
CD44 is the principal receptor for the extracellular matrix macromolecule hyaluronan 
(Aruffo et al., 1990) and  was first discovered in human white blood cells. CD44 was 
initially called a number of names which include: Hermes-1 antigen (Jalkanen et al., 
1986), Pgp-1 (Hughes and August, 1981; Trowbridge et al., 1982), and ECMRIII 
(Gallatin et al., 1989; Wayner et al., 1988). The Hermes-1 monoclonal antibody blocked 
the tissue-specific homing of lymphocytes to the high-walled endothelial venules of 
lymph nodes and thus this antibody defined a class of 85-95 kDa cell surface 
glycoproteins on lymphocytes as receptors to direct lymphocytes (Jalkanen et al., 
1987). In 1986, CD44 was given the official name at the Third International Workshop 
and Conference on Human Leukocyte Differentiation Antigens, which stands for 
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Clusters of Differentiation 44 (Cobbold, 1987). Since then, CD44 has been detected on 
cell surface of most vertebrate cells (Ponta et al., 2003).  
 
CD44 is a cell surface single-pass transmembrane glycoprotein receptor, which consists 
of the distal extracellular domain, the membrane-proximal extracellular domain, the 
highly conserved transmembrane domain, and the cytoplasmic domain (Fig 2). The 
distal extracellular domain represents the N-terminus of CD44 and binds hyaluronan. 
Members of the link protein superfamily, including CD44, TSG-6, LYVE-1, versican, the 
link protein of cartilage, and aggrecan, contain a similar link module hyaluronan-binding 
domain (Mahoney et al., 2001). The membrane-proximal extracellular domain generates 
many of the variant CD44 isoforms due to alternative splicing of variant exons (Screaton 
et al., 1992). The highly conserved transmembrane domain regulates not only the 
binding of the distal extracellular domain to hyaluronan but also the interaction of the 
cytoplasmic domain with the cytoskeleton. The cytoplasmic domain represents the C-
terminal of CD44 and interacts with cytoskeleton linker proteins such as ERM proteins 
(ezrin, radixin, moesin and merlin) and ankyrin (Knudson and Peterson, 2004). The 
interaction of CD44 with the cytoskeleton plays a role in cell adhesion, motility, 
migration, and cell shape (Isacke, 1994; Ponta et al., 2003). The sequences of link 
module hyaluronan-binding domain, transmembrane domain and cytoplasmic domain of 
CD44 and its different isoforms are highly conserved among the isoforms and between 
species (Bajorath, 2000; Cichy and Pure, 2003; Lesley et al., 1993; Naor et al., 1997; 
Thorne et al., 2004). 
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Figure 2. The structure of CD44. The cartoon illustrates the structure and four 
domains of CD44: distal extracellular domain, proximal extracellular domain, 
transmembrane domain and cytoplasmic domain. CD44 is a single transmembrane 
glycoprotein. The distal extracellular domain is responsible for hyaluronan binding. The 
proximal extracellular domain varies among the different CD44 isoforms. The 
cytoplasmic domain interacts with elements of the cytoskeleton and other cortical 
proteins.  
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The CD44 gene is a single gene containing 20 exons localized to chromosome 11. 
Inclusion of alternatively spliced-variant exons (exon v1 to exon v10) generates 
numerous isoforms of CD44 (Gunthert, 1993; Screaton et al., 1992). These isoforms fall 
into three groups: first group is multiple isoforms with extensions of the extracellular 
domain (Lesley et al., 1993). The most wide spread isoform is the standard isoform of 
CD44, CD44s, in which there is no expression of any of the 10 variant exons (Ponta et 
al., 2003). CD44s is the most abundant form of CD44 protein in tissues and is 
expressed by cells developed from mesoderm. Second group is one rare isoform with a 
truncation of the extracellular domain resulting in CD44 secretion from the cell, called 
soluble CD44 (Yu and Toole, 1996); and the last group is one isoform with a truncation 
of the  cytoplasmic tail encoded by transcripts containing exon 19 in lieu of exon 20 
(Knudson and Peterson, 2004). Human chondrocytes variably express CD44 exon 19 
transcripts ranging from 5% to 40% of the total CD44 mRNA (Jiang et al., 2001).  The 
homology of CD44 gene sequence among human, murine and bovine is listed in Table 
1. 
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Table 1. Identity of nucleotide sequences coding for  
mouse, human and bovine CD44 mRNA 
 
Mus musculus 
(NM_009851.2) 
Homo sapiens 
(NM_000610.3) 
Bos taurus 
(NM_174013.3) 
mRNA = 5655 nt 
Coding region =  
320 – 2662 nt 
mRNA = 5748 nt 
Coding region =  
435 – 2843 nt 
mRNA = 5748 nt 
Coding region =  
181 – 1287 nt 
1134-3300 nt 
1129-3284 nt 
79% (Identity) 
- 
2285-3314 nt - 
910-1956 nt 
79% (Identity) 
 
The table shows the CD44 identity of nucleotide sequences coding for three examples 
of mouse, human and bovine mRNA present in the National Center for Biotechnology 
Information (NCBI) nucleotide database. Each sequence examined is listed by the 
species name and data base accession number. For each mRNA, the nucleotide 
number (nt) designating the start and stop of the coding region is listed. The mouse 
CD44 mRNA sequence between 1134 – 3300 nt shows a 79% identity with the human 
CD44 mRNA sequence between 1129 – 3284 nt. The mouse CD44 mRNA sequence 
between 2285 – 3314 nt shows a 79% identity with the bovine CD44 mRNA sequence 
between 910-1956 nt.    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Extensive post-translational modifications of CD44 include: glycosylation, 
phosphorylation, and palmitoylation. These post-translational modifications result in a 
range of CD44 molecular weights from ~ 37kDa to 85 to 250 kDa. CD44 glycosylation is 
a necessary prerequisite for hyaluronan binding in primary culture of bovine articular 
chondrocytes and some cell lines (Bartolazzi et al., 1996; Skelton et al., 1998). CD44 
palmitoylation is required for CD44 association with lipid rafts, hyaluronan endocytosis, 
and CD44 turnover (Thankamony and Knudson, 2006). Due to its different isoforms and 
post-translational modifications, CD44 gene encodes a variety of protein products and 
performs a wide variety of functions.  
 
3.2 Physiological Functions 
 
CD44 plays a number of important roles which include hyaluronan binding (Aruffo et al., 
1990; Knudson, 1993), hyaluronan internalization (Culty et al., 1992) (Hua et al., 1993), 
cell migration and adhesion (Berg et al., 1989), tumor invasion and metastasis 
(Gunthert et al., 1991), signal transduction (Okamoto et al., 2001), cell apoptosis (Yu et 
al., 1997) and lymphocyte homing (Jalkanen et al., 1991).  
 
CD44-negative COS7 cells gain the ability to bind hyaluronan and to assemble a 
hyaluronan-dependent pericellular matrix in the presence of exogenous hyaluronan and 
proteoglycan when transfected with functional CD44 constructs (Knudson et al., 1993). 
However, COS-7 cells do not gain the ability to bind hyaluronan or to assemble a 
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hyaluronan-dependent pericellular matrix when transfected with CD44 constructs that 
generate the short-tail (CD44exon19) form of CD44 (Jiang et al., 2002).  
 
In articular cartilage, CD44 functions as the primary hyaluronan receptor involved in 
pericellular matrix assembly by chondrocytes (Knudson et al., 1996).  After treatment 
with CD44 sequence-specific antisense oligonucleotides, bovine chondrocytes and 
bovine cartilage in explant culture exhibit a loss of the pericellular matrix. Seventy 
percent of bovine chondrocytes exhibit no pericellular matrix and thirty percent of bovine 
chondrocytes exhibit very small pericellular matrix (Chow et al., 1998). In addition, 
transfection of bovine articular chondrocytes with dominant-negative CD44 constructs 
(CD44Δ67 that mimics the short-tail CD44exon 19) inhibits pericellular matrix assembly. 
Collectively, these results indicate an obligatory requirement for the CD44 receptor 
cytoplasmic domain in order for hyaluronan binding and retention of the pericellular 
matrix to occur (Jiang et al., 2002). There are both occupied and unoccupied CD44 
receptors on the plasma membrane. Therefore, it suggests that not all the CD44 located 
on the cell membrane functions in anchoring the pericellular matrix. In this regard, 
trypsin-treated chondrocytes can establish a pericellular matrix even when cell surface 
CD44 expression levels reach only 25% of total baseline as determined by flow 
cytometry. This suggests that chondrocytes only need 25% of total cell surface CD44 to 
retain a pericellular matrix. So the unoccupied cell surface CD44 may be involved in 
cellular activation of signaling or other functions (Knudson et al., 1999).  
 
CD44 not only binds growth factors, but also acts as a co-receptor for mediating 
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receptor kinase activity, which facilitates its association with intracellular mediators of 
signal transduction. For example, the CD44 isoform with exon v3 (which carries 
heparan sulfate side chains) binds hepatocyte growth factor/scatter factor, the ligand of 
the receptor kinase c-Met to promote tumor growth and metastasis (Fromont Hankard et 
al., 1998). Moreover, CD44 interacts with the EGF receptor through a PDZ domain in 
head and neck squamous carcinoma cells. Hyaluronan binding to CD44 triggers EGF 
receptor kinase activity, thereby stimulating downstream phosphorylation (Wang and 
Bourguignon, 2006).  
 
In addition, the cytoplasmic domain of CD44 interacts with SMAD1, the downstream 
mediator of the BMP-7 signaling pathway. However, this interaction between CD44 and 
SMAD1 decreases upon BMP-7 stimulation such that SMAD1 becomes phosphorylated 
and translocates into the nucleus. In chondrocytes overexpressing a truncated CD44 
(CD44Δ67 that mimics the short-tail CD44exon 19), SMAD1 no longer translocates into 
nucleus upon BMP7 stimulation (Peterson et al., 2004).  
 
CD44 mediates communication between the matrix and the cell. Pre-treatment of 
chondrocytes with Streptomyces hyaluronidase, which disrupts hyaluronan-CD44 
interactions, inhibits SMAD1 phosphorylation and nuclear translocation upon BMP7 
stimulation (Peterson et al., 2004). BMP7 treatment initiates SMAD1 nuclear 
translocation in CD44-negative COS7 cells transfected with functional CD44 constructs. 
And expression of dominant-negative CD44 in bovine chondrocytes diminishes SMAD1 
nuclear translocation upon BMP7 stimulation (Peterson et al., 2004).  
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CD44 also mediates the internalization of hyaluronan on chondrocytes, by delivering to 
lysosomes by an unclear mechanism that does not appear to involve clathrin, caveolae 
or pinocytosis, and leading to its degradation in a low pH intracellular compartment 
(Ariyoshi et al., 2010; Hua et al., 1993; Knudson et al., 2002).  
 
CD44 can be cleaved in vivo to generate three fragments. The first cleavage involves 
metalloproteinases and generates soluble extracellular CD44 fragments which are shed 
plus a C-terminal fragment (CD44-EXT). The CD44-EXT in the plasma membrane is a 
substrate for γ-secretase cleavage generating the CD44 intracellular domain (ICD) 
(Lammich et al., 2002; Nabeshima et al., 2004; Thorne et al., 2004). Shedding of CD44 
can be blocked by inhibitors of matrix metalloproteinases (MMPs) or ADAM10 (a 
disintegrin and metalloproteinase) or ADAM17 or two of the membrane type (MT)-
MMPs; MT3-MMP or MT1-MMP (Julovi et al., 2004; Kajita et al., 2001; Nabeshima et 
al., 2004; Stoeck et al., 2006), while inhibition of γ-secretase can block the formation of 
the CD44-ICD (Lammich et al., 2002). Primary bovine articular chondrocytes exhibit no 
detectable CD44 fragmentation but treatment of primary chondrocytes with interleukin-
1β enhanced CD44 fragmentation. Chondrocytes from osteoarthritic cartilage exhibit 
CD44 fragmentation as low molecular mass bands, corresponding to CD44-EXT and 
CD44-ICD bands and chondrocytes that have been passed multiple times in cell culture 
and have undergone de-differentiation also exhibit a naturally-occurring degradation of 
CD44 (Takahashi et al., 2010).  Direct cartilage extracts also contain intact CD44 and 
fragmented CD44 (Hida, unpublished observations). Fragmentation of CD44 in 
chondrocytes was blocked in the presence of metalloproteinase inhibitors and γ-
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secretase inhibitors. The cytoplasmic domain of CD44 (CD44-ICD) translocates to the 
nucleus and functions as a transcription factor; CD44 itself is one potential target of 
CD44-ICD transcription activity (Okamoto et al., 2001).  
 
3.3 CD44 Knockout Mice 
 
The transient absence of CD44 expression by intravenous injection injection of CD44 
antibody into pregnant rats results in weak CD44 expression in the fetal tissues most 
likely due to antibody-induced internalization and shedding of CD44, and delayed 
growth and development of the fetuses, including skeletal elements (Zoller et al., 1997). 
In addition, CD44 transgenic mice that express an antisense CD44 cDNA driven by the 
keratin-5 promoter demonstrate no detectable CD44 expression in skin keratinocytes 
and corneal epithelium, decreased skin elasticity, impaired local inflammatory response 
and tissue repair, delayed hair regrowth, and failure of the epidermis to undergo 
hyperplasia in response to carcinogen (Kaya et al., 1997).  
 
However, the above results are in stark contrast to classic CD44 knockout mice. 
Despite a complete loss of CD44, CD44 knockout mice develop normally without 
developmental or neurological defects and originally showed no overt abnormalities as 
adults (Kaya et al., 1997; Protin et al., 1999; Schmits et al., 1997). The first strain of 
CD44 knockout mice was generated by Dr. Mak at University of Toronto in 1997 
(Schmits et al., 1997). The 3′ region of exon 2 and the complete exon 3 were replaced 
with pMC1-Neomycin, which was inserted in the antisense orientation, leading to 
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several stop codons in all three reading frames. The selected recombinant colonies 
were injected into 3.5-day-old C57Bl/6J blastocysts, and the chimeras were 
backcrossed into C57Bl/6J mice. This CD44 knockout mice show impaired hematology, 
defective progenitor egress from bone marrow, exaggerated granuloma and higher 
incidence of tumor formation.  Another strain of CD44 knockout mice was generated by 
Dr. Mikecz at Rush University in 2001 to study collagen-induced arthritis (Stoop et al., 
2001). Most of exons 4 and 5, which include a substantial part of the hyaluronan binding 
domain and the CD44 monoclonal antibody extracellular recognition site, were deleted 
and replaced with neomycin and thymidine kinase selectable markers. The selected 
recombinant colonies were injected into C57Bl/6J blastocysts, and the chimeras were 
backcrossed into DBA/1LacJ mice. This CD44 knockout mice show significant 
reductions in the incidence and severity of collagen-induced arthritis. To study aggrecan 
induced arthritis, the second strain of CD44 knockout mice were backcrossed into 
BALB/c background (Szanto et al., 2004), which was the strain used in our laboratory. 
There is another strain of CD44 knockout mice that are commercially available from the 
Jackson Laboratory.  In these mice, exon 1 and a portion of intron 1 of CD44 were 
disrupted with a neomycin resistance/lacZ cassette. The selected ES cells were injected 
into C57Bl/6J blstocysts, and the chimeras were backcrossed into C57Bl/6J mice.  
 
Although originally suggested to exhibit no phenotype, subsequent research has found 
that CD44 knockout mice display an impaired immune response (Teder et al., 2002), a 
delayed recovery of the epidermal barrier function, a loss of apical polarization of 
lamellar bodies, and changes of tight junction proteins (Kirschner et al., 2011). In 
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addition, female CD44 knockout mice exhibit impaired lactation and smaller uteri with 
reduced wall thickness and disorganized myometrium (Yu et al., 2002).  
 
Stoop et al. found that CD44-deficient DBA/1 mice exhibit decreased incidence and 
severity of arthritis in a collagen-induced arthritis mouse model compared to wild type 
mice (Stoop et al., 2001). However, using the same model, Nedvetzki et al found that 
CD44 knockout mice exhibit increased joint inflammation compared to wild type mice 
(Nedvetzki et al., 2004). The increased joint inflammation in the CD44 knockout mice 
was an unexpected finding and opposite of what had been predicted. A possible 
explanation is that another hyaluronan receptor termed the Receptor for Hyaluronan-
Mediated Motility (RHAMM) compensates for the lost CD44 functions of hyaluronan 
binding, cell migration, and inflammation. Interestingly, the RHAMM compensation that 
was observed was caused by hyaluronan accumulation which enhances signaling via 
RHAMM, not by increased RHAMM expression (Nedvetzki et al., 2004).  
 
Previous work in our laboratory found that CD44 knockout murine chondrocytes and 
fibroblast exhibit limited potential for retention and internalization of G1-VTEGE, the 
residual at N-terminal G1 domains of cleaved aggrecan, which remains bound to 
hyaluronan. Along these lines, CD44 knockout mice accumulate the G1-VTEGE within 
the cartilage (Ariyoshi et al., 2010). 
 
CD44 knockout mice, with absolutely CD44 negative background in vivo, provide a 
useful tool to study various physiological roles of CD44. Among these physiological 
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roles, the relationship between CD44 and hyaluronan and its affect on both the BMP7 
and EGF signaling pathways using isolated CD44 knockout murine chondrocytes may 
be important to address. 
 
4. Bone Morphogenetic Proteins 
 
4.1 The Bone Morphogenetic Protein Family 
 
In 1971, Marshal Urist proposed the name “Bone Morphogenetic Protein (BMP)” after 
the key discovery that demineralized cell-free bone extracellular matrix induced new 
bone formation when implanted in muscle pouches in rabbits (Urist, 1965). Since then, 
twenty genes that encode functional BMPs have been identified in the human genome 
(Kang and Reddi, 1996; Reddi, 1981). Today, BMPs are more aptly called “Body 
Morphogenetic Proteins” due to their various functions in embryonic pattering, 
development, tissue homeostasis and regeneration (Reddi, 2005; Wagner et al., 2010; 
Yang et al., 2005b). BMPs belong to transforming growth factor (TGF)-β superfamily 
which consists of different isoforms of TGF-βs, activins, and BMPs. 
 
BMP7 was initially called osteogenic protein one (OP-1) when it was first cloned and 
sequenced (Ozkaynak et al., 1990) due to its early known function to induce new bone 
formation (Sampath et al., 1992). In addition to BMP7, BMP2, BMP4, and BMP6 also 
induce new bone as well as cartilage formation (Miyazono et al., 2005).  BMP7 and 
BMP2 form both homodimers (BMP7/BMP7 and BMP2/BMP2) as well as heterodimers 
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(BMP7/BMP2).  However, some members of the TGF-β superfamily do not induce new 
bone formation, that is, BMP1 (a metalloprotease) and TGF-β (Sampath and Reddi, 
1983).  
 
The mechanism of action of BMPs in general follows the canonical pathway (Miyazono 
et al., 2005), which includes multiple steps. First, BMPs bind to serine/threonine kinase 
cell surface receptors in order to initiate a cellular response. Type II BMP receptor 
dimers recruit and phosphorylate Type I BMP receptor dimers. The Type I and Type II 
BMP receptor dimers then form a hetero-tetrameric complex with various ligands. Then, 
the phosphorylated Type I BMP receptor dimer phosphorylates receptor-regulated 
SMADs (R-SMADs), specifically SMAD1, SMAD5, and SMAD8. R-SMADs include 
SMAD-1, 2, 3, 5, 8.  SMAD2 and SMAD3 are downstream molecules of TGF-β signaling 
pathway. The phosphorylated SMAD1, SMAD5, and SMAD8 form a complex with 
SMAD4, the common-mediator (co-SMAD). The complex enters into the nucleus where 
it binds to transcription co-activator, causing target gene transcription.  
 
Specifically, the canonical pathway of the mechanism of action of BMP7 (Fig 3) includes 
specific receptors and R-SMADs. BMP7 binds the ActRII Type II BMP receptor and 
recruits the ALK2 Type I BMP receptor in order to initiate a cellular response (Macias-
Silva et al., 1998). This recruitment phosphorylates and activates R-SMADs, specifically 
SMAD1 and SMAD5 (but not SMAD8) and forms SMAD1-SMAD4 heteromeric 
complexes (Ebisawa et al., 1999). The mechanism of action of BMP7 specifically 
follows not only the canonical pathway but also the mitogen-activated protein kinase 
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(MAPK) pathway whereby MAPK target gene expression are activated (Miyazono et al., 
2005). 
 
The signaling pathway of BMPs is regulated at different molecular levels by extracellular 
antagonists, intracellular inhibitors, and small-molecule inhibitors (Yoon and Lyons, 
2004). The extracellular antagonists include Noggin and Chordin. Noggin and Chordin 
bind to BMPs and prevent BMPs from binding their receptors. The intracellular inhibitors 
include: inhibitory-SMADs (I-SMADs), such as SMAD6 and SMAD7, and SMAD-
ubiquitination regulatory factor (Smurf). I-SMADs interfere with R-SMAD 
phosphorylation and heterodimerization with co-SMAD4. Smurf1 (an ubiquitin ligase) 
functions in the ubiquitination of SMAD1 and SMAD5 that results in subsequent 
proteasomal degradation. Moreover, Smurf1 enhances the interaction of I-SMADs, thus 
further inhibiting BMP signaling. Phosphorylation of R-SMADs by MAPK blocks their 
nuclear translocation (Verheyen, 2007) and promotes their ubiquitination. The small 
molecule inhibitors include dorsomorphin. Dorsomorphin inhibits the phosphorylation of 
R-SMADs, but does not alter MAPK p38 phosphorylation, indicating the specificity for 
SMAD-dependent signaling. In addition, dorsomorphin demonstrates limited effects on 
other members of TGF-β superfamily, such as TGF-β1 and activin A, which indicates 
considerable specificity for BMPs signaling (Anderson and Darshan, 2008).  
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Figure 3. BMP7 canonical signaling pathway. When BMP7 binds to the complexes of 
type I and type II receptors, the constitutively active serine-threonine kinase domain of 
Act RII receptor phosphorylates ALK 2 receptor, which in turn phosphorylates 
SMAD1/5. The phosphorylated SMAD1/5 forms a complex with SMAD4 that 
translocates to the nucleus to regulate target genes (e.g., Cd44, Has2, Col II and 
Aggrecan) transcription. This pathway through the SMAD protein is well characterized 
and often called the canonical pathway. CD44, a single-pass transmembrane 
glycoprotein, binds to hyaluronan with residues in the extracellular domain and binds to 
SMAD1 with residues in the cytoplasmic domain.  
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In the TGF-β signaling pathway, a FYVE domain protein, SMAD anchor for receptor 
activation (SARA) recruits SMAD2 to the TGF-β receptor so that phosphorylation 
occurs. The phosphorylated SMAD2 dissociates from SARA and forms a 
SMAD2/SMAD4 complex that translocates to nucleus (Tsukazaki et al., 1998). 
However, SARA does not bind SMAD1, which is the downstream molecule of BMPs 
signaling pathway. An endosome-associated FYVE-domain protein, endofin, has been 
considered as a SARA in BMPs signaling pathway. Endofin binds to SMAD1 and 
enhances its phosphorylation and nuclear localization upon BMP stimulation (Shi et al., 
2007).  
 
Previous work in our laboratory using yeast-two-hybrid analysis and co-
immunoprecipitation techniques indicates that the cytoplasmic domain of CD44 interacts 
with SMAD1. Upon BMP7 stimulation, the interaction of CD44 with SMAD1 weakens 
followed by SMAD1 phosphorylation and SMAD1 translocation into nucleus. However, 
when the cytoplasmic domain of CD44 is truncated (CD44Δ67), SMAD1 translocation 
into the nucleus vanishes upon BMP7 stimulation (Peterson et al., 2004). These results 
indicate that CD44 may function as SARA in the BMP7 signaling pathway in 
chondrocytes. 
 
4.2 Physiological Functions 
 
The regulation of chondrocyte/cartilage metabolism is indeed a complex system. In 
“healthy state” articular cartilage, a delicate balance exists between anabolic 
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morphogens and catabolic cytokines (Nishihara et al., 2003). On the positive side, 
anabolic morphogens induce cartilage morphogenesis and maintain cartilage 
homeostasis. On the negative side, catabolic cytokines lead to cartilage degradation. A 
disruption of this delicate balance results in arthritis.  
 
BMPs are anabolic morphogens and play an important role in cartilage development, 
cartilage homeostasis, and even in osteoarthritis. More specifically, BMP7 stimulates 
proteoglycan and Type II collagen synthesis in human and bovine articular 
chondrocytes without proliferation (Flechtenmacher et al., 1996). In addition, BMP7 
promotes the synthesis and retention of the extracellular matrix within bovine articular 
cartilage and chondrocyte cultures (Nishida et al., 2000a). 
 
As one might expect, endogenous BMP7 and aggrecan expression levels are reduced 
in osteoarthritic chondrocytes (Merrihew et al., 2003). This reduction of endogenous 
BMP7 expression levels in osteoarthritic chondrocytes can be obviated by the addition 
of recombinant BMP7 to cultured osteoarthritic chondrocytes which stimulates 
proteoglycan synthesis (Stove et al., 2006). In addition, BMP7 rescues the osteoarthritic 
injury in a post-traumatic osteoarthritis model (Fan et al., 2004). Finally, weekly intra-
articular injections of BMP7 inhibit osteoarthritic progression in rabbits (Hayashi et al., 
2008). The above findings have led to Food and Drug Administration (FDA) approval of 
BMP7 (marketed as osteogenic protein; OP-1) for clinical use in humans (White et al., 
2007). BMP7 has been used clinically to aid in the fusion of vertebral bodies, fracture 
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non-union, and arthritis (Brown et al., 2006; Fajardo et al., 2009; Honsawek et al., 
2009). 
 
BMP7 knockout mice are postnatal lethal due to the severe defects in kidney. However, 
BMP7 knockout mice show several defects in the appendicular skeleton, such as, an 
additional single preaxial digit, the failure of 7th pair of ribs fuse to sternum, and 
underdevelopment vertebrae (Dudley et al., 1995). In conditional BMP7 knockout mice, 
which have no BMP7 expression in the embryonic limb prior to the onset of 
skeletogenesis, the absence of BMP7 produces no effect in the formation of 
appendicular skeletal elements, the growth and maturation of limb bones, the formation 
of articular cartilage, or fracture healing. This suggests that other BMPs compensate for 
the absence of BMP7 in the formation of skeletal structures. The limb-specific 
conditional BMP4 and BMP7 double knockout mice exhibit loss of specific skeletal 
structures, but in the remaining skeletal structures endochondral ossification appears 
normal. This finding suggests that BMP4 and BMP7 are functionally redundant (Dudley 
et al., 1995; Tsuji et al., 2008). 
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5.  Specific Aims 
 
From previous studies, the loss of hyaluronan-CD44 interactions, either with dominant 
negative CD44 expression or with hyaluronidase pretreatment, exerts a negative effect 
on the canonical BMP/ BMPR/ SMAD1 signaling pathway.   Furthermore, our laboratory 
reported that CD44 interacts with SMAD1 (Peterson et al., 2004).  The negative effect of 
hyaluronidase pretreatment on the canonical BMP/ BMPR/ SMAD1 signaling pathway 
can be rescued by hyaluronan synthase transfection or the addition of hyaluronan 
(Andhare et al., 2009). In addition, CD44 negative/LNCaP cells show a diminished 
SMAD1 phosphorylation upon BMP7 stimulation when compared to CD44 positive/PC3 
cells (Yang et al., 2005a). Taken together, these data suggest a mechanism whereby 
hyaluronan-CD44 interactions may impact the BMP7 canonical signaling pathway 
representing another potential mechanism whereby the extracellular matrix influences 
cell behavior. Our hypothesis is that hyaluronan-CD44 interactions will promote the 
BMP7 canonical signaling pathway. Since classic CD44 knockout mice demonstrate a 
normal appendicular skeleton/cartilage and exhibit no overt phenotype when compared 
to wild type mice, CD44 knockout mice may provide an important tool to explore 
physiological roles of CD44 and to investigate the effect of its interaction with 
hyaluronan on the BMP7 canonical signaling pathway. Using CD44 knockout mice, two 
specific aims are proposed which will contribute to our understanding of cartilage repair 
and may impact our ability to facilitate cartilage repair through manipulation of CD44 
and/ or hyaluronan. 
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Specific Aim 1. To investigate the role of CD44 in the BMP7 canonical signaling 
pathway. 
 
Hypothesis 1: Following BMP7 stimulation, the interaction between CD44 and 
SMAD1 will promote SMAD1 presentation to and phosphorylation by the BMP 
receptor kinase.  
Corollary 1: The CD44 expression level will affect BMP7-mediated SMAD1 
phosphorylation.  
 
In order to address this specific aim, the CD44 expression level and the BMP7 
concentration threshold to induce cellular responses were studied by three different 
experimental approaches:  
• BALB/c wild type murine chondrocytes versus CD44 knockout murine 
chondrocytes 
• BALB/c wild type murine chondrocytes versus BALB/c wild type murine 
chondrocytes transfected with mouse CD44 small interference RNA (siRNA) 
• CD44 knockout murine chondrocytes versus CD44 knockout murine 
chondrocytes transfected with human CD44 plasmid 
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Specific Aim 2:  To investigate the role of hyaluronan in the BMP7 canonical signaling 
pathway. 
 
Hypothesis 2: Upon BMP7 stimulation, the presence of pericellular hyaluronan 
will promote SMAD1 phosphorylation by the BMP receptor kinase.  
 
Corollary 2: Hyaluronan-CD44 interactions will affect BMP7 – mediated SMAD1 
phosphorylation. 
 
In order to address this specific aim, BMP7 cellular responses were studied in both 
BALB/c wild type murine chondrocytes and CD44 knockout murine chondrocytes as 
well as two standard cell models; namely, primary cultures of adult bovine articular 
chondrocytes and the rat chondrosarcoma cell line.  Two experimental approaches to 
perturb hyaluronan-chondrocytes interactions were used: 
• Pretreatment with testicular hyaluronidase which degrades hyaluronan in the 
pericellular matrix 
• Pretreatment with 4-methylumbelliferone (4-MU) which inhibits hyaluronan 
synthase 
 
 
 
 
CHAPTER 2. METHODS 
 
1. Tissue and Cell Culture 
 
1.1 Mice femoral heads and knee joints isolation and explant culture 
 
One-week-old and eight-month-old BALB/cJ wild type [JAX Mice (Charles River, 
Wilmington, MA)] and CD44 -/- mice (Szanto et al., 2004) were euthanized by open 
drop Isoflurane inhalation. The mice were placed in the face-up position on a petri dish, 
and skin and soft tissues were removed from the hind legs using foceps. Femoral heads 
and knee joints were freed of surrounding muscles, tendons, and connective tissue and 
were either fixed directly with 4% paraformaldehyde, or cultured in DMEM [Mediatech 
(Herndon, VA)] supplemented with 10% fetal bovine serum (FBS) [Hyclone (South 
Logan, UT)]. 
 
1.2 Primary bovine articular chondrocytes isolation and cell culture 
 
Bovine articular chondrocytes were isolated using the method previously published 
(Ohno et al., 2006) Articular cartilage was removed from the metacarpophalangeal 
joints of adult steers about 18-month-old obtained from a local slaughterhouse. For 
most experiments, the superficial layer, representing approximately 30% of the total 
articular cartilage thickness, was removed by a cartilage abrasion technique. The 
cartilage slices were subjected to sequential digestion with 0.2% pronase [EMD 
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Scientific (San Diego, CA)] for 1 hour at 37°C, 5% CO2, followed by 0.0025% 
collagenase P [Roche (Indianapolis, IN)] for overnight at 37°C, 5% CO2. The second 
day, the cell suspension was filtered through a sterile 40 µm cell strainer set over a 50-
ml tube to obtain a single cell suspension and centrifuged at 300 g for 5 minutes at 
room temperature. The pellet was resuspended with 10 ml DMEM/F12 [Mediatech 
(Herndon, VA)] supplemented with 10% FBS and 1 µg/ml ascorbic acid. The cells were 
counted using a hemocytometer. Primary bovine articular chondrocytes were cultured at 
37°C, 5% CO2 in DMEM/F12 supplemented with 10% FBS, 2mM L-glutamine and 1 
µg/ml ascorbic acid with penicillin and streptomycin prior to initiation of experimental 
conditions. 
 
1.3 Primary murine articular chondrocytes isolation and cell culture 
 
Primary murine articular chondrocytes were isolated from the femoral heads and knee 
joints of 1-week-old wild type and CD44 -/- mice. The mice were euthanized by open 
drop Isoflurane inhalation and were placed in the face-up position on a petri dish. The 
skin and soft tissues were removed from the hind legs using forceps. Femoral heads 
and knee joints were freed of surrounding muscle, tendons, and connective tissue and 
were subjected to sequential digestion of twice incubation with 5 ml 0.25% 
Trypsin/EDTA [Mediatech (Herndon, VA)] in a 50 ml tube for 30 minutes at 37 °C, 5% 
CO2, followed by 5 ml 3 mg/ml collagenase D [Roche (Indianapolis, IN)] overnight at 
37°C, 5% CO2. The second day, the cell suspension was filtered through a sterile 40 µm 
cell strainer set over a 50-ml tube to obtain a single cell suspension and centrifuged at 
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300 g for 5 minutes at room temperature. The pellet was resuspended with 10 ml 
DMEM supplemented with 20% FBS. On average, about 106 murine chondrocytes were 
obtained per mouse (Fig 4). Primary murine chondrocytes were cultured at 37°C, 5% 
CO2 in DMEM supplemented with 10% FBS, 2mM L-glutamine and 1 µg/ml ascorbic 
acid with penicillin and streptomycin prior to initiation of experimental conditions. 
 
1.4 COS7 cells culture 
 
COS7 cells (Simian virus 40- transformed African Green Monkey Kidney Epithelial 
Cells; American Type Culture Collection; Manassas, VA) were thawed from liquid 
nitrogen and cultured in DMEM supplemented with 10% FBS, 2mM L-glutamine with 
penicillin and streptomycin prior to initiation of experimental conditions. 
 
1.5 Rat chondrosarcoma cells culture 
 
Rat chondrosarcoma (RCS) cells (King and Kimura, 2003; Knudson, 1996) were thawed 
from liquid nitrogen and cultured in DMEM supplemented with 10% FBS, 2mM L-
glutamine with penicillin and streptomycin prior to initiation of experimental conditions. 
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1.6 Human osteosarcoma MG63 cells culture 
 
MG63 cells were thawed from liquid nitrogen and cultured in DMEM supplemented with 
10% FBS, 2mM L-glutamine with penicillin and streptomycin prior to initiation of 
experimental conditions. 
 
1.7 Human prostate cancer PC3 cells culture 
 
PC3 cells were thawed from liquid nitrogen and cultured in RMPI-1640 [Mediatech 
(Herndon, VA)] supplemented with 10% FBS, 2mM L-glutamine with penicillin and 
streptomycin prior to initiation of experimental conditions. 
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Figure 4. Primary murine articular chondrocytes isolation. Primary mouse articular 
chondrocytes were isolated from the femoral heads and knee joints of 1-week-old 
BALB/cJ +/+ and CD44 -/- mice. The mice were euthanized by open drop Isoflurane 
inhalation. The mice were placed in the face-up position on a Petri dish and the skin and 
soft tissues were removed from the hind legs using forceps. Femoral heads and knee 
joints were freed of surrounding muscle, tendons, and connective tissue and were 
subjected to sequential digestion of two times incubation with 5 ml 0.25% Trypsin/EDTA 
in a 50 ml tube for 30 minutes at 37 °C, 5% CO2, followed by 5 ml 3 mg/ml collagenase 
D overnight at 37°C, 5% CO2. The second day, the cell suspension was filtered through 
a sterile 40 µm cell strainer set over a 50-ml tube and centrifuged at 300 g, 5 minutes, 
room temperature. The pellet was resuspended with 10 ml DMEM supplemented with 
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20% fetal bovine serum. On average, about 106 chondrocytes were obtained per 
mouse. 
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2 Characterization 
 
2.1 Safranin O and Fast Green staining 
 
Mice femoral heads and knee joints were stained with Safranin O and fast green to 
visualize proteoglycan and type II collagen in the extracellular matrix of cartilage 
(Rosenberg, 1971). After decalcification with 5% EDTA for about 1 week and embedded 
with paraffin, mice femoral heads and knee joints were cut into 8 µm sections and 
stained with Safranin O and counterstained with fast green, followed by dehydration 
with ethanol. Then, the sections were mounted before observation under microscope. 
 
Safranin O Stock Solution Preparation: five gram of Safranin O was dissolved in 500mL 
of dH2O. 
 
Safranin O Working Solution Preparation: Safranin O stock solution was diluted 1:9 (v:v) 
with dH2O for a concentration of 0.1%. 
 
Fast Green Stock Solution Preparation: five gram of Fast Green was dissolved in 
500mL of dH2O. 
 
Fast Green Working Solution Preparation: Fast Green stock solution was diluted 1:9 
(v:v) with dH2O for a concentration of 0.1%. 
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2.2 Live/Dead cell viability assay 
 
Primary bovine chondrocytes were plated at a density of 2x105 per well with 2ml DMEM 
plus 10% FBS in a 6-well plate. Forty-eight hours later, bovine chondrocytes were 
treated with different concentrations of testicular hyaluronidase [Sigma (St. Louis, MO)] 
(0-200 units/ml) for overnight. Then the cells were incubated with 1 ml freshly prepared 
2 µM Calcein AM and 4 µM ethidium homodimer [Invitrogen (Carlsbad, CA)] working 
solution for 30 minutes at room temperature to stain live and dead cells simultaneously. 
Following with incubation, the cells were washed 3 times with 1X PBS and the cultures 
were observed under fluorescence microscope. 
 
Calcein AM and Ethidium homodimer working solution preparation 
 
Calcein AM and ethidium homodimer stock solution were removed from freezer and 
warm to room temperature. Five microliter of 4 mM Calcein AM and 20 µl of 2mM 
ethidium homodimer solution were added to the 10 ml of sterile PBS solution. A vortex 
was used to ensure thorough mixing. 
 
Cell viability assay working mechanism 
 
Nonfluorescent calcein AM is permeable to cells and following intracellular esterase 
activity, nonfluorescent calcein AM is converted to the non-membrane permeable, 
intensely green fluorescent calcein and well retained within live cells. Ethidium 
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homodimer enters cells through damaged membranes of dead cells and produces a red 
fluorescence when it binds to nucleic acids. 
 
2.3 Visualization of pericellular matrix by particle exclusion assay 
 
Wild type and CD44 -/- primary murine chondrocytes were plated at a density of 2x105 
per well with 2 ml DMEM plus 20% FBS in a 6-well plate. Forty-eight hours later, the 
cells were incubated with 1 ml freshly prepared 2 µM Calcein AM working solution for 30 
minutes at room temperature. Followed with particle exclusion assay, of which 750 µl of 
formalin-fixed horse red blood cell suspension (108 cells/ml in Ham’s F-12 Media) was 
added to murine chondrocytes and the cultures were observed under fluorescence 
microscope 10 minutes later to allow the red blood cells to settle down on the culture 
dish (Underhill, 1982). 
 
2.4 Visualization of hyaluronan with hyaluronan binding protein 
 
A biotinylated hyaluronan binding protein (HABP) [Cosmo Bio Co., Ltd. (Japan)] was 
used to visualize hyaluronan by fluorescence microscopy (Embry Flory et al., 2006; 
Knudson et al., 2002). Wild type and CD44 -/- primary murine chondrocytes were plated 
at a density of 1x105 per chamber with 1ml DMEM plus 20% FBS in a 4-well chamber 
slide [Thermo (Rochester, NY)]. Forty-eight hours later, cells were treated with 200 
units/ml testicular hyaluronidase or 10 unis/ml Streptomyces hyaluronidase [Sigma (St. 
Louis, MO)] for 3 hours. Then the cells were washed 3 times with sterile 1xPBS and 
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fixed with 0.5 ml 0.5% paraformaldehyde for 15 minutes at 4 °C. The cells were then 
blocked with 500 µl Amplifying Antibody Dilution Buffer [ProHisto, (Columbia, SC)] for 1 
hour at room temperature and incubated with 2 µg/ml biotintylated HABP for overnight 
at 4 °C. The second day, cells were washed 3 times with 1X Amplifying IHC Wash 
Buffer [ProHisto, (Columbia, SC)], followed by incubation with 1 µg/ml neutravidin-FITC 
[Pierce, (Rockford, IL)] at room temperature for 1 hour. The coverslip were applied 
using 4', 6-diamidino-2-phenylindole (DAPI) [Vector labs, (Burlingame, CA)] and 
chondrocytes HABP staining was visualized by fluorescence microscopy. 
 
Primary bovine chondrocytes were plated at a density of 1x105 per chamber with 1ml 
DMEM plus 10% FBS in a 4-well chamber slide with or without the presence of 4-
methylumbelliferone for 48 hours. Then the cells were washed 3 times with sterile 
1xPBS and fixed with 0.5 ml 0.5% paraformaldehyde for 15 minutes at 4 °C. The cells 
were then blocked with 500 µl Amplifying Antibody Dilution Buffer [ProHisto, (Columbia, 
SC)] for 1 hour at room temperature and incubated with 2 µg/ml biotintylated HABP for 
overnight at 4 °C. The second day, cells were washed 3 times with 1X Amplifying IHC 
Wash Buffer [ProHisto, (Columbia, SC)], followed by incubation with 1 µg/ml 
neutravidin-FITC at room temperature for 1 hour. The coverslip were applied using 
DAPI and chondrocytes HABP staining was visualized by fluorescence microscopy. 
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2.5 Toluidine blue staining 
 
Toluidine blue staining was used to visualize proteoglycan deposition around the 
chondrocytes (Geyer and Linss, 1978). Wild type and CD44 -/- primary murine 
chondrocytes were plated at a density of 1x105 per chamber with 1ml DMEM plus 20% 
FBS in a 4-well chamber slide. Forty-eight hours later, cells were treated with 200 
units/ml testicular hyaluronidase or 10 units/ml Streptomyces hyaluronidase for 3 hours. 
Then the cells were washed 3 times with sterile 1xPBS and fixed with 0.5 ml 0.5% 
paraformaldehyde for 15 minutes at 4 °C. The cells were then incubated with 0.5% 
toluidine blue O solution at room temperature for 3 minutes, washed 3 times with sterile 
1X PBS. The cultures were observed under microscope. 
 
Primary bovine chondrocytes were plated at a density of 1x105 per chamber with 1ml 
DMEM plus 10% FBS in a 4-well chamber slide with or without the presence of 4-
methylumbelliferone for 48 hours. Then the cells were washed 3 times with sterile 
1xPBS and fixed with 0.5 ml 0.5% paraformaldehyde for 15 minutes at 4 °C. The cells 
were then incubated with 0.5% toluidine blue o solution at room temperature for 3 
minutes, washed 3 times with sterile 1X PBS. The cultures were observed under 
microscope. 
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0.5% toluidine blue staining solution preparation: 
 
0.25 g toluidine blue O was dissolved in 50 ml 20% ethanol and 2 drops of acetic acid 
were added to the solution to lower the pH to promote binding to sulfated proteoglycans. 
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3 Cell Treatments 
 
3.1 BMP7 stimulation 
 
Wild type and CD44 -/- primary murine chondrocytes after collagenase D overnight 
digestion, were plated at a high density of 2x105 per well in a 48-well plate in DMEM 
supplemented with 10% FBS. Twenty-four hours later, the medium was changed to 
serum free DMEM for overnight incubation. The second day, the murine chondrocytes 
were stimulated with different concentrations (0 ng/ml – 100 ng/ml) of BMP7 [Stryker 
Biotech (Hopkinton, MA)] for 1 hour. Then the cells were lysed for protein assay. 
 
Primary bovine chondrocytes after collagenase P overnight digestion, were plated at a 
high density of 2x106 per well in a 6-well plate in DMEM/E12 supplemented with 10% 
FBS. Twenty-four hours later, the medium was changed to serum free DMEM for 
overnight incubaton. The second day, the bovine chondrocytes were stimulated with 
different concentrations (0 ng/ml – 100 ng/ml) of BMP7 for 1 hour. Then the cells were 
lysed for protein assay. 
 
3.2 Testicular hyaluronidase treatment 
 
Wild type and CD44 -/- primary murine chondrocytes after collagenase D overnight 
digestion, were plated at a high density of 2x105 per well in a 48-well plate in DMEM 
supplemented with 10% FBS. Twenty-four hours later, the medium was changed to 
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serum free DMEM with or without the presence of 200 units/ml testicular hyaluronidase 
[Sigma (St. Louis, MO)] for overnight incubation. On the second day, the murine 
chondrocytes were stimulated with 100 ng/ml BMP7 for 1 hour. Then the cells were 
lysed for protein assay. 
 
Primary bovine chondrocytes after collagenase P overnight digestion, were plated at a 
high density of 2x106 per well in a 6-well plate in DMEM/F12 supplemented with 10% 
FBS. Twenty-four hours later, the medium was changed to serum free DMEM with or 
without the presence of different concentrations of testicular hyaluronidase (0-200 
units/ml) for different time periods (0, 3, 6 and 12 hours). On the second day, the bovine 
chondrocytes were stimulated with 100 ng/ml BMP7 for 1 hour. Then the cells were 
lysed for protein assay. 
 
3.3 Hyaluronan regrowth after testicular hyaluronidase treatment 
 
Wild type and CD44 -/- primary murine chondrocytes after collagenase D overnight 
digestion, were plated at a high density of 2x105 per well in a 48-well plate in DMEM 
supplemented with 10% FBS. Twenty-four hours later, the medium was changed to 
serum free DMEM with or without the presence of 200 units/ml testicular hyaluronidase 
for overnight incubation. The second day, the murine chondrocytes were either directly 
stimulated with 100 ng/ml BMP7 for 1 hour, or cultured another 24 hours in serum free 
DMEM followed with 100 ng/ml BMP7 stimulation for 1 hour. Then the cells were lysed 
for protein assay. 
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3.4 Streptomyces hyaluronidase treatment 
 
Wild type and CD44 -/- primary murine chondrocytes after collagenase D overnight 
digestion, were plated at a high density of 2x105 per well in a 48-well plate in DMEM 
supplemented with 10% FBS. Twenty-four hours later, the medium was changed to 
serum free DMEM with or without the presence of 10 units/ml Streptomyces 
hyaluronidase [Sigma (St. Louis, MO)] for 3 hours. Then the murine chondrocytes were 
stimulated with 100 ng/ml BMP7 for 1 hour and the cells were lysed for protein assay. 
 
3.5 4-Methylumbelliferone treatment 
 
Wild type and CD44 -/- primary murine chondrocytes after collagenase D overnight 
digestion, were plated at a high density of 1x106 per well in a 12-well plate in DMEM 
supplemented with 10% FBS with or without the presence of 1mM 4-
methylumbelliferone [Sigma (St. Louis, MO)]. Twenty-four hours later, the mouse 
chondrocyte cultures were given another aliquot of 4-Methylumbelliferone for another 24 
hours incubation. Then the murine chondrocytes were stimulated with 100 ng/ml BMP7 
for 1 hour and the cells were lysed for protein assay. 
 
Primary bovine chondrocytes after collagenase P overnight digestion, were plated at a 
high density of 2x106 per well in a 6-well plate in DMEM/F12 supplemented with 10% 
FBS with or without the presence of 1mM 4-methylumbelliferone. Twenty-four hours 
later, the bovine chondrocyte cultures were given aliquot of 1mM 4-Methylumbelliferone 
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for another 24 hours incubation. Then the bovine chondrocytes were stimulated with 
100 ng/ml BMP7 for 1 hour and the cells were lysed for protein assay. 
 
Rat chondrosarcoma cells were plated at a high density of 2x106 per well in a 6-well 
plate in DMEM supplemented with 10% FBS with or without the presence of 1mM 4-
methylumbelliferone. Twenty-four hours later, the rat chondrosarcoma cells were given 
another aliquot of 4-Methylumbelliferone for another 24 hours. Then the bovine 
chondrocytes were stimulated with 100 ng/ml BMP7 for 1 hour and the cells were lysed 
for protein assay. 
 
3.6 Epidermal growth factor stimulation 
 
Wild type and CD44 -/- primary murine chondrocytes after collagenase D overnight 
digestion, were plated at a high density of 2x105 per well in a 48-well plate in DMEM 
supplemented with 10% FBS. Twenty-four hours later, the medium was changed to 
serum free DMEM for overnight incubation. The second day, the murine chondrocytes 
were stimulated with different concentrations (0 ng/ml – 50 ng/ml) of epidermal growth 
factor (EGF) [Sigma (St. Louis, MO)] for different time periods. Then the cells were 
lysed for protein assay. 
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3.7 Anti-human BMP7 hammerhead ribozyme transfection of PC3 cells 
 
PC3 cells were rinsed once with serum free DMEM and detached from the flask with 
0.25% Trypsin/EDTA, followed by centrifugation at 500 g for 5 minutes. Cells were 
rinsed again with serum free DMEM and counted with a hemocytometer. 2x106 cells 
were prepared for each transfection. The cell pellet was carefully resuspended with 100 
µl room temperature cell line Nucleofector solution V [Lonza Walkersville Inc, 
(Walkersville, MD)] and mixed with 4 µg empty plasmid and anti-human BMP7 
hammerhead ribozyme plasmids.  These plasmids were provided by Dr. Ye (Fukuda et 
al., 2008). The cell/DNA suspension was transferred to a certified cuvette and applied 
with Nucleofector Program T-13. 500 µl of the pre-equilibrated RPMI-1640 plus 20% 
FBS was added to the cuvette and the sample was gently transferred immediately into 
the pre-incubated 6-well plate filled with 2 ml of DMEM plus 20% FBS. The cells were 
cultured in a humidified 37°C, 5% CO2 incubator for 48 hours before analysis. 
 
Anti-human BMP7 hammerhead ribozyme working mechanism 
 
The hammerhead ribozyme with an appropriately folded shape can serve as an 
enzyme, which base pairs with a second RNA and catalyzes the cleavage of a second 
RNA at a specific site. The catalytic reaction requires metal ions at their active sites.  
(Adapted from T.R. Cech and O.C. Uhlenbeck, Nature 372:39–40, 1994.) 
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3.8 BMP Receptor plasmids transfection of COS-7 cells 
 
COS7 cells were rinsed once with serum free DMEM and detached from the flask with 
0.25% Trypsin/EDTA, followed by centrifugation at 500 g for 5 minutes. Cells were 
rinsed again with serum free DMEM and counted with a hemocytometer. 2x106 cells 
were prepared for each transfection. The cell pellet was carefully resuspended with 100 
µl room temperature cell line Nucleofector solution V [Lonza Walkersville Inc, 
(Walkersville, MD)] and mixed with 4 µg different isoforms of BMP receptor plasmids 
(pALK2Q207P, pALK2CAR206H, pALK3Q233D).  These plasmids were provided by Dr. 
Fukuda (Fukuda et al., 2008). The cell/DNA suspension was transferred to a certified 
cuvette and applied with Nucleofector Program A-024. 500 µl of the pre-equilibrated 
DMEM plus 20% FBS was added to the cuvette and the sample was gently transferred 
immediately into the pre-incubated 6-well plate filled with 2 ml of DMEM plus 20% FBS. 
The cells were cultured in a humidified 37°C, 5% CO2 incubator for 48 hours before 
analysis. 
 
3.9 Mouse CD44 siRNA transfection of wild type murine chondrocytes 
 
The CD44 siRNA was constructed as the murine orthologue of a human CD44 siRNA 
sequence originally described by Ghatak et al. (Ghatak et al., 2005). The mouse 
sequence for CD44 (M27130) was used to determine the sequence for the siRNA.   The 
control siRNA (D-001206-09-05, Dharmacon) was used (Takahashi et al., 2010). CD44 
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and control siRNAs were obtained from Thermo Scientific Dharmacon RNAi 
Technologies (Chicago, IL). 
 
Mouse CD44 siRNA sequences 
 
Sense Sequence: GAA CAC ACC AAG AAG ACA UCG UU 
Antisense Sequence: CGA UGU CUU CUU GGU GUG UUC UU 
 
To prepare the mouse CD44 siRNA for use, after brief centrifugation, mouse CD44 
siRNA was resuspended with 1 ml 1X RNase-free PBS at the final concentration of 40 
pmol/µl. To ensure complete resuspension, the solution was brought up and down 
within a micropipette five times followed by 30 minutes of shaking at room temperature. 
The siRNA was stored at -80°C in aliquots for single use with 2x106 cells. 
 
Wild type primary murine chondrocytes in monolayer culture were rinsed once with 
serum free DMEM and incubated with 1 mg/ml pronase/ collagenase solution for 4 
hours at 37 °C to detach the cells and produce a single cell suspension. The cells were 
separated from the enzyme by centrifugation at 500 g for 5 minutes and rinsed with 
serum free DMEM and counted with a hemocytometer. 2x106 cells were prepared for 
each transfection. The cell pellet was carefully resuspended with 100 µl room 
temperature human chondrocyte Nucleofector solution and mixed with 4 µg mouse 
CD44 siRNA. The cell/RNA suspension was transferred to a certified cuvette which was 
placed into the Amaxa Nucleofector® device [Lonza Walkersville Inc, (Walkersville, MD)] 
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and applied with Nucleofector Program U-028.  500 µl of the pre-equilibrated DMEM 
plus 20% FBS was added to the cuvette and the sample was gently transferred 
immediately into the pre-incubated 6-well plate filled with 2 ml of DMEM plus 20% FBS. 
The cells were cultured in a humidified 37°C, 5% CO2 incubator for 48 hours before 
analysis. 
 
3.10 Human CD44 full length plasmid transfection of CD44 -/- murine 
chondrocytes 
 
CD44 -/- primary murine chondrocytes in monolayer culture were rinsed once with 
serum free DMEM and incubated with 1 mg/ml pronase/ collagenase solution for 4 
hours at 37 °C to detach the cells and produce a single cell suspension.  The cells were 
separated from the enzyme solution by centrifugation at 500 g for 5 minutes, rinsed with 
serum free DMEM and counted with hemocytometer. 2x106 cells were prepared for 
each transfection. The cell pellet was carefully resuspended with 100 µl Amaxa™ 
human chondrocyte Nucleofector solution at room temperature and mixed with 4 µg 
human CD44 full length plasmid.  The cDNA encoding the full length standard isoform 
of human CD44 within the pCDM8 vector was cloned previously (Jiang et al., 2002). 
The cell/DNA suspension was transferred to a certified cuvette and the cells were 
transfected using an Amaxa Nucleofector® device with Nucleofector Program U-028. 
500 µl of the pre-equilibrated DMEM plus 20% FBS was added to the cuvette and the 
sample was gently transferred immediately into the pre-incubated 6-well plate filled with 
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2 ml of DMEM plus 20% FBS. The cells were cultured in a humidified 37°C, 5% CO2 
incubator for 48 hours before analysis. 
 
3.11 Human CD44 Arg 41 point mutation plasmid transfection of CD44 -/- murine 
chondrocytes 
 
Two clusters of basic amino acids in the extracellular domain of CD44 were shown to be 
associated with hyaluronan binding activity and mutation of Arg 41 in CD44 completely 
abolished hyaluronan binding (Peach et al., 1993). Therefore, a point mutation in the 
human pCD44 full length expression vector was generated such that an alanine was 
encoded in the location of the Arg 41 in the CD44 protein based on the strategies 
described in (Jiang et al., 2002; Knudson and Knudson, 1999; Peach et al., 1993) 
 
CD44 -/- primary murine chondrocytes in monolayer culture were rinsed once with 
serum free DMEM and incubated with 1 mg/ml pronase/ collagenase solution for 4 
hours at 37 °C to detach the cells and produce a single cell suspension. The cells were 
separated from the enzyme solution by centrifugation at 500 g for 5 minutes. Cells were 
rinsed with serum free DMEM and counted with a hemocytometer.  2x106 cells were 
prepared for each transfection. The cell pellet was carefully resuspended with 100 µl 
room temperature human chondrocyte Nucleofector solution and mixed with 4 µg 
human CD44 Arg 41 point mutation plasmid. The cell/DNA suspension was transferred 
to a certified cuvette and the cells were transfected using an Amaxa Nucleofector® 
device with Nucleofector Program U-028. 500 µl of the pre-equilibrated DMEM plus 20% 
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FBS was added to the cuvette and the sample was gently transferred immediately into 
the pre-incubated 6-well plate filled with 2 ml of DMEM plus 20% FBS. The cells were 
cultured in a humidified 37°C, 5% CO2 incubator for 48 hours before analysis. 
 
4. Western Blotting 
 
4.1 Cell lysis 
 
High density plated cells after corresponding pre-treatment and BMP7 stimulation were 
washed 2 times with cold, sterile 1X PBS, then 1X Lysis Buffer supplemented with 
protenase inhibitor and phosphotase inhibitor was added. After 5 minutes on ice, the 
cells were scraped and transferred to a 1.5 ml microtube. The microtube was placed on 
ice for another 15 minutes, followed by centrifugation at 13000g for10 minutes at 4 °C. 
The supernatant was transferred to a new tube followed with Bicinchoninic Acid (BCA) 
Protein Assay [Pierce, (Rockford, IL)]. Normally, for high-density plated cells cultured at 
48-well plate, thirty micro liter Lysis Buffer is needed. For high-density plated cells 
cultured at 6-well plate, eighty micro liter Lysis Buffer is needed. 
 
4.2 BCA assay 
 
Following cell lysis, a 25 aliquot per sample (diluted 5 folds) was used to determine the 
protein concentration using a BCA kit protein concentration assay (Pierce). On a 96-well 
plate, 9 aliquots of sequential 1:10 dilutions of Bovine Serum Albumin (BSA) in lysis 
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buffer were set up as a standard. Two hundred and fifty micro liter BCA protein assay 
reagent (Reagent A: Reagent B=50:1) was added to each well. The mixture was 
incubated at 37 °C for 30 minutes, followed by reading absorbance at 562 nm. Protein 
concentration was calculated with the equation derived from BSA standard readings. 
 
4.3 NuPAGE and western blotting 
 
Twenty micro gram protein lysate was mixed with NuPAGE LDS Sample Buffer (4X) 
[Invitrogen] and NuPAGE Reducing Agent (10X) [Invitrogen]. DNase and RNase free 
water was used to obtain an equal volume of each sample. The samples were heated at 
70 °C for 10 minutes and then loaded into the wells of 4 - 12% NuPAGE Novex Bis-Tris 
Mini gel [Invitrogen]. The NuPAGE Mini gel was run at 200 volt for 35 minutes. 
 
After NuPAGE, protein samples were transferred to pure nitrocellulose membrane. The 
membrane was transferred at 500 milliamperes for 2 hours at 4 °C, followed by 5% non-
fat milk blocking for 1 hour at room temperature on the shaker. The membrane was 
incubated with corresponding primary antibody (Table 2) overnight at 4 °C and washed 
3 times with 1XTBS/Tween-20. After incubation with corresponding secondary antibody 
for 1 hour at room temperature, the membrane was exposed to chemiluminescence 
[Invitrogen] for 1 minute at room temperature to detect the specific bands. Normally, the 
membrane was stripped in order to reprobe with another antibody. 
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Table 2. Antibodies 
 
 Host Type Antigen 
Reported 
species of 
target 
Catalog 
rabbit polyclonal 
Phospho-Smad1 (Ser 
463/465)/Smad5 (Ser 
463/465)/Smad8 (Ser 
426/428) 
H, M, R, Mi, X 
Cell 
Signaling 
Cat # 9511 
rabbit polyclonal 
Phospho-Smad1 (Ser 
206) 
H, (M, R, Mk) 
Cell 
Signaling 
Cat # 9553 
rabbit polyclonal Smad1 
H, M, R, B, 
Mk, Pg 
Invitrogen 
Cat # 
385400 
rabbit polyclonal ACVR1 H, M, Mk 
Cell 
Signaling 
Cat # 4398 
P
rim
ary an
tib
o
d
ies 
rabbit monoclonal 
Phospho-p38 MAPK 
(Thr 180/Tyr 182) (3D7) 
H, M, R, Mk, 
Dm, Pg, Sc, 
(Mi, Z, B) 
Cell 
Signaling 
Cat # 9215 
 
rabbit polyclonal 
p38 MAP Kinase 
antibody 
H, M, R, Mk, 
Ant, Pg 
Cell 
Signaling 
Cat # 9212 
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rabbit monoclonal 
Phospho-p44/42 MAPK 
(Erk 1/2) (Thr 202/Tyr 
204) (D 13.14.4E) XPTM 
H, M, R, Mk, 
Mi, Pg, Sc, 
Hm, B, Dm, Z, 
(Dg, Ce) 
Cell 
Signaling 
Cat # 4370 
rabbit monoclonal p44/42 (Erk1/2) (137F5) 
H, M, R, Mk, 
Mi, Pg, Hm, B, 
Dm, Z, (C) 
Cell 
Signaling 
Cat # 4695 
rabbit monoclonal 
Phospho-Akt (Ser 473) 
(D9E) XPTM 
H, M, R, Hm, 
B, Dm, Z 
Cell 
Signaling 
Cat # 4060 
rabbit polyclonal Akt 
H, M, R, C, 
Hm, Dr, Mk, 
Pg, Guinea 
Pig 
Cell 
Signaling 
Cat # 9272 
mouse polyclonal CD44/BU52 H 
Ancell 
Cat # 193-
050 
rat monoclonal CD44/IM7.8.1 H, M, R, B 
Invitrogen 
Cat # 
RM5700 
 
rabbit polyclonal CD44/Cytotail H, M, R, B 
(Takahashi 
et al., 2010) 
goat polyclonal GAPDH H, M, R, B 
Santa cruz 
Cat # sc-
48167 
 
mouse monoclonal β-actin 
H, M, R, B, C, 
Dg, Pg 
Sigma 
Cat # A1978 
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H-human; M-mouse; R-rat; Hm-hamster; Mk-monkey; Mi-mink; C-chicken; Dm-D. 
melanogaster; X-Xenopus; Z-zebra fish; B-bovine; Dg-dog; Pg-pig; Sc-S. cerevisiae 
Species enclosed in parentheses are predicted to react based on 100% homology.
goat polyclonal Anti-Rat IgG-HRP  
Pierce 
Cat # 31226 
 
donkey polyclonal Anti-goat IgG-HRP  
Santa cruz 
Cat # sc-
2020 
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4.4 Densitometry 
 
Densitometry analysis of western blotting P-SMAD1, total SMAD1, and GAPDH bands 
was done with Quantity One 4.6.9 ChemiDoc XRS [Bio-Rad (Hercules, CA)] software. 
The densitometry analysis includes following steps: 
• A digital picture was taken of western blotting film using the ChemiDoc and 
saved as a TIFF file. 
• The area of the P-SMAD1 band was selected within a defined box (Fig 5 A, U1 to 
U8).  
• The same size box was selected in the clear space of the same film as a 
Background for each P-SMAD1 band (Fig 5A, U9 to U16). 
• A pixel number was determined and assigned to each box based on the density 
within defined area (Fig 5C, i.e., U1 to U8 for P-SMAD1; U9 to U16 for 
Background). 
• Background was subtracted from P-SMAD1 in order to obtain a corrected pixel 
number for P-SMAD1 of each lane (i.e., 1st lane=U1-U9; 2nd lane=U2-U10; etc.). 
• The area of the GAPDH band was selected within a defined box (Fig 5 B, U1 to 
U8).  
• The same size box was selected in the clear space of the same film as a 
Background for each GAPDH band (Fig 5B, U9 to U16). 
• A pixel number was determined and assigned to each box based on the density 
within defined area (Fig 5D, i.e., U1 to U8 for GAPDH; U9 to U16 for 
Background) 
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• Background was subtracted from GAPDH in order to obtain a corrected pixel 
number for GAPDH of each lane (i.e., 1st lane=U1-U9; 2nd lane=U2-U10; etc.). 
• Corrected P-SMAD1 pixel number was divided by corrected GAPDH pixel 
number of each lane in order to obtain a normalized pixel number for P-
SMAD1 (P-SMAD1) of each lane. 
• A Normalized pixel number for total SMAD1 (total SMAD1) was obtained in 
the same way. 
• A ratio of P-SMAD1/total SMAD1 was calculated for each experimental condition. 
Therefore, this ratio has no units. Statistical analysis when n≥5 experiments were 
performed using a student t-test. P<0.01 or p<0.05 were considered to be 
statistically significant as noted. 
 
4.5 Data Analysis 
 
Data are presented as means + standard deviation of the replicates. Statistical 
significance was determined by Independent-Sample Student’s t-test and significant 
differences were noted at two-tailed probability p < 0.05 (*) or p < 0.01 (**). 
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Figure 5. Illustration of densitometry analysis of western blotting bands with 
Quantity One 4.6.9 ChemiDoc XRS software. Panel A shows eight P-SMAD1 bands 
labeled as U1 to U8 in the upper row. In the lower row shows eight background bands 
labeled as U9 to U16. Panel B shows eight GAPDH bands labeled as U1 to U8 in the 
upper row. In the lower row shows eight background bands labeled as U9 to U16. Panel 
C shows the pixel number of P-SMAD1 (U1-U8) and background (U9-U16) of panel A, 
and the equation of Corrected P-SMAD1 pixel number. Panel D shows the pixel 
number of GAPDH (U1-U8) and background (U9-U16) of panel B, and the equation of 
Corrected GAPDH pixel number. At the end, the figure shows the equation of 
Normalized P-SMAD1 pixel number. 
  69 
5. CD44 Immunocytochemistry 
 
CD44 -/- primary murine chondrocytes after human CD44 full length plasmid and human 
CD44 Arg 41 point mutation plasmid Nucleofector transfection, were plated at a density  
of 1x105 per chamber with 1ml DMEM plus 20% FBS in a 4-well chamber slide. 48 
hours later, cells were washed 3 times with sterile PBS and fixed with 0.5 ml 0.5% 
paraformaldehyde for 15 minutes at 4 °C. Then the cells were blocked with 500 µl 
Amplifying Antibody Dilution Buffer for 1 hour at room temperature and incubated with 
anti-human CD44 antibody (BU52) (1:250, v: v) overnight at 4 °C. The second day, cells 
were washed 3 times with 1X Amplifying IHC Wash Buffer, followed by incubation with 
anti-mouse Cy3 (1:3000, v: v) at room temperature for 1 hour. The coverslip were 
applied using 4', 6-diamidino-2-phenylindole (DAPI) and immunofluorescence was 
visualized by fluorescence microscopy. 
 
6. RNA Isolation and RT-PCR 
 
6.1 RNA isolation 
 
Wild type and CD44 -/- primary murine chondrocytes after collagenase D overnight 
digestion, were plated at a density of 1x106/mm2 in a 35 mm dish. Forty-eight hours 
later, the cells were washed 3 times with sterile 1XPBS following with 1 ml TRIzol to 
lyse cells. Then cell lysate was transferred to a 1.5 ml microtube and incubated for 5 
minutes at room temperature to permit the complete dissociation of nucleoprotein 
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complexes. Two hundred micro liter of chloroform was added to the 1.5 ml tube followed 
by 15 seconds vigorously shaking. The samples were incubated at room temperature 
for 3 minutes and centrifuged at 13,000 g for 15 minutes at 4 °C. After centrifugation, 
the aqueous phase was transfered to a fresh tube and mixed with 0.5 ml isopropyl 
alcohol to precipitate the RNA. After incubation of 10 minutes at room temperature, the 
tube was centrifuged at 13,000 g for 15 minutes at 4°C. The RNA pellet was washed 
once with 1 ml 75% ethanol followed by centrifugation at 7,500 g for 5 minutes at 4 °C. 
The RNA pellet was dried for 10 minutes at room temperature and re-dissolved with 
appropriate volume of DNase and RNase free water. 
 
6.2 Determine RNA concentration 
 
5 µl isolated RNA was diluted with 495 µl DNase and RNase free water and mixed well. 
500 µl DNase and RNase free water was used as a blank control. The optical density 
(OD) reading of RNA at 260 nm and 280 nm was measured using DU 530 
Spectrophotometer [Beckman (Pasadena, CA)]. 
 
RNA concentration (µg/ml) = OD at 260nm x dilution factor x 40 µg/ml 
 
6.3 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) 
 
Total RNA from wild type and CD44 -/- primary murine chondrocytes was extracted 
using TRIzol. Aliquots of total RNA were then amplified by reverse transcriptase 
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polymerase chain reaction (RT-PCR).  One microgram of total RNA was converted to 
cDNA using recombinant Moloney murine leukemia virus reverse transcriptase in the 
presence of 0.15 mM of the specific antisense (reverse) primers for the targets for 30 
minutes at 42°C in single PCR tube. The synthesized cDNA was subsequently amplified 
using the PCR process in the presence of 0.15 mM of the specific sense (forward) 
primers for the targets and other RT-PCR reagents listed in Table 3. The specific 
primers (Table 4) and programs (Table 5) for each target were listed in following chart.  
 
6.4 Agarose Gel Electrophoresis 
 
1.5% Agarose Gel containing Ethidium Bromide was prepared and electrophoresis at 90 
volts for 1 hour. 10 µl of PCR product with 2 µl 6X Loading Buffer was mixed well before 
loading to each well. After electrophoresis, the PCR products were visualized using 
Quantity One 4.6.9 ChemiDoc XRS. 
 
 
 
 
  72 
Table 3. RT-PCR Reagents (GeneAmp® RNA PCR Core Kit, Applied Science) 
 
RT 1x 
MgCl2 (25 mM) 2 µl 
10X Buffer 1 µl 
dNTPs (12.5 mM) 4 µl 
RNase inhibitor (20 units/µl) 0.5 µl 
Reverse primer (0.15 mM) 0.5 µl 
Reverse transcriptase (50 units/µl) 0.5 µl 
RNA (1 µg) 
DNase & RNase free water 
Total 1.5 µl 
 
 
PCR 1x 
MgCl2 2 µl 
10X Buffer 4 µl 
Forward primer 0.5 µl 
Taq polymerase (5 units/µl) 0.5 µl 
DNase & RNase free water 33 µl 
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Table 4. Primer Sequences 
 
 
Target Sequence 5’-3’ 
Product 
Size 
Forward: GGA GAC GAT GTC ACG AGG CC ActR-IIB 
(Akiyama et al., 2000) Reverse: CAG GTC CAC ATT GGT GAC GG 
643 bp 
Forward: GTT GGT TAC TTC GCC TCC AG Aggrecan 
(Salvat et al., 2005) Reverse: GTC CTC CAA GCT CTG TGA CC 
103 bp 
Forward: GGA GTA ATG ATC CTT CCT GTG C Alk-2 
(de Sousa Lopes et 
al., 2004) 
Reverse: TCT TAC ACG TCA TCT TCC CCT G 
238 bp 
Forward: GTC GGA CCT CTT CTT GCT GG Bmp7 
(Akiyama et al., 2000) Reverse: GAC CGG ATA CTA CGG AGA TGG 
264 bp 
Forward: TGT CAA CCG TGA TGG TAC TCG C Cd44 
(Glant, personal 
communication) 
Reverse: GTA TCC TGA TCT CCA GTA GGC 
184 bp 
Forward: CAG GTG AAC CTG GAC GAG AG Collagen II 
(Salvat et al., 2005) Reverse: ACC ACG ATC TCC CTT GAC TC 
86 bp 
Forward: CAC CAT GGA GAA GGC CGG GG Gapdh 
(Oreffo et al., 2005) Reverse: GAC GGA CAC ATT GGG GGT AG 
418 bp 
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Forward: ATT GTT GGC TAC CAG TTT ATC CAA 
AC 
Has-2 
(Luo et al., 2011, in 
preparation) 
Reverse: TTT CTT TAT GGG ACT CTT CTG TCT 
CAC C 
409 bp 
Forward: GGA AAT CAG TTC TGG GCT ATA CGA 
GG Mmp-3 
(Ogawa et al., 2005) Reverse: CCA ACT GCG AAG ATC CAC TGA AGA 
AAG 
301 bp 
Forward: GGT CCC AAA CGA ACT TAA CTT ACA Mmp-13 
(Yang et al., 2004) Reverse: CCT TGA ACG TCA TCA TCA GGA AGC 
445 bp 
Forward: AAA TAG AAG ATC TTA AAC TGG Rhamm 
(Spicer et al., 1995) Reverse: TTT GAG TTG GCT ATT TTC ATC 
528 bp 
Forward: CTG AAG GGC TAC GAC TGG AC Sox-9 
(Oreffo et al., 2005) Reverse: GAG GAG GAA TGT GGG GAG TC 
406 bp 
Forward: AGT GGG TCA AGG AAC AGA AGC A Tlr4 
(Iwami et al., 2000) Reverse: CTT TAC CAG CTC ATT TCT CAC C 
311 bp 
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Table 5. PCR Programs 
 
 
Bmp7 and ActR-IIB Program 
Denature 94 °C 30 seconds 
Annealing 60 °C 1 minute 
Extension 72 °C 1 minute 
30 cycles 
 
Collagen II and Aggrecan Program 
Denature 94 °C 15 minutes 
Denature 94 °C 1 minute 
Annealing 54 °C 1 minute 
Extension 72 °C 90 seconds 
40 cycles 
 
Alk-2 Program 
Denature 94 °C 2 minutes 
Denature 94 °C 15 seconds 
Annealing 60 °C 30 seconds 
Extension 72 °C 2 minutes 
30 cycles 
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Cd44 Program 
Denature 95 °C 2 minutes 
Denature 95 °C 15 seconds 
Annealing 55 °C 1 minute 
Extension 72 °C 1 minute 
35 cycles 
Extension 72 °C 4 minutes 
 
Gapdh, Has-2 and Tlr4 Program 
Denature 95 °C 2 minutes 
Denature 95 °C 1 minute 
Annealing 60 °C 1 minute 
Extension 72 °C 1 minute 
35 cycles 
Extension 72 °C 5 minutes 
 
Mmp-3 Program 
Denature 95 °C 10 minutes 
Denature 95 °C 15 seconds 
Annealing 60 °C 1 minute 
Extension 72 °C 15 seconds 
40 cycles 
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Mmp-13 Program 
Denature 94 °C 1 minute 
Annealing 62 °C 1 minute 
Extension 72 °C 2 minutes 
30 cycles 
 
Rhamm Program 
Denature 95 °C 45 seconds 
Annealing 56 °C 45 seconds 
Extension 72 °C 2 minutes 
30 cycles 
 
Sox-9 Program 
Denature 95 °C 5 minutes 
Denature 95 °C 35 seconds 
Annealing 58 °C 40 seconds 
Extension 72 °C 1 minute 
28 cycles 
Extension 72 °C 5 minutes 
 
 
 
 
 
 
 
CHAPTER 3. RESULTS 
 
1. Isolation and Characterization of articular cartilage and primary murine 
articular chondrocytes from BALB/c wild type and CD44 -/- mice 
 
CD44 -/- mice (with absolutely CD44 negative background in in vivo) exhibit no overt 
abnormalities (Protin et al., 1999; Schmits et al., 1997), and provide a useful tool to 
study the various physiological roles of CD44 in vivo. To study the role of CD44 in 
BMP7 signaling pathway in chondrocytes, an isolation method for murine articular 
chondrocytes was developed for further investigation of CD44 function in chondrocytes. 
 
Femoral heads isolated from 1-week-old wild type and CD44 -/- mice were embedded in 
paraffin, sectioned and stained with safranin O and fast green, which is a typical 
staining method for cartilage (Nishida et al., 2000a). Safranin O stains proteoglycan 
showing a red color, and fast green stains collagen showing a green color. The staining 
results on mouse femoral heads showed high concentration of proteoglycans in the 
matrix and type II collagen was only observed at the surface of the cartilage due to the 
intense red color proteoglycan staining within all the tissue (Fig 6). However, no 
difference was detected between wild type and CD44 -/- femoral heads stained with 
Safranin O and fast green. 
 
Primary murine articular chondrocytes isolated from femoral heads and knee joints of 1-
week-old wild type and CD44 -/- mice exhibited the characteristic rounded chondrocyte 
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morphology (Fig 7), which suggested the murine chondrocytes isolation method 
established in this project was successful. RT-PCR and Western blot results (Fig 8) 
confirmed no CD44 Mrna (panel A) or protein (panel B) expression in CD44 -/- murine 
chondrocytes, but showed CD44 expression in wild type murine chondrocytes.  The 
particle exclusion assay, which is a method to visualize the pericellular matrix around 
live chondrocytes revealed similar pericellular matrix assembly on wild type and CD44 -
/- murine chondrocytes (Fig 9). 
 
There was also no difference in the mRNA expression levels for the chondrocytes 
marker genes Aggrecan and Collagen II between wild type and CD44 -/- murine 
chondrocytes (Fig 10). In contrast, less endogenous Bmp7 expression was detected in 
CD44 -/- murine chondrocytes compared to wild type murine chondrocytes (Fig 11). No 
difference in the mRNA expression level of the BMP7 receptor, Alk2 between wild type 
and CD44 -/- murine chondrocytes (Fig 11). 
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Figure 6. Histology of articular cartilage isolated from one-week-old wild type and 
CD44 -/- mice. Femoral heads isolated from one-week-old wild type and CD44 -/- mice 
were fixed directly, embedded in paraffin and 8 µm sections stained with safranin O and 
fast green for extracellular matrix. Articular cartilage from both one-week-old wild type 
and CD44 -/- mice showed intense staining for proteoglycan in the matrix. 
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Figure 7. Morphology of primary murine chondrocytes. Primary murine 
chondrocytes isolated from femoral heads and knee joints were plated at a high density 
(2 x 106 cells/mm2) in DMEM with 20% FBS. Two days after plating, using inverted 
phase contrast microscopy, these cells exhibited a rounded morphology characteristic 
of chondrocytes. 
 
 
 
  81 
 
 
Figure 8. Analysis of CD44 expression in wild type and CD44 -/- primary murine 
chondrocytes. Wild type and CD44-/- murine chondrocytes isolated from femoral 
heads of one-week-old mice were cultured in high density monolayer for 48 hours.  
Total RNA was isolated and analyzed for the expression of Cd44 by conventional RT-
PCR using Gapdh as a control (panel A).  Total cell lysates from high density primary 
cultures of wild type and CD44-/- murine chondrocytes were analyzed by Western 
blotting using IM7.8.1, an anti-mouse CD44 antibody (panel B). Aliquots of cell lysates 
used represent equivalent protein of samples, verified by Western blotting for β-actin.  
No CD44 expression was detected in CD44 -/- murine chondrocytes. 
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Figure 9. Particle Exclusion Assay of wild type and CD44 -/- primary murine 
chondrocytes. Wild type and CD44 -/- primary murine chondrocytes were plated at a 
low density and cultured in a 6-well plate for 48 hours. Then formalin-fixed horse red 
blood cells were added to the washed murine chondrocytes to visualize the pericellular 
matrix of wild type and CD44 -/- murine chondrocytes.  To visualize an individual 
chondrocyte with a well-defined plasma membrane, murine chondrocytes were stained 
with Calcein AM. No difference of the size of pericellular matrix was detected between 
wild type and CD44 -/- murine chondrocytes. Panels show representative cells. Bars 
indicate 10 µm. 
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Figure 10. Analysis of aggrecan and type II collagen mRNA expression in wild 
type and CD44 -/- primary murine chondrocytes. Total RNA isolated from wild type 
and CD44-/- murine chondrocytes was analyzed for the expression of aggrecan (Acan) 
and type II collagen (Col II) by conventional RT-PCR using Gapdh as a control. No 
difference of aggrecan and type II collagen mRNA expression levels was detected 
between wild type and CD44 -/- murine chondrocytes. Representative of 2 experiments. 
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Figure 11. Analysis of endogenous Bmp7 and type I BMP receptor (Alk2) mRNA 
expression in wild type and CD44 -/- primary murine chondrocytes.  Total RNA 
isolated from wild type and CD44-/- murine chondrocytes was analyzed for the 
expression of endogenous Bmp7 and Alk2 by conventional RT-PCR using Gapdh as a 
control. The apparent mRNA expression of endogenous Bmp7 in CD44 -/- murine 
chondrocytes was less than that of wild type murine chondrocytes. No difference of type 
I BMP receptor, Alk2, mRNA expression level was detected between wild type and 
CD44-/- murine chondrocytes. Representative of 2 experiments. 
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2. Responsiveness to BMP7: a comparison of wild type murine articular 
chondrocytes and CD44 -/- murine articular chondrocytes 
 
Hypothesis: CD44-SMAD1 interactions will promote the presentation of SMAD1 to the 
BMP receptor. Therefore, the strength of responses to BMP7 will be positively 
correlated with the level of CD44 expression. 
 
To explore CD44 function in BMP7 signaling pathway, the cellular responses of wild 
type and CD44 -/- murine chondrocytes to BMP7 (SMAD1 phosphorylation level) were 
examined following stimulation with different concentration of BMP7 or over a period of 
15 to 180 minutes of BMP7 stimulation. 
 
Primary bovine chondrocytes were used to optimize the BMP7 experimental treatment 
conditions because it is easy to collect large numbers of bovine chondrocytes at one 
time and bovine chondrocytes are the common popular chondrocytes being used in 
cartilage field. Bovine chondrocytes were stimulated with different concentrations of 
BMP7 (0-100 ng/ml) for 1 hour and SMAD1 phosphorylation was detected using an anti-
phosphorylated SMAD1 antibody. With the increase of BMP7 concentration, the SMAD1 
phosphorylation was also increased. The minimum BMP7 concentration to initiate a 
strong increase of SMAD1 phosphorylation in bovine chondrocytes was 50 ng/ml (Fig 
12). 100 ng/ml BMP7 is the typical concentration of BMP7 used in in vitro experiments 
with articular chondrocytes (Flechtenmacher et al., 1996; Nishida et al., 2000a; Nishida 
et al., 2000b). 
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Figure 12. SMAD1 phosphorylation in response to different concentrations of 
BMP7 by primary bovine articular chondrocytes. Primary bovine chondrocytes were 
plated at a high density of 2x106 per well in a 6-well plate. Forty-eight hours later, the 
medium was changed to serum free for overnight incubation, and bovine chondrocytes 
were stimulated with different concentrations (0-100 ng/ml) of BMP7 for 1 hour, then 
analyzed by Western blotting for SMAD1 phosphorylation (P-SMAD1). The 
concentration of 100 ng/ml BMP7 is the typical concentration used in in vitro 
experiments with articular chondrocytes by our lab and others lab. The results showed 
that with the increase of BMP7 concentration, the cellular response to BMP7 by SMAD1 
phosphorylation was increased in bovine chondrocytes. 50 ng/ml BMP7 is required to 
initiate a strong increase of P-SMAD1 upon BMP7 stimulation of bovine articular 
chondrocytes. Aliquots used represent equivalent protein of samples, verified by 
reprobing the Western blotting for total SMAD1 and GAPDH. Representative of 2 
experiments. 
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Wild type and CD44 -/- murine chondrocytes were stimulated with different 
concentrations of BMP7 (0-100 ng/ml) for 1 hour and SMAD1 phosphorylation was 
detected using an anti-phosphorylated SMAD1 antibody. Densitometry analysis of pixel 
intensity was performed for five separate experiments in order to perform the student’s 
t-test (Table 6 A and B). With the increase of BMP7 concentration, SMAD1 
phosphorylation level was increased in both wild type (black bars) and CD44 -/- 
(hatched bars) murine chondrocytes (Fig 13 A and B). However, CD44 -/- murine 
chondrocytes were less responsive to BMP7 compared to wild type murine 
chondrocytes (Fig 13 B). The minimum BMP7 concentration to initiate a statistically 
significant increase of SMAD1 phosphorylation in wild type murine chondrocytes was 10 
ng/ml; whereas, the minimum BMP7 concentration to initiate a statistically significant 
increase of SMAD1 phosphorylation in CD44 -/- murine chondrocytes was 50 ng/ml (Fig 
13 B). In the analysis of wild type murine chondrocytes, between 0 ng/ml and 10 ng/ml 
BMP7, the p value is < 0.05; between 0 ng/ml and ≥ 20 ng/ml ng/ml, the p value is < 
0.01. In the analysis of CD44 -/- murine chondrocytes, stimulation with BMP7 never 
reaches a p<0.01 but reaches p<0.05 at 50 ng/ml (Table 6 A and B). At BMP7 
concentration >= 20 ng/ml, the difference of cellular responses to BMP7 between wild 
type and CD44 -/- murine chondrocytes is significant (p<0.05) (Table 6 C). The line 
graph (Fig 13 C) shows the normalized ratio in pixel intensity for P-SMAD1: total 
SMAD1 in each BMP7 concentration, derived from the same five separate experiments, 
of the wild type (black lines) and the CD44 -/- murine chondrocytes (red lines and purple 
line). The black lines group together reflecting the stronger responses by the wild type 
chondrocytes. The red lines also group together indicating the lower responses by the 
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CD44 -/- murine chondrocytes. The purple line is the one higher densitometry value set 
of P-SMAD1: total SMAD1 for the CD44 -/- murine chondrocytes in response to 0 to 100 
ng/ml BMP7 in one experiment that immersed into wild type BMP7 responses range. 
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Figure 13. SMAD1 phosphorylation in response to different concentrations of 
BMP7 by wild type and CD44 -/- primary murine chondrocytes. Wild type and CD44 
-/- primary murine chondrocytes were plated at a density of 2x105 per well in a 48-well 
plate. Forty-eight hours later, the medium was changed to serum free for overnight 
incubation, and wild type and CD44 -/- murine chondrocytes were stimulated with 
different concentrations (0-100 ng/ml) of BMP7 for 1 hour, then analyzed by Western 
blotting for SMAD1 phosphorylation (P-SMAD1). The results showed that with the 
increase of BMP7 concentration, the cellular responses to BMP7 by SMAD1 
phosphorylation was increased in both wild type and CD44 -/- murine chondrocytes. 
However, CD44 -/- murine chondrocytes are less responsive to BMP7 compared to wild 
type murine chondrocytes. In wild type murine chondrocytes, 10 ng/ml BMP7 initiated a 
significant increase of P-SMAD1, but for CD44 -/- murine chondrocytes, 50 ng/ml BMP7 
was required to initiate a significant increase of P-SMAD1 upon BMP7 stimulation. 
Aliquots used represent equivalent protein of samples, verified by reprobing of the 
Western blotting for GAPDH. The bar graph (panel B) shows the normalized average 
ratio in pixel intensity for P-SMAD1: total SMAD1 in each concentration, derived from 
five separate experiments of the wild type (black bars) and the CD44 -/- murine 
chondrocytes (hatched bars). Error bars depict standard deviation; significant 
differences were at P < 0.05. The line graph (panel C) shows the normalized ratio in 
pixel intensity for P-SMAD1: total SMAD1 in each BMP7 concentration, derived from the 
same five separate experiments, of the wild type (black lines) and the CD44 -/- murine 
chondrocytes (red lines and purple line). The purple line is the highest densitometry 
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value of P-SMAD1: total SMAD1 for the CD44 -/- murine chondrocytes in response to 0 
to 100 ng/ml BMP7. 
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Table 6 . Scanning results and bio-statistical analysis of SMAD1 phosphorylation 
in response to different concentrations of BMP7 by wild type and CD44 -/- primary 
murine chondrocytes 
 
A. P-SMAD1/total SMAD1 densitometry ratio in response to different concentrations of 
BMP7 and p values between BMP7-treated groups and control group by wild type 
murine chondrocytes 
BMP7 conc. 0 ng/ml 10 ng/ml 20 ng/ml 50 ng/ml 100 ng/ml 
1 0.2112 0.4338 0.4612 0.5564 0.6523 
2 0.2276 0.4121 0.4434 0.7110 0.8862 
3 0.2623 0.3729 0.3775 0.5624 0.7914 
4 0.2239 0.2650 0.3641 0.4672 0.5525 
5 0.2132 0.2291 0.3544 0.4203 0.5414 
Mean 0.2276 0.3426 0.4001 0.5435 0.6847 
SD 0.0206 0.0908 0.0487 0.1113 0.1508 
P value -- 0.0247 0.0001 0.0002 0.0002 
The table shows the ratio calculated from densitometry pixel numbers of 5 
determinations of P-SMAD1/total SMAD1 intensity on western blots in response to 
different concentrations of BMP7, mean and standard deviation (SD) of the P-
SMAD1/total SMAD1 ratio, and p values from the Student’s t-test of analyzing the 
responses to different concentrations of BMP7 comparing control (0/ng/ml) and BMP7 
treated (10, 20, 50 or 100 ng/ml) groups by wild type murine chondrocytes. 
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B. P-SMAD1/total SMAD1 densitometry ratio in response to different concentrations of 
BMP7 and p values between BMP7-treated groups and control group by CD44 -/- 
murine chondrocytes 
KO 0 ng/ml 10 ng/ml 20 ng/ml 50 ng/ml 100 ng/ml 
1 0.2011 0.2918 0.3012 0.3886 0.4577 
2 0.2106 0.3601 0.3866 0.5279 0.7182 
3 0.2166 0.2282 0.2663 0.3358 0.4008 
4 0.2052 0.1996 0.2013 0.2404 0.2616 
5 0.2482 0.2201 0.2562 0.3016 0.3475 
Mean 0.2163 0.2600 0.2823 0.3589 0.4372 
SD 0.0187 0.0657 0.0684 0.1087 0.1729 
P value -- 0.1912 0.0711 0.0202 0.0218 
The table shows the ratio calculated from densitometry pixel numbers of 5 
determinations of P-SMAD1/total SMAD1 intensity on western blots in response to 
different concentrations of BMP7, mean and standard deviation (SD) of the P-
SMAD1/total SMAD1 ratio, and p values from the Student’s t-test of analyzing the 
responses to different concentrations of BMP7 comparing control (0/ng/ml) and BMP7 
treated (10, 20, 50 or 100 ng/ml) groups by CD44 -/- murine chondrocytes. 
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C. Bio-statistical analysis of the response to different concentrations of BMP7 by wild 
type and CD44 -/- murine chondrocytes (p values) 
ng/ml WT 0 WT 10 WT 20 WT 50 WT 100 
KO 0 0.3908     
KO 10  0.1380    
KO 20   0.0139   
KO 50    0.0291  
KO 100     0.0423 
The table shows p values from the Student’s t-test of analyzing the responses to 
different concentrations of BMP7 by wild type and CD44 -/- murine chondrocytes 
comparing between wild type and CD44 -/- murine chondrocytes. 
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BMP7 stimulation time course was also studied in wild type and CD44 -/- murine 
chondrocytes. Wild type and CD44 -/- murine chondrocytes were stimulated with 100 
ng/ml BMP7 for different time periods, and SMAD1 phosphorylation was detected using 
an anti-phosphorylated SMAD1 antibody. In wild type murine chondrocytes, 30 minutes 
of stimulation with BMP7 could initiate SMAD1 phosphorylation. However, 60 minutes of 
stimulation with BMP7 was required to initiate a strong increase of SMAD1 
phosphorylation in both wild type and CD44 -/- murine chondrocytes and SMAD1 
phosphorylation levels were still strong 3 hours following stimulation with BMP7 (Fig 
14). 
 
To further test the role of CD44 in BMP7 signaling pathway, wild type murine 
chondrocytes were transfected with mouse CD44 siRNA or a non-specific control 
siRNA. CD44 protein expression level was reduced by mouse CD44 siRNA transfection 
(Fig 15).  Concomitant with the decrease of CD44 protein, SMAD1 phosphorylation 
levels were decreased in comparison to control siRNA-transfected wild type murine 
chondrocytes upon stimulation with 20 ng/ml BMP7 (Fig 15). However, after stimulation 
with 50 ng/ml BMP, SMAD1 phosphorylation was observed in both control siRNA and 
mCD44 siRNA-transfected murine chondrocytes. Thus, as shown in Figure 12 CD44 -/- 
murine chondrocytes and as shown in Figure 15 wild type murine chondrocytes with 
decreased CD44 expression (from mCD44 siRNA treatment) both exhibit a response to 
50 ng/ml BMP7. However, at 20 ng/ml BMP7, both CD44 -/- murine chondrocytes and 
wild type murine chondrocytes with reduced CD44 expression following siRNA 
transfection exhibit weak SMAD1 phosphorylation. 
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Figure 14. Time course study of BMP7 stimulation in wild type and CD44 -/- 
primary murine chondrocytes. Wild type and CD44 -/- murine chondrocytes were 
plated at a density of 2x105 per well in a 48-well plate. Forty-eight hours later, the 
medium was changed to serum free for overnight incubation, and murine chondrocytes 
were stimulated with 100 ng/ml BMP7 for different time points, then analyzed by 
Western blotting for SMAD1 phosphorylation (P-SMAD1). The results showed that 30 
minutes treatment of BMP7 initiated a SMAD1 phosphorylation in wild type 
chondrocytes. However, 60 minutes of treatment with BMP7 of both wild type and CD44 
-/- murine chondrocytes is required to initiate a strong increase of SMAD1 
phosphorylation. And 3 hours following the addition of BMP7, the signal of SMAD1 
phosphorylation was still strong. Representatvie of 1 experiment. 
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Figure 15.  Mouse CD44 siRNA transfection of wild type primary murine 
chondrocytes. Wild type murine chondrocytes were either transfected with control 
siRNA or mouse-specific CD44 siRNA. Forty-eight hours after transfection, the cells 
were stimulated with 0, 20 or 50 ng/ml BMP7 for 1 hour and then analyzed by Western 
blotting for SMAD1 phosphorylation (P-SMAD1). The results showed that with the 
decrease of CD44 expression, wild type murine chondrocytes transfected with mouse 
CD44 siRNA are less responsive to BMP7 stimulation at 20 ng/ml for SMAD1 
phosphorylation compared to wild type murine chondrocytes transfected with control 
siRNA. However, after stimulation with 50 ng/ml BMP7, SMAD1 phosphorylation was 
observed in both control siRNA and mCD44 siRNA transfected murine chondrocytes. 
CD44 protein expression on Western blotting probed with an anti-CD44 cytotail 
antibody. Aliquots used represent equivalent protein of samples, verified by reprobing of 
the Western blotting for total SMAD1 and GAPDH. Ctr, control. The blot is 
representative of three replicate transfection experiments. 
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CD44 -/- murine chondrocytes were also used further to test the role of CD44 in BMP7 
signaling pathway. CD44 -/- murine chondrocytes were transfected with human CD44 
full length plasmid or an empty plasmid.  CD44 protein expression was detected in 
CD44 full length plasmid-transfected CD44 -/- murine chondrocytes by western blotting 
(Fig 16). CD44 immunocytochemistry as detected by fluorescence microscopy 
demonstrated surface expression of CD44 (Fig 19 B), although the transfection 
efficiency was only ~20%. Therefore, with the concomitant gain of CD44 protein, 
SMAD1 phosphorylation levels were increased in comparison to empty plasmid 
transfected chondrocytes after stimulation with 20 ng/ml BMP7 (Fig 16). However, both 
CD44 -/- and CD44 -/- transfectants expressing CD44 exhibit SMAD1 phosphorylation 
in response to the stimulation with 50 ng/ml BMP7. 
 
Amino acid Arg 41 of the extracellular domain of CD44 is a critical residue for binding to 
hyaluronan and mutation of Arg 41 completely abolished the ability of CD44 to bind to 
hyaluronan (Peach et al., 1993). The red circle designates the point mutation in CD44 
from Arg 41 to Ala 41 (R41A) (Fig 17). CD44 -/- murine chondrocytes were transfected 
with human CD44 R41A point mutation plasmid or an empty plasmid. In R41A-
transfected CD44 -/- murine chondrocytes, CD44 expression was detected by western 
blotting (Fig 18) and immunofluorescence microscopy revealed its expression on the 
plasma membrane (Fig 19 C), although the transfection efficiency was only ~10%. 
However, the response to BMP7 for SMAD1 phosphorylation by R41A-transfected 
CD44 -/- murine chondrocytes was similar compared to empty plasmid-transfected 
CD44 -/- murine chondrocytes (Fig 18), which suggested that expression of functional  
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Figure 16.  Human CD44 full length plasmid transfection of CD44 -/- primary 
murine chondrocytes. CD44 -/- murine chondrocytes were either transfected with 
empty plasmid or human CD44 full length plasmid (hCD44FL). Forty-eight hours after 
transfection, the cells were stimulated with 0, 20 or 50 ng/ml BMP7 and then analyzed 
by Western blotting for SMAD1 phosphorylation (P-SMAD1). The results showed that 
with the gain of CD44 expression, CD44 -/- murine chondrocytes transfected with 
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human CD44 full length plasmid are more responsive to BMP7 for SMAD1 
phosphorylation compared to CD44 -/- murine chondrocytes transfected with empty 
plasmid and initiate a response at 20 ng/ml BMP7. CD44 protein expression was 
detected by Western blotting probed with an anti-CD44 cytotail antibody. Aliquots used 
represent equivalent protein of samples, verified by reprobing of the Western blots for 
total SMAD1 and GAPDH. Ctr, control. Representatvie of 3 experiments. 
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Figure 17. Human CD44 R41A point mutation sequence. Arg 41 of CD44 is a critical 
residue in hyaluronan binding. Red circle designates the point mutation of CD44 from 
Arg 41 to Ala 41 (R41A). 
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Figure 18.  Human CD44 Arg41 point mutation plasmid transfection of CD44 -/- 
primary murine chondrocytes. CD44 -/- murine chondrocytes were either transfected 
with empty plasmid or human CD44 R41A point mutation plasmid (Arg41). Forty-eight 
hours after transfection, the cells were stimulated with 0, 50 or 100 ng/ml BMP7 and 
then analyzed by Western blotting for SMAD1 phosphorylation (P-SMAD1). The results 
showed that with human CD44 R41A point mutation plasmid transfection, CD44 
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expression can be detected in CD44 -/- murine chondrocytes. However, due to the lack 
of hyaluronan binding, human CD44 R41A point mutation plasmid transfection did not 
change cellular responses to BMP7 for SMAD1 phosphorylation compared to CD44 -/- 
murine chondrocytes transfected with empty plasmid. CD44 protein expression on 
Western blotting probed with an anti-CD44 cytotail antibody. Aliquots used represent 
equivalent protein of samples, verified by reprobing of the Western blotting for total 
SMAD1 and GAPDH. Ctr, control. Representatvie of 3 experiments. 
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Figure 19. Detection of CD44 expression in CD44 -/- murine chondrocytes either 
transfected with CD44 full length plasmid or CD44 Arg 41 point mutation plasmid 
by immunofluorescence. CD44-/- murine chondrocytes transfected with empty 
plasmid (panel A), human CD44 full length plasmid (panel B) or CD44 Arg 41points 
mutation plasmid (panel C). forty-eight hours after transfection, the cells were fixed and 
stained with anti-CD44 cytotail antibody, followed by anti-rabbit IgG conjugated with 
Cy3. The cells were mounted in medium containing DAPI and visualized by 
fluorescence microscopy. Shown are digital overlay images of red and blue 
fluorescence channels.  With human CD44 full length plasmid or CD44 Arg 41 point 
mutation plasmid transfection, CD44 was detected on CD44 -/- murine chondrocytes 
compared to the ones transfected with empty plasmid. Cell shown are representative 
images of two experiments. Bars indicate 10 µm. Representatvie of 1 experiment. 
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CD44, with the capacity to bind hyaluronan, was important for robust BMP7 responses 
of chondrocytes.  
 
Taken together, these data suggest that expression of functional CD44 with hyaluronan 
binding ability promotes cellular responses to BMP7, especially at lower concentration 
of BMP7, as revealed by assay for SMAD1 phosphorylation. 
 
3. Chondrocyte responsiveness to BMP7 is dependent on hyaluronan  
 
Hypothesis: Hyaluronan-CD44 interaction is one mechanism whereby the extracellular 
matrix will promote the response to BMP7 by enhancing the assembly of components of 
the signal transduction pathway. 
 
Corollary: Hyaluronan-chondrocyte interactions will promote pericellular matrix 
assembly and retention as well as the assembly of components of the BMP7 signal 
transduction pathway. 
 
To test the role of the hyaluronan-dependent pericellular matrix in BMP7 signaling 
pathway, wild type and CD44 -/- murine chondrocytes were treated with testicular 
hyaluronidase to enzymatically degrade hyaluronan and remove the pericellular matrix. 
 
First, the testicular hyaluronidase treatment condition was optimized with bovine 
articular chondrocytes.  Bovine articular chondrocytes were pre-treated with different 
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concentrations of testicular hyaluronidase for 12 hours, followed with 100 ng/ml BMP7 
stimulation for 1 hour and SMAD1 phosphorylation was detected using an anti-
phosphorylated SMAD1 antibody. The results showed that without testicular 
hyaluronidase pre-treatment, there was a strong increase of SMAD1 phosphorylation 
with BMP7 stimulation. The level of SMAD1 phosphorylation in response to BMP7 
decreased with the increase of testicular hyaluronidase concentration. Treatment with 
the concentration of 200 units/ml testicular hyaluronidase almost eliminated SMAD1 
phosphorylation upon BMP7 stimulation compared to control group without testicular 
hyaluronidase treatment (Fig 20). 
 
Next, bovine articular chondrocytes were treated with 200 units/ml testicular 
hyaluronidase for different time periods, followed with 100 ng/ml BMP7 stimulation for 1 
hour and SMAD1 phosphorylation was detected using an anti-phosphorylated SMAD1 
antibody. The results showed that the expression of SMAD1 phosphorylation decreased 
with the increase of testicular hyaluronidase treatment time. Twelve hours treatment of 
testicular hyaluronidase almost eliminated SMAD1 phosphorylation upon BMP7 
stimulation compared to the control group without testicular hyaluronidase treatment 
(Fig 21). 
 
To test whether bovine chondrocytes were still alive after testicular hyaluronidase 
treatment for 12 hours, a viability assay was performed. The bovine chondrocytes were 
stained with two fluorescent dyes, calcein AM and ethidium homodimer to stain live and 
dead cells simultaneously. Live cells are stained with calcein AM showing a green color,  
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Figure 20. SMAD1 phosphorylation in primary bovine articular chondrocytes in 
response to BMP7 following treatment with different concentrations of testicular 
hyaluronidase. Primary bovine articular chondrocytes were pre-treated with different 
concentrations of testicular hyaluronidase (0-200 units/ml) for 12 hours followed with 
100 ng/ml BMP7 stimulation for 1 hour, then analyzed by Western blotting for 
SMAD1phosphorylation (P-SMAD1). The results showed that with the increase of 
testicular hyaluronidase concentration, SMAD1 phosphorylation was decreased. Pre-
treatment with 200 units/ml testicular hyaluronidase almost diminished P-SMAD1 upon 
BMP7 stimulation. Aliquots used represent equivalent protein of samples, verified by 
reprobing of the western blots for GAPDH. Representative of 1 experiment. 
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Figure 21. SMAD1 phosphorylation in primary bovine articular chondrocytes in 
response to BMP7 following treatment for different time periods with testicular 
hyaluronidase. Primary bovine articular chondrocytes were pre-treated with 200 
units/ml testicular hyaluronidase for different time periods (0 hour, 3 hours, 6 hours and 
12 hours) followed with 100 ng/ml BMP7 stimulation for 1 hour, then analyzed by 
Western blotting for SMAD1 phosphorylation (P-SMAD1). The results showed that with 
the increase of testicular hyaluronidase treatment time, SMAD1 phosphorylation was 
decreased. 12 hours of treatment with testicular hyaluronidase almost eliminated P-
SMAD1 upon BMP7 stimulation. Aliquots used represent equivalent protein of samples, 
verified by reprobing of the western blots for GAPDH. Representative of 1 experiment. 
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whereas dead cells are stained with ethidium homodimer showing a red color. The 
results showed that treatment with 50, 100 or 200 units/ml testicular hyaluronidase for 
12 hours did not affect bovine chondrocyte viability of visualized adherent cells (Fig 22). 
Very few floating cells were observed in the cultures following testicular hyaluronidase 
treatment. In summary, based on all these results, the concentration of 200 units/ml 
testicular hyaluronidase and 12 hours treatment time were used for murine 
chondrocytes treatment condition. 
 
To test whether the testicular hyaluronidase effect on SMAD1 phosphorylation as a 
response to BMP7 stimulation was due to a contaminating protease activity, primary 
bovine chondrocytes were treated with testicular hyaluronidase (Knudson, 1982) in the 
absence or presence of fetal bovine serum. Others have reported that components 
within fetal bovine serum inhibit some of the contaminating protease activity (Shulman, 
1952). The results showed that in both the presence and absence of serum, there was 
an increase of SMAD1 phosphorylation upon BMP7 stimulation. And SMAD1 
phosphorylation decreased when the cells pre-treated with testicular hyaluronidase 
followed by BMP7 stimulation, compared to the cells stimulated with BMP7 only (Fig 
23). The results indicated that the testicular hyaluronidase effect on SMAD1 
phosphorylation as a response to BMP7 stimulation was not likely due to a 
contaminating protease activity, but due to the degradation of hyaluronan with testicular 
hyaluronidase treatment. However, bovine chondrocytes seems less healthy in the 
absence of serum with less GAPDH or total SMAD1 expression. 
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Figure 22. Viability assay of primary bovine articular chondrocytes following pre-
treatment with different concentrations of testicular hyaluronidase for 12 hours. 
Primary bovine articular chondrocytes were treated with different concentrations of 
testicular hyaluronidase (50, 100, 200 units/ml) for 12 hours, then stained with calcein 
AM and ethidium homodimer to examine cell viability. Live cells stained with calcein AM 
showing a green color and dead cells stained with ethidium homodimer showing a red 
color (circels delineate red cells). The results showed that 12 hours of treatment with 
testicular hyaluronidase did not affect the viability of primary bovine chondrocytes. Ctr 
(control) no testicular hyaluronidase pre-treatment. Representatvie of 1 experiment. 
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Figure 23. The presence or absence of serum does not alter the changes in 
SMAD1 phosphorylation in response to BMP7 after testicular hyaluronidase 
treatment. Primary bovine articular chondrocytes were pre-treated with 200 units/ml 
testicular hyaluronidase overnight with or without the presence of 10% FBS, followed by 
a 1 hour stimulation with 100 ng/ml BMP7, and Western blotting for SMAD1-
phosphorylation (P-SMAD1). The results showed that with the presence of serum, the 
decrease of P-SMAD1 due to testicular hyaluronidase pre-treatment, still occurred as 
compared to BMP7 stimulation only. The results suggested that the decrease of SMAD1 
phosphorylation was due to testicular hyaluronidase pre-treatment removing hyaluronan 
from the pericellular matrix around the chondrocytes, not due to the contaminating 
protease activity. Aliquots used represent equivalent protein of samples, verified by 
reprobing of the Western blotting for GAPDH and total SMAD1. Representative of 2 
experiments. 
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Additional control experiments were performed to determine whether the diminished 
BMP7 responses follow testicular hyaluronidase treatment was due to an unintended of 
target alteration or the BMP7 receptor or total SMAD1 expression itself. An ALK2 
antibody (Table 2) was purchased to detect BMP7 receptor (Macias-Silva et al., 1998) 
by Western blotting. To validate the specificity of this antibody, we use lysates from 
COS7 transfectants. Three different isoforms of type I BMP receptor, pALK2Q207P, 
pALK2CAR206H, and pALK3Q233D, were examined by transfection of COS7 cells. 
pALK2Q207P is a normal function ALK2 expression plasmid. pALK2CAR206H is a 
constitutively active ALK2 expression plasmid, and pALK3Q233D is a ALK3, BMP2/4 
type I receptor, expression plasmid. Western blotting showed a good specificity of anti-
ALK2 antibody, as it only detects ALK2 expression, not ALK3 expression (Fig 24). 
Bovine chondrocytes were pre-treated with 200 units/ml testicular hyaluronidase for 12 
hours followed with BMP7 stimulation. The results showed no change of BMP7 receptor 
expression or total SMAD1 expression with testicular hyaluronidase pre-treatment (Fig 
25), which suggested that the testicular hyaluronidase effect on BMP7 signaling 
pathway was due to the removal of hyaluronan from the pericellular matrix, not due to 
the altered expression of BMP7 receptor or total SMAD1. 
 
To visualize hyaluronan in tissues and on cells, a biotinylated hyaluronan-binding 
protein (HABP) can be used, with detection with Neutravidin-FITC and visualization by 
fluorescence microscopy. Wild type and CD44 -/- murine chondrocytes treated with 
testicular hyaluronidase results in the removal of hyaluronan and aggrecan from the 
cell-associated pericellular matrix as detected by HABP and toluidine blue staining (Fig  
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Figure 24. Transfection of COS7 cells with different isoforms of the BMP 
Receptor. To test the BMP7 receptor antibody (anti-ALK2) specificity, COS7 cells were 
transfected with different isoforms of BMP receptor plasmids (pALK2Q207P, 
pALK2CAR206H,pALK3Q233D) using Amaxa Nucleofection. COS7 cells lysates were 
prepared for Western blotting 48 hours after transfection. The results showed that there 
was a increase of ALK2 expression in COS7 cells transfected with ALK2 plasmids 
(pALK2Q207P, pALK2CAR206H). No change of ALK2 expression was detected in 
COS7 cells transfected with BMP2/4 receptor plasmid (pALK3Q233D). The results 
indicated that the ALK2 antibody exhibited specificity for ALK2 immunoreactivity. 
Representatvie of 2 experiments. 
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Figure 25. Changes in SMAD1 phosphorylation of primary bovine chondrocytes 
with testicular hyaluronidase pre-treatment were not due to alterations of BMP7 
receptor or total SMAD1 expression. Bovine articular chondrocytes were pre-treated 
with 200 units/ml testicular hyaluronidase for 12 hours followed with 100 ng/ml BMP7 1 
hour stimulation, then analyzed by Western blotting for BMP7 receptor expression 
(ALK2), total SMAD1 and SMAD1 phosphorylation (P-SMAD1). The blots are 
representative of two replicate experiments. The results showed that the decrease of 
SMAD1 phosphorylation with testicular hyaluronidase pre-treatment upon BMP7 
stimulation was not due to the decrease of BMP7 receptor or total SMAD1. Aliquots 
used represent equivalent protein of samples, verified by reprobing of the Western 
blotting for GAPDH. Representatvie of 2 experiments. 
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Figure 26.  Testicular hyaluronidase pre-treatment removed hyaluronan and 
aggrecan from the pericellular matrix of wild type and CD44 -/- primary murine 
chondrocytes. Wild type (panels A, C, E and G) and CD44-/- (panels B, D, F and H) 
primary murine chondrocytes were grown on chamber slides and left untreated (panels 
A, B, E and F), or treated with 200 units/ml testicular hyaluronidase for 3 h at 37 oC 
(panels C, D, G and H). The washed cells were fixed and stained for hyaluronan (panels 
A-D) using biotinylated HABP followed by neutravidin-FITC. The cells were mounted in 
medium containing DAPI and visualized by fluorescence microscopy. Shown are digital 
overlay images of green and blue fluorescence channels. Next, wild type and CD44-/- 
murine chondrocytes, grown on chamber slides, were stained with toluidine blue (panels 
E-H). Cells shown are representative images, of 5 experiments and approximately 8 
fields per condition per experiment. Bars indicate 20 µm. The results showed that there 
was an intense hyaluronan and aggrecan staining in both wild type and CD44 -/- murine 
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chondrocytes. With testicular hyaluronidase treatment, hyaluronan and aggrecan were 
removed from the pericellular matrix in both wild type and CD44 -/- murine 
chondrocytes. 
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26). Stimulation of matrix-intact murine chondrocytes with BMP7 for 1 hour resulted in 
enhanced SMAD1 phosphorylation. Treatment with testicular hyaluronidase alone did 
not alter the baseline level of SMAD1 phosphorylation; however, following matrix 
disruption, SMAD1 phosphorylation upon BMP7 stimulation was reduced (Fig 27).  
Previously these same changes in bovine articular chondrocytes were reported by the 
Knudson labs (Andhare et al., 2009; Peterson et al., 2004).  Therefore, both matrix-
depleted wild type and CD44 -/- murine chondrocytes exhibited reduced SMAD1 
phosphorylation upon BMP7 stimulation (Fig 27 A and B, wild type, dark bars; CD44 -/-, 
white bars). Densitometry analysis of pixel intensity was performed for five separate 
experiments in order to statistically evaluate the data (Table 7 A and B). In wild type 
mouse chondrocyte, between control and BMP7, control and t. h’ase+BMP7, t.h’ase 
and t.h’ase+BMP7, the p value is < 0.05. In CD44 -/- murine chondrocytes, between 
control and BMP7, control and t. h’ase+BMP7, t.h’ase and t.h’ase+BMP7, the p value is 
< 0.05. In wild type mouse chondrocyte, between BMP7 and t.h’ase+BMP7, the p value 
is < 0.01; however, in CD44 -/- murine chondrocytes, between BMP7 and 
t.h’ase+BMP7, the p value is < 0.05 (Table 7 A and B). 
 
Diminished cellular response to BMP7 with testicular hyaluronidase treatment in both 
wild type and CD44 -/- murine chondrocytes was not due to alteration of BMP7 receptor 
or total SMAD1 expression (Fig 28). Protein lysates from wild type and CD44 -/- murine 
chondrocytes following testicular hyaluronidase treatment were examined by western 
blotting using an anti-ALK2 antibody and an anti-SMAD1 antibody. ALK2, the principal 
BMP type I receptor for BMP7 (Macias-Silva et al., 1998), did not change its expression  
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Figure 27.  The effect of testicular hyaluronidase pre-treatment on SMAD1 
phosphorylation in response to BMP7 in wild type and CD44 -/- primary murine 
chondrocytes. Wild type and CD44 -/- primary murine chondrocytes were pre-treated 
with 200 units/ml testicular hyaluronidase (h’ase) for 12 hours followed by stimulation 
with 100 ng/ml BMP7 for 1 hour, then analyzed by Western blotting for SMAD1 
phosphorylation (P-SMAD1). The results showed that in both wild type and CD44 -/- 
murine chondrocytes, with BMP7 1 hour stimulation, there was an increase of P-
SMAD1. However, after pre-treatment of murine chondrocytes with testicular 
hyaluronidase for 12 hours, SMAD1 phosphorylation was diminished in response to 
BMP7 stimulation. Aliquots used represent equivalent protein of samples, verified by 
reprobing of the Western blotting for GAPDH. Ctr, control.  The bar graph (panel B) 
shows the normalized average ratio in pixel intensity for P-SMAD1: total SMAD1 in each 
condition, derived from five separate experiments, of the wild type (black bars) and the 
CD44 -/- murine chondrocytes (hatched bars).  Error bars depict standard deviation; 
significant differences were at P < 0.05. 
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Table 7.  Scanning results and bio-statistical analysis of SMAD1 phosphorylation 
in response to BMP7 with or without testicular hyaluronidase treatment by wild 
type and CD44 -/- primary murine chondrocytes 
 
A. P-SMAD1/total SMAD1 densitometry ratio and p values of testicular hyaluronidase 
effect on BMP7 signaling by wild type murine chondrocytes 
WT Ctr BMP7 h'ase h'ase+BMP7 
1 0.2506 0.5531 0.1798 0.3426 
2 0.1860 0.5571 0.2010 0.3042 
3 0.2376 0.4883 0.1760 0.3476 
4 0.2456 0.5321 0.2617 0.2937 
5 0.2112 0.6523 0.2379 0.2888 
6 0.2276 0.8862   
7 0.2623 0.7914   
8 0.2239 0.5525   
9 0.2132 0.5414   
Mean 0.2287 0.6172 0.2113 0.3154 
SD 0.0234 0.1348 0.0374 0.0277 
p value  0.0001[1] 0.2999[1] 0.0001[1] 
    0.0004[2] 
    0.0011[3] 
The table shows the ratio calculated from densitometry pixel numbers of 9 (control; 
BMP7) or 5 (h’ase; h’ase+BMP7) determinations of P-SMAD1/total SMAD1 intensity on 
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western blots, mean and standard deviation (SD) of the P-SMAD1/total SMAD1 
densitometry ratio, and p values from the Student’s t-test of analyzing the responses to 
BMP7 with or without testicular hyaluronidase treatment by wild type murine 
chondrocytes. [1] refers to the p value comparing control group and BMP7, h’ase, or 
h’ase+BMP7 group; [2] refers to the p value comparing BMP7 group and h’ase+BMP7 
group; [3] refers to the p value comparing h’ase group and h’ase+BMP7 group. 
 
B. P-SMAD1/total SMAD1 densitometry ratio and p values of testicular hyaluronidase 
effect on BMP7 signaling by CD44 -/- murine chondrocytes 
KO Ctr BMP7 h'ase h'ase+BMP7 
1 0.2854 0.5512 0.1713 0.3558 
2 0.2626 0.4075 0.1550 0.2794 
3 0.2733 0.4453 0.1816 0.3380 
4 0.2011 0.4577 0.1157 0.3798 
5 0.2106 0.7182 0.2919 0.3121 
6 0.2166 0.4008   
7 0.2482 0.3475   
Mean 0.2425 0.4755 0.1831 0.3330 
SD 0.0332 0.1241 0.0658 0.0389 
p value  0.0004[1] 0.0648[1] 0.0015[1] 
    0.0342[2] 
    0.0023[3] 
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The table shows the ratio calculated from densitometry pixel numbers of 9 (control; 
BMP7) or 5 (h’ase; h’ase+BMP7) determinations of P-SMAD1/total SMAD1 intensity on 
western blots, mean and standard deviation (SD) of the P-SMAD1/total SMAD1 
densitometry ratio, and p values from the Student’s t-test of analyzing the responses to 
BMP7 with or without testicular hyaluronidase treatment by CD44 -/- murine 
chondrocytes. [1] refers to the p value comparing control group and BMP7, h’ase, or 
h’ase+BMP7 group; [2] refers to the p value comparing BMP7 group and h’ase+BMP7 
group; [3] refers to the p value comparing h’ase group and h’ase+BMP7 group. 
 
C. Bio-statistical analysis of P-SMAD1/total SMAD1 of testicular hyaluronidase effect on 
BMP7 signaling by wild type and CD44 -/- murine chondrocytes (p values) 
 KO-Ctr KO-BMP7 KO-h'ase 
KO-
h'ase+BMP7 
WT-Ctr 0.3432    
WT-BMP7  0.0489   
WT-h'ase   0.4295  
WT-h'ase+BMP7    0.4331 
The table shows p values from the Student’s t-test of analyzing the responses to BMP7 
with or without testicular hyaluronidase treatment between wild type and CD44 -/- 
murine chondrocytes. 
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Figure 28. Changes in SMAD1 phosphorylation of wild type and CD44 -/- primary 
murine chondrocytes with testicular hyaluronidase treatment were not due to 
alterations of BMP7 receptor or total SMAD1 expression. Wild type and CD44 -/- 
primary murine chondrocytes were pre-treated with 200 unites/ml testicular 
hyaluronidase for 12 hours followed with 100 ng/ml BMP7 1 hour stimulation, then 
analyzed by Western blotting for BMP7 receptor expression (ALK2) and SMAD1 
phosphorylation (P-SMAD1). The blots are representative of two replicate experiments. 
The results showed that the decrease of SMAD1 phosphorylation with testicular 
hyaluronidase pre-treatment upon BMP7 stimulation was not due to the decrease of 
BMP7 receptor or total SMAD1 expression. Aliquots used represent equivalent protein 
of samples, verified by reprobing of the Western blotting for GAPDH. Representatvie of 
2 experiments. 
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level with hyaluronidase treatment in either wild type or CD44 -/- murine chondrocytes. 
Total SMAD1 protein also did not change in expression level following hyaluronidase 
treatment of wild type or CD44 -/- murine chondrocytes (Fig 28). 
 
To test if the cellular responsiveness to BMP7 could be restored with the restoration of 
pericellular matrix, wild type and CD44 -/- murine chondrocytes were cultured for a 24 
hours recovery (REC) period after testicular hyaluronidase pre-treatment. With 
restoration of the pericellular matrix, both wild type and CD44 -/- murine chondrocytes 
exhibited strong signals for SMAD1 phosphorylation upon BMP7 stimulation compared 
to SMAD1 phosphorylation levels of BMP7-stimulated matrix-depleted chondrocytes 
(Fig 29). 
 
To further test the importance of the hyaluronan-dependent pericellular matrix in the 
BMP7 signaling pathway, wild type and CD44 -/- murine chondrocytes were stimulated  
with higher concentrations of BMP7 (100-500 ng/ml or 100-1000 ng/ml) for 1 hour after 
testicular hyaluronidase pre-treatment. With the increase of BMP7 concentration, 
matrix-depleted wild type and CD44 -/- murine chondrocytes had stronger responses to 
BMP7 as seen by increased levels of SMAD1 phosphorylation. However, even with 500 
ng/ml or 1000 ng/ml BMP7, SMAD1 phosphorylation levels on matrix-depleted 
chondrocytes were less than those of matrix-intact chondrocytes (Fig 30 and 31). 
However, with the CD44 -/- murine chondrocytes, stronger SMAD1 phosphorylation 
responses were observed at the highest concentration of BMP7. This suggests that 
expression of CD44 promotes the response to the lower concentration of BMP7,  
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Figure 29. Wild type and CD44 -/- primary murine chondrocytes regain cellular 
responses to BMP7 after testicular hyaluronidase pre-treatment. Following 
overnight pre-treatment of wild type and CD44 -/- primary murine chondrocytes with 200 
units/ml testicular hyaluronidase, murine chondrocytes were either stimulated with 100 
ng/ml BMP7 for 1 hour directly (h’ase) or cultured for another 24 hours for recovery 
(h’ase+REC) of hyaluronan regrowth in the pericellular matrix and then stimulated with 
100 ng/ml BMP7 for 1 hour. Control (Ctr) chondrocytes received no hyaluronidase pre-
treatment. Chondrocyte lysates were probed for SMAD1 phosphorylation (P-SMAD1) by 
Western blotting.  The results showed that with hyaluronan regrowth in the pericellular 
matrix, both wild type and CD44 -/- murine chondrocytes regain their cellular responses 
to 100ng/ml BMP7, as shown by increased SMAD1 phosphorylation, similar to 
untreated control murine chondrocytes (Ctr). Aliquots used represent equivalent protein 
of samples, verified by reprobing of the Western blotting for GAPDH. The blots are 
representative of two replicate experiments. 
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Figure 30. The effect of testicular hyaluronidase treatment on BMP7 signaling 
pathway of wild type and CD44 -/- primary murine chondrocytes cannot be 
compensated with higher concentrations of BMP7. Wild type and CD44 -/- primary 
murine chondrocytes were pre-treated with 200 units/ml testicular hyaluronidase 
overnight, followed by stimulation with higher concentrations (100-500 ng/ml) of BMP7, 
then Western blotting for SMAD1 phosphorylation (P-SMAD1). The blots are 
representative of two replicate experiments. The results showed with the increase of 
BMP7 concentration, P-SMAD1 was increased after testicular hyaluronidase pre-
treatment. However, with 500 ng/ml BMP7, which is 5 times higher than the standard 
BMP7 concentration in use, there was no restoration of P-SMAD1 levels to those 
observed following stimulation with 100 ng/ml BMP7. Aliquots used represent equivalent 
protein of samples, verified by reprobing of the Western blotting for total SMAD1 and 
GAPDH. Representatvie of 2 experiments. 
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Figure 31. The effect of testicular hyaluronidase treatment on BMP7 signaling 
pathway of wild type and CD44 -/- primary murine chondrocytes cannot be 
compensated with higher concentrations of BMP7. Wild type and CD44 -/- primary 
murine chondrocytes were pre-treated with 200 units/ml testicular hyaluronidase 
overnight, followed by stimulation with higher concentrations (100-1000 ng/ml) of BMP7, 
then analyzed by Western blotting for SMAD1 phosphorylation (P-SMAD1). The blots 
are representative of two replicate experiments. The results showed with the higher 
BMP7 concentrations, P-SMAD1 was increased after testicular hyaluronidase pre-
treatment. However, even stimulation of hyaluonidase-treated cells with 1000 ng/ml 
BMP7, which is 10 times higher than the standard BMP7 concentration in use, could not 
restore P-SMAD1 levels to the level observed after stimulation of matrix-intact cells with 
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100 ng/ml BMP7. Aliquots used represent equivalent protein of samples, verified by 
reprobing of the Western blotting for total SMAD1 and GAPDH. Representatvie of 2 
experiments. 
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perhaps regulating the threshold for cellular response. The results suggested that the 
hyaluronan-dependent pericellular matrix effects on the BMP7 signaling pathway can 
not be compensated by stimulation with higher BMP7 concentrations. 
 
As an alternative approach to test the role of hyaluronan in BMP7 signaling pathway, 
wild type and CD44 -/- murine chondrocytes were pre-treated with 4-
methylumbelliferone (4-MU), a hyaluronan synthase inhibitor, followed with 1 hour 
stimulation of BMP7.  In this approach no hyaluronidase treatment was used; rather 4-
MU was used to reduce hyaluronan synthesis and thus the cell-associated hyaluronan.  
RCS cells and bovine chondrocytes were used to optimize the 4-MU treatment 
conditions. DMSO, as a vehicle control, has no effect on SMAD1 phosphorylation level 
in RCS cells. Stimulation of vehicle control (Ctr) chondrocytes with BMP7 for 1 hour 
resulted in enhanced expression of SMAD1 phosphorylation. However, if cells were 
plated and cultured for 48 hours in the presence of 1 mM 4-MU, SMAD1 
phosphorylation upon BMP7 stimulation was reduced in both RCS cells and bovine 
chondrocytes (Fig 32 and 34). HABP staining for hyaluronan in bovine chondrocytes 
showed a decrease of hyaluronan in 4-MU treated cells compared to vehicle control 
treated cells (Fig 33). Forty-eight hour treatment of 1 mM 4-MU on wild type and CD44 -
/- murine chondrocytes also resulted in decreased SMAD1 phosphorylation upon BMP7 
stimulation compared to vehicle control treated chondrocytes (Fig 35). Taken together, 
these data suggest that hyaluronan, as the scaffold of pericellular matrix, is required for 
a robust response by chondrocytes to BMP7. 
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Figure 32. The effect of 4-methylumbelliferone, a hyaluronan synthase inhibitor, 
treatment on BMP7 signaling pathway in rat chondrosarcoma cells. Rat 
chondrosarcoma (RCS) cells were plated at a density of 1x106 per well in a 12-well 
plate with or without the presence of 4-methylumbelliferone (4-MU) for 48 hours, 
followed with 100 ng/ml BMP7 stimulation for 1 hour, then analyzed by Western blotting 
for SMAD1 phosphorylation (P-SMAD1). The results showed that BMP7 initiated a 
strong increase of P-SMAD1 in RCS cells. And 4-MU pre-treatment decreased P-
SMAD1 upon BMP7 stimulation. DMSO, as a vehicle control for 4-MU, did not affect P-
SMAD1 as compared to control (Ctr) group. Aliquots used represent equivalent protein 
of samples, verified by reprobing of the Western blotting for total SMAD1 and GAPDH. 
Representatvie of 2 experiments. 
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Figure 33. The effect of 4-methylumbelliferone, a hyaluronan synthase inhibitor, 
treatment on hyaluronan and proteoglycan deposition in primary bovine articular 
chondrocytes. Primary bovine articular chondrocytes were plated at a density of 1x105 
per chamber in a 4-well chamber slide with (panels B and D) or without (panels A and 
C) the presence of 4-methylumbelliferone (4-MU). Forty-eight hours later, the washed 
cells were fixed and either stained with biotinylated hyaluronan binding protein (HABP) 
for hyaluronan, followed by neutravidin-FITC (panels A and B),  or stained with toluidine 
blue for aggrecan (panels C and D). The cells were mounted in medium containing 
DAPI and visualized by fluorescence microscopy.  Toluidine blue stained cells were 
mounted in PBS and visualized by inverted phase contrast microscopy (panel C and D). 
Shown are digital overlay images of green and blue fluorescence channels for 
representative fields for the four condition.  The results showed that there was intense 
hyaluronan and aggrecan staining in primary bovine chondrocytes. However, with 4-MU 
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pre-treatment, staining for hyaluronan (panel B) and aggrecan (panel D) in pericellular 
matrix of bovine chondrocytes was reduced. Representatvie of 2 experiments. 
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Figure 34. The effect of 4-methylumbelliferone, a hyaluronan synthase inhibitor, 
treatment on BMP7 signaling pathway in primary bovine articular chondrocytes. 
Bovine articular chondrocytes after collagenase P overnight digestion, were plated at a 
density of 1x106 per well in a 12-well plate with or without the presence of 4-
methylumbelliferone (4-MU) for 48 hours, followed with 100 ng/ml BMP7 stimulation for 
1 hour, then analyzed by Western blotting for SMAD1 phosphorylation (P-SMAD1). The 
results showed that BMP7 initiated a strong increase of P-SMAD1 in bovine 
chondrocytes. 4-MU pre-treatment decreased P-SMAD1 upon BMP7 stimulation. 
Aliquots used represent equivalent protein of samples, verified by reprobing of the 
Western blots for GAPDH. Representatvie of 2 experiments. 
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Figure 35. The effect of 4-methylumbelliferone, a hyaluronan synthase inhibitor, 
treatment on BMP7 signaling pathway in wild type and CD44 -/- primary murine 
chondrocytes. Wild type and CD44 -/- primary murine chondrocytes after collagenase 
D overnight digestion, were plated at a density of 1x106 per well in a 12-well plate with 
or without the presence of 4-methylumbelliferone (4-MU) for 48 hours, followed with 100 
ng/ml BMP7 stimulation for 1 hour, then analyzed by Western blotting for SMAD1 
phosphorylation (P-SMAD1). The results showed that BMP7 initiated a strong increase 
of P-SMAD1 in both wild type and CD44 -/- murine chondrocytes. And 4-MU pre-
treatment decreased P-SMAD1 upon BMP7 stimulation with both wild type and CD44 -/- 
murine chondrocytes. In wild type murine chondrocytes, the expression level of CD44 
was increased with 4-MU pre-treatment. Aliquots used represent equivalent protein of 
samples, verified by reprobing of the Western blotting for total SMAD1 and GAPDH. 
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4. Wild type and CD44 -/- murine articular chondrocytes responsiveness to 
Epidermal Growth Factor 
 
CD44 has been shown to directly interact and influence several growth factor receptors 
(Palyi-Krekk et al., 2008; Wakahara et al., 2005; Yu et al., 2002).  To test the selectivity 
of CD44 involvement in another signaling pathway, wild type and CD44 -/- murine 
chondrocytes were stimulated with varying concentrations of EGF (0-50 ng/ml) for 
different time periods, and Akt, Erk and p38 phosphorylation were detected using anti-
phosphorylated Akt, Erk and p38 antibodies.  The minimum EGF concentration needed 
to initiate p38, Akt and Erk phosphorylation in both wild type and CD44 -/- murine 
chondrocytes was 10 ng/ml (Fig 36, 37 and 38).  The peak response to EGF was 
observed 5 minutes after stimulation. With the increase of time following the stimulation 
with EGF, the phosphorylation levels of p38, Akt and Erk were decreased. EGF 
stimulation did not influence SMAD1 phosphorylation level (Fig 36 and 37). However, no 
difference of p38, Akt and Erk phosphorylation level upon EGF stimulation was detected 
between wild type and CD44 -/- murine chondrocytes (Fig 36,37 and 38).  Taken 
together, these data suggested that, in chondrocytes, CD44 affects a more select 
influence over BMP7 responsiveness than EGF mediated signaling. 
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Figure 36. Cellular responses to different concentrations of EGF and different 
time periods of EGF stimulation in wild type primary murine chondrocytes. Wild 
type primary murine chondrocytes after collagenase D overnight digestion, were plated 
at a density of 2x105 per well in a 48-well plate. Twenty-four hours later, the medium 
was changed to serum free for overnight incubation and wild type murine chondrocytes 
were stimulated with different concentrations (0-50 ng/ml) of EGF and different time 
points, then were analyzed by Western blotting for p38, SMAD1, Akt and Erk 
phosphorylation (P-p38, P-SMAD1, P-Akt and P-Erk). The results showed that with the 
increase of EGF treatment time, cellular responses of wild type murine chondrocytes (P-
Akt, P-p38 and P-Erk) were decreased. 10 ng/ml EGF initiated a strong increase of P-
Akt, P-p38 and P-Erk. No difference of cellular responses to 10 ng/ml EGF and to 50 
ng/ml EGF was detected. There was no effect on SMAD1 phosphorylation upon EGF 
stimulation. Aliquots used represent equivalent protein of samples, verified by reprobing 
of the Western blotting for total Akt and total Erk. The blots are representative of two 
replicate experiments. 
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Figure 37. Cellular responses to different concentration and different time periods 
of EGF in CD44 -/- primary murine chondrocytes. CD44 -/- primary murine 
chondrocytes after collagenase D overnight digestion, were plated at a density of 2x105 
per well in a 48-well plate. Twenty-four hours later, the medium was changed to serum 
free for overnight incubation and CD44 -/- murine chondrocytes were stimulated with 
different concentrations (0-50 ng/ml) of EGF and different time points, then were 
analyzed by Western blotting for p38, SMAD1, Akt and Erk phosphorylation (P-p38, P-
SMAD1, P-Akt and P-Erk). The results showed that following EGF stimulation, cellular 
responses of CD44 -/- murine chondrocytes (P-Akt, P-p38 and P-Erk) peaked at 5 
minutes at were decreased thereafter. 10 ng/ml EGF initiated a strong increase of P-
Akt, P-p38 and P-Erk. No difference of cellular responses to 10 ng/ml EGF and to 50 
ng/ml EGF was detected. There was no effect on SMAD1 phosphorylation upon EGF 
stimulation. Aliquots used represent equivalent protein of samples, verified by reprobing 
of the Western blotting for total Akt and total Erk. The blots are representative of two 
replicate experiments. 
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Figure 38. Cellular responses to different concentrations of EGF in wild type and 
CD44 -/- primary murine chondrocytes. Wild type and CD44 -/- primary murine 
chondrocytes after collagenase D overnight digestion, were plated at a density of 2x105 
per well in a 48-well plate. Twenty-four hours later, the medium was changed to serum 
free for overnight incubation, and wild type and CD44 -/- murine chondrocytes were 
stimulated with different concentrations (1-10ng/ml) of EGF for 5 minutes, then analyzed 
by Western blotting for p38, SMAD1, Akt and Erk phosphorylation (P-Akt and P-Erk). 
The blots are representative of four replicate experiments. The results showed that 10 
ng/ml EGF initiated an increase of P-Akt and P-Erk. However, no difference of cellular 
responses to EGF was detected between wild type and CD44 -/- primary murine 
chondrocytes. Aliquots used represent equivalent protein of samples, verified by 
reprobing of the Western blotting for total Akt and total Erk. Representatvie of 2 
experiments. 
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5. Pilot studies 
 
The effects of Streptomyces hyaluronidase on BMP7 signaling pathway in wild type and 
CD44 -/- murine chondrocytes were examined. Streptomyces hyaluronidase exhibits a  
higher specificity for hyaluronan as a substrate (Ohya and Kaneko, 1970). Hyaluronan 
binding protein and toluidine blue staining showed that following Streptomyces 
hyaluronidase treatment, hyaluronan and aggrecan deposition were reduced in the cell-
associated pericellular matrix of both wild type and CD44 -/- murine chondrocytes (Fig 
39 and 40). However, the effects of Streptomyces hyaluronidase on SMAD1 
phosphorylation upon BMP7 stimulation were not substantial (Fig 41) as compared to 
testicular hyaluronidase effect. 
 
There has been a report that MAPK-dependent phosphorylation of the linker region of 
R-SMADs alters the kinetics of R-SMADs activation, which delays R-SMADs 
phosphorylation by BMP receptor kinase and terminates the phosphorylation signals 
earlier, and decreases the level of R-SMADs phosphorylation by BMP receptor kinase 
(Elshaier et al., 2009). Experiments were designed to test if testicular hyaluronidase 
effect on the cellular response to BMP7 in bovine chondrocytes, wild type and CD44 -/- 
murine chondrocytes was due to the activation of a p38 MAPK-mediated inhibition of 
BMP7 signaling. Bovine chondrocytes, wild type and CD44 -/- murine chondrocytes 
were pre-treated with 200 units/ml testicular hyaluronidase for 12 hours followed with 1 
hour stimulation of 100 ng/ml BMP7 stimulation; there was a decrease of SMAD1 
phosphorylation in all three cell models as compared to BMP7 stimulation only.  
  141 
 
 
Figure 39.  Streptomyces hyaluronidase treatment removed hyaluronan from the 
pericellular matrix of wild type and CD44 -/- primary murine chondrocytes. Wild 
type and CD44-/- primary murine chondrocytes after collagenase D overnight digestion, 
were plated at a density of 1x105 per chamber in a 4-well chamber slide. Forty-eight 
hours later, the medium was changed to serum free for overnight incubation and the 
wild type and CD44 -/- murine chondrocytes were pre-treated with 10 units /ml 
Streptomyces hyaluronidase for 3 h at 37 oC. The washed cells were fixed and stained 
for hyaluronan with biotinylated hyaluronan binding protein (HABP), followed with 
Neutravidin-FITC. The results showed that there was an intense hyaluronan staining in 
both wild type and CD44 -/- murine chondrocytes (Panel A and C). With Streptomyces 
hyaluronidase treatment, hyaluronan was partially removed from the pericellular matrix 
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in both wild type and CD44 -/- murine chondrocytes as revealed by a decrease in HABP 
staining (Panel B and D). Cells shown are representative images, of 5 experiments and 
approximately 8 fields per condition per experiment.  Bars indicate 10 µm. 
Representatvie of 2 experiments. 
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Figure 40.  Streptomyces hyaluronidase treatment removed aggrecan from the 
pericellular matrix of wild type and CD44 -/- primary murine chondrocytes. Wild 
type and CD44-/- primary murine chondrocytes after collagenase D overnight digestion, 
were plated at a density of 1x105 per chamber in a 4-well chamber slide. Forty-eight 
hours later, the medium was changed to serum free for overnight incubation and the 
wild type and CD44 -/- primary murine chondrocytes were treated with 10 units /ml 
Streptomyces hyaluronidase for 3 h at 37 oC. The washed cells were fixed and stained 
for aggrecan with toluidine blue. The results showed that there was an intense aggrecan 
staining in both wild type and CD44 -/- primary murine chondrocytes (Panel A and C). 
With Streptomyces hyaluronidase treatment, aggrecan was removed from the 
pericellular matrix in both wild type and CD44 -/- primary murine chondrocytes as 
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revealed by decrease in toluidine blue staining (Panel B and D). Cells shown are 
representative images, of 5 experiments and approximately 8 fields per condition per 
experiment.  Bars indicate 10 µm. Representatvie of 2 experiments. 
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Figure 41.  The effect of Streptomyces hyaluronidase treatment on BMP7 
signaling pathway of wild type and CD44 -/- primary murine chondrocytes. Wild 
type and CD44 -/- primary murine chondrocytes after collagenase D overnight digestion, 
were plated at a density of 2x105 per well in a 48-well plate. Twenty-four hours later, the 
medium was changed to serum free for overnight incubation and wild type and CD44 -/- 
primary murine chondrocytes were pre-treated with 10 units/ml Streptomyces 
hyaluronidase (s.h’ase) for 3 hours followed with 100 ng/ml BMP7 stimulation for 1 hour, 
then analyzed by Western blotting for SMAD1 phosphorylation (P-SMAD1). The results 
showed that BMP7 initiated a strong increase of P-SMAD1 in both wild type and CD44 -
/- primary murine chondrocytes. However, even with Streptomyces hyaluronidase pre-
treatment, BMP7 still initiated a strong increase of P-SMAD1 in both wild type and CD44 
-/- primary murine chondrocytes, and no difference was detected compared to the group 
stimulated with BMP7 only. The expression level of CD44 was not changed with 
Streptomyces hyaluronidase pre-treatment. Aliquots used represent equivalent protein 
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of samples, verified by reprobing of the Western blotting for total SMAD1 and GAPDH. 
Representatvie of 2 experiments. 
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However, with 12 hours incubation of testicular hyaluronidase, there was no 
phosphorylation of p38 itself and only a very weak indication of Ser206 phosphorylation 
in SMAD1 (linkage region of SMAD1) (Fig 42 and 43). The results indicated that 
diminished cellular responses to BMP7 with testicular hyaluronidase pre-treatment were 
not due to the activation of p38-mediated phosphorylation of Ser206 in SMAD1. 
 
To study if other molecules compensate for CD44 to interact with hyaluronan in CD44 -
/- murine chondrocytes, the expression levels of candidate molecules were detected 
with RT-PCR. RT-PCR results showed no difference of the mRNA expression levels for 
Has2 between wild type and CD44 -/- murine chondrocytes (Fig 44).  A hyaluronan 
enzyme-linked immunosorbent assay showed both wild type and CD44 -/- murine 
chondrocytes responded to BMP7 by an increase of hyaluronan synthesis as 
determined by analysis of hyaluronan accumulation in the media. However, no 
significant difference in hyaluronan amount was detected between wild type and CD44 -
/- murine chondrocytes (Fig 45). 
 
Also RT-PCR results showed no difference of the mRNA expression levels for toll-like 
receptor 4 (Tlr4), one of the member of the Toll family, (Chang et al., 2007; Muto et al., 
2009; Yamawaki et al., 2009), between wild type and CD44 -/- murine chondrocytes 
(Fig 46). 
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Figure 42. The effect of testicular hyaluronidase effect on BMP7 signaling 
pathway in bovine chondrocytes was not due to activation of a p38-mediated 
inhibition of BMP7 signaling. When SMAD1 is phosphorylated in the linkage region 
by P-p38, it is blocked from the canonical BMP7 signaling pathway. Pre-treatment of 
bovine chondrocytes with 200 units/ml testicular hyaluronidase for 12 hours followed 
with 1 hour stimulation of 100 ng/ml BMP7, there was a decrease of SMAD1 
phosphorylation as compared to BMP7 stimulation only. However, with 12 hours 
incubation of testicular hyaluronidase, there was no phosphorylation of p38 or Ser206 in 
SMAD1 (linkage region of SMAD1). These results indicated that diminished cellular 
responses to BMP7 with testicular hyaluronidase pre-treatment were not due to 
activation of p38, or Ser206 phosphorylation of SMAD1. Representatvie of 2 
experiments. 
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Figure 43. The effect of testicular hyaluronidase effect on BMP7 signaling 
pathway in wild type and CD44 -/- murine chondrocytes was not due to activation 
of a p38-mediated inhibition of BMP7 signaling. When SMAD1 is phosphorylated in 
the linkage region by P-p38, it is blocked from the canonical BMP pathway. After pre-
treatment of murine chondrocytes with 200 units/ml testicular hyaluronidase for 12 
hours followed with 1 hour stimulation of 100 ng/ml BMP7, there was a decrease of 
SMAD1 phosphorylation as compared to BMP7 stimulation of matrix-intact 
chondrocytes. However, with 12 hours incubation of testicular hyaluronidase, there was 
no phosphorylation of p38 or Ser206 in SMAD1 (linkage region of SMAD1). The results 
indicated that diminished cellular responses to BMP7 with testicular hyaluronidase pre-
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treatment were not due to activation of p38, or Ser206 phosphorylation of SMAD1. 
Representatvie of 2 experiments. 
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Figure 44. Analysis of hyaluronan synthase 2 mRNA expression in wild type and 
CD44 -/- primary murine chondrocytes. Total RNA was isolated from wild type and 
CD44-/- murine chondrocytes and analyzed for the expression of hyaluronan synthase 2 
(Has2) by conventional RT-PCR using Gapdh as a control. No difference of Has2 
mRNA expression levels was detected between wild type and CD44-/- murine 
chondrocytes. Representatvie of 2 experiments. 
 
 
 
 
 
 
  152 
 
 
Figure 45. Hyaluronan enzyme-linked immunosorbent assay of wild type and 
CD44 -/- murine chondrocytes treated with BMP7 for 48 hours. Primary wild type 
(WT) and CD44 -/- (KO) murine chondrocytes were plated at a density of 1x106 per well 
in a 12-well plate. Twenty-four hours later, the medium was changed to serum free with 
the absence (Ctr) or presence (BMP) of 100 ng/ml BMP7 for 48 hours. Then the 
supernatant was collected and the amount of hyaluronan was analyzed with hyaluronan 
enzyme-linked immunosorbent assay and reported as ng/ml. The results showed that 
BMP7 treatment resulted in increased hyaluronan accumulation in the media; however, 
no significant difference in hyaluronan amount was detected between wild type and 
CD44-/- murine chondrocytes. Representatvie of 1 experiment. 
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Figure 46. Analysis of toll-like receptor 4 mRNA expression in wild type and CD44 
-/- primary murine chondrocytes. Total RNA was isolated from wild type and CD44-/- 
murine chondrocytes and analyzed for the expression of toll-like receptor 4 (Tlr4) by 
conventional RT-PCR using Gapdh as a control. No difference of Tlr4 mRNA 
expression levels was detected between wild type and CD44-/- murine chondrocytes. 
Representatvie of 2 experiments. 
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The receptor for hyaluronan-mediated motility (RHAMM) is another hyaluronan receptor 
not in the hyaladhesin family (Turley et al., 2002). The mRNA expression level of  
Rhamm was increased in CD44 -/- murine chondrocytes compared to that of wild type 
murine chondrocytes (Fig 47), which suggested that Rhamm might compensate for 
CD44 to interact with hyaluronan in CD44 -/- murine chondrocytes. However, despite 
the loss of Rhamm mRNA expression in de-differentiated CD44 -/- murine chondrocytes 
(Fig 48), de-differentiated CD44 -/- murine chondrocytes still have a testicular 
hyaluronidase response; with decreased SMAD1 phosphorylation as well as ID2 in 
response to BMP7 (Fig 49). ID2 is an early response gene up-regulated by BMP7 
(Kowanetz et al., 2004).  
 
Age-related changes in the response of chondrocytes to growth factors have been 
reported (Loeser et al., 2003; Martin and Buckwalter, 2002; Nishida et al., 2000b). 
Femoral heads isolated from 18-month-old wild type and CD44 -/- mice were 
decalcified, embedded in paraffin, sectioned and stained with safranin O and fast green. 
The staining results showed less Safranin O red color indicative of the loss of matrix 
proteoglycans in samples from 18-month-old mice (Fig 50) compared to femoral heads 
isolated from 1-week-old mice. Moreover, the responses of CD44 -/- murine 
chondrocytes from 18-month-old animals and 1-week-old animals to BMP7 were 
analyzed. The results suggested the possibility that due to the loss of matrix 
proteoglycans, murine chondrocytes isolated from 18-month-old mice were less 
responsive to BMP7 compared to chondrocytes isolated from 1-week-old mice (Fig 50). 
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Figure 47. Analysis of receptor for hyaluronan-mediated motility mRNA 
expression in wild type and CD44 -/- primary murine chondrocytes. Total RNA was 
isolated from wild type and CD44-/- murine chondrocytes and analyzed for the 
expression of receptor for hyaluronan-mediated motility (Rhamm) by conventional RT-
PCR using Gapdh as a control. The expression level of Rhamm mRNA in CD44-/- 
murine chondrocytes was higher than that in wild type murine chondrocytes. 
Representatvie of 2 experiments. 
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Figure 48. Analysis of receptor for hyaluronan-mediated motility mRNA 
expression in de-differentiated wild type and CD44 -/- murine chondrocytes. Total 
RNA was isolated from wild type and CD44-/- murine chondrocytes and analyzed for the 
expression of receptor for hyaluronan-mediated motility (Rhamm) by conventional RT-
PCR using Gapdh as a control. The expression level of Rhamm was higher in primary 
CD44 -/- murine chondrocytes (P0), however, the expression level of Rhamm was lower 
in de-differentiated CD44 -/- murine chondrocytes (P3) compared to wild type murine 
chondrocytes. Representatvie of 2 experiments. 
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Figure 49.  The effect of pre-treatment with testicular hyaluronidase on BMP7 
signaling pathway in CD44 -/- de-differentiated murine chondrocytes. De-
differentiated CD44 -/- murine chondrocytes were pre-treated with 200 units/ml 
testicular hyaluronidase (h’ase) for 90 minutes followed with 100 ng/ml BMP7 1 hour 
stimulation, then analyzed by Western blotting for SMAD1 phosphorylation (P-SMAD1) 
and ID2. The results showed that de-differentiated CD44 -/- murine chondrocytes 
responded to BMP7 stimulation with an increase of P-SMAD1 as well as ID2. However, 
pre-treatment of these de-differentiated CD44 -/- murine chondrocytes with testicular 
hyaluronidase resulted in diminished SMAD1 phosphorylation, and more apparent, 
diminished ID2 expression in response to BMP7 stimulation. There was no increase of 
total SMAD1 in response to BMP7 following treatment with testicular hyaluronidase. 
Aliquots used represent equivalent protein of samples, verified by reprobing of the 
Western blotting for β-actin. Representatvie of 1 experiment. 
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Figure 50. Histology of articular cartilage isolated from 18-month-old wild type 
and CD44 -/- mice.  Femoral heads isolated from 18-month-old wild type and CD44 -/- 
mice were fixed directly, decalcified, embedded in paraffin and 8 µm sections were 
stained with safranin O and fast green for extracellular matrix. Articular cartilage from 
18-month-old wild type and CD44 -/- mice showed lost of proteoglycan staining in the 
matrix. With the loss of proteoglycan in the matrix, 18-month-old CD44 -/- murine 
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chondrocytes was less responsive to BMP7 for SMAD1 phosphorylation compared to 1-
week-old CD44 -/- murine chondrocytes. 
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ATDC5 cells are a murine chondrocytic cell line and have been widely used as a cell 
model system to study the chondrogenesis in vitro (Altaf et al., 2006; Shukunami et al., 
1996; Tare et al., 2005). C3H10T1/2 cells are a murine mesenchymal stem cell line and 
have also been used as a cell model system to study the chondrogenetic differentiation 
(Denker et al., 1999; Lisignoli et al., 2005; Seghatoleslami et al., 2003). Both of these 
cell lines express CD44, HAS2 and Sox9 (Fig 51 and 52). 
 
The pellet culture technique has been developed by Johnstone and his colleagues to 
facilitate the chondrogenesis with mesenchymal progenitor cells (Johnstone et al., 
1998). The system provides cell-cell interactions that mimic in vivo cartilage 
environment. 
 
To establish pellet cultures, C3H10T1/2 mesenchymal stem cells recovered from 
monolayer culture with trypsin, were resuspended with DMEM supplemented with 
10%FBS at a density of 1x106/ml. One ml of C3H10T1/2 cells in suspension were 
transferred to a 15 ml tube followed by centrifugation at 300g for 5 minute. The 
C3H10T1/2 were cultured as a cell pellet in 15 ml tubes for 1 week, in the absence or 
presence of BMP7 to induce chondrogenesis and the medium was changed daily. 
Alcian blue staining of the tissues showed matrix deposition in both the control and the 
BMP7 treated group, and the BMP7 treatment promoted more matrix deposition (Fig 
53). 
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Figure 51. RT-PCR analysis of ATDC5 cells. Total RNA was isolated from ATDC5 
cells and analyzed for the expression of Cd44, hyaluronan synthase 2 (Has2) and Sox9 
by conventional RT-PCR using Gapdh as a control. 
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Figure 52. RT-PCR analysis of C3H10T1/2 cells. Total RNA isolated from C3H10T1/2 
cells was analyzed for the expression of Cd44, hyaluronan synthase 2 (Has2) and Sox9 
by conventional RT-PCR using Gapdh as a control. 
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Figure 53. Alcian blue staining of C3H10T1/2 mesenchymal stem cells pellet 
cultures incubated with or without BMP7 for 7 days. The pellet culture was fixed 
with 4% paraformaldehyde, sectioned at 8 µm and stained with alcian blue. 
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Next, primary murine articular chondrocytes were used to establish pellet cultures.  
Primary wild type and CD44 -/- murine articular chondrocytes after collagenase D 
digestion, were resuspended with DMEM supplemented with 20%FBS at a density of 
1x106/ml. One ml of murine chondrocytes were transferred to 1.5 ml microtube followed 
by centrifugation at 300g for 5 minute. Both wild type and CD44 -/- murine chondrocytes 
were cultured as cell pellets in the microtube for 1 week, and the medium was changed 
everyday. A disc–like cartilage tissue was regenerated from this culture strategy (Fig 
54). 
 
The neo-cartilage was examined histologically by safranin O and fast green staining of 8 
µm sections. The chondrocytes within these tissues were round in morphology and the 
neo-cartilage formed by both wild type and CD44 -/- murine chondrocytes has intense 
red matrix staining with Safranin O (Fig 55). Western blotting of signaling molecules in 
wild type murine chondrocytes pellet culture showed that pellet cultures expressed more 
CD44 and P-Akt, but less of P-p38 and P-Erk. Moreover, wild type murine chondrocytes 
cultured in pellet cultures were less responsive to 100 ng/ml BMP7 as determined by 
analysis of SMAD1 phosphorylation compared to those cultured in monolayer (Fig 56). 
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Figure 54. Neo-cartilage tissue generated by wild type murine chondrocytes in 
pellet culture for 1 week. One million wild type murine chondrocytes were cultured in 
the microtube for 1 week and showed disc-like cartilage. 
 
 
 
 
 
 
 
 
 
  166 
 
 
Figure 55. Safranin O and fast green staining of wild type and CD44 -/- murine 
chondrocytes pellet culture. The pellet culture was fixed with 4% paraformaldehyde, 
sectioned at 8 µm and stained with Safranin O and fast green. The murine chondrocytes 
in the pellet culture maintained chondrocytes round morphology and both wild type and 
CD44 -/- murine chondrocytes pellet cultures have intense matrix staining. 
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Figure 56. Characterization of signaling molecules in wild type murine 
chondrocytes pellet culture by Western blotting. One million wild type murine 
chondrocytes were cultured in the microtube for 1 week and stimulated with 100 ng/ml 
BMP7 for 1 hour, then analyzed by Western blotting for SMAD1, p38, Akt and Erk 
phosphorylation. Compared to monolayer culture, wild type murine chondrocytes in 
pellet cultures showed more expression of CD44 and P-Akt, but less expression of P-
p38 and P-Erk. Moreover, wild type murine chondrocytes cultured in pellets were less 
responsive to 100 ng/ml BMP7 as determined by SMAD1 phosphorylation compared to 
those cultured in monolayer. Representatvie of 1 experiment. 
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6. Preliminary Studies in Support of Development of Specific Aims 
 
Two cell lines were used to develop the specific aims of this dissertation, MG63 and 
PC3. 
 
Human MG63 osteosarcoma cells, which exhibit large pericellular matrices around the 
cells (Fig 57), and express CD44 and HAS2, are a model system to study the BMP7 
signaling pathway (Xu-Dong et al., 2009). 
 
For initial preliminary studies, MG63 cells were transfected with human CD44 siRNA to 
test the role of CD44 in BMP7 signaling. 24 hours and 48 hours after transfection, total 
RNA was extracted and followed by reverse transcription and PCR amplification. RT-
PCR results showed that 24 hours after transfection, the mRNA expression levels of 
relevant molecules in the BMP7 signaling pathway were increased, such as, 
endogenous BMP7, BMP-RII, follistatin (BMPs inhibitor) and HAS2, although a slight 
decrease of the mRNA expression level of CD44 was detected (Fig 58). 48 hours after 
transfection with human CD44 siRNA, CD44 mRNA expression level was reduced. With 
the concomitant decrease of CD44 expression level, the expression levels of relative 
molecules in BMP7 signaling pathway were increased, such as, endogenous BMP7, 
BMP-RII, follistatin (BMPs inhibitor) and HAS2. The data suggested that anabolic 
factors involved in BMP7 signaling pathway were augmented in expression to 
compensate decreased CD44 expression level. 
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Figure 57. Particle exclusion assay showing the pericellular matrix around MG63 
cells. MG63 cells were plated at a low density in 35 mm dish for 48 hours. The particle 
exclusion assay showed a large pericellular matrix around MG63 cells as observed by 
phase contrast microscopy. 
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Figure 58. RT-PCR analysis of anabolic factors involved in BMP7 signaling 
pathway in MG63 cells transfected with CD44 siRNA. Total RNA isolated from MG63 
cells transfected with human CD44 siRNA or non-specific control siRNA was analyzed 
for the expression of CD44, endogenous BMP7, follistatin, BMP-RII and HAS2 by 
conventional RT-PCR using GAPDH as a control. CD44 expression level was 
decreased with CD44 siRNA transfection. The expression levels of endogenous BMP7, 
follistatin, BMP-RII and HAS2 were increased. 
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Next, MG63 cells were treated with Streptomyces hyaluronidase to test the role of 
hyaluronan in BMP7 signaling. 24 hours and 48 hours after Streptomyces hyaluronidase 
treatment, total RNA was extracted and followed by reverse transcription and PCR 
amplification. Streptomyces hyaluronidase treatment removed the pericellular matrix 
from MG63 cells (Fig 59). RT-PCR results showed that Streptomyces hyaluronidase 
treatment decreased the expression level of HAS2. Treatment for 24 hours with 
Streptomyces hyaluronidase slightly increased the expression levels of relative 
molecules in BMP7 signaling pathway, such as, endogenous BMP7, BMP-RII, and 
follistatin (BMPs inhibitor) and CD44 (Fig 60). However, 48 hours treatment of 
Streptomyces hyaluronidase decreased the expression levels of relative molecules in 
BMP7 signaling pathway, such as, endogenous BMP7, BMP-RII, and follistatin (BMPs 
inhibitor). The expression level of CD44 decreased compared to that of CD44 in MG63 
cells treated with Streptomyces hyaluronidase for 24 hours. The data suggested that the 
anabolic factors involved in BMP7 signaling pathway increased in expression as a 
response to compensate for the hyaluronan-dependent pericellular matrix with 24 hours 
treatment of Streptomyces hyaluronidase. However, with 48 hours treatment of 
Streptomyces hyaluronidase, the anabolic factors involved in BMP7 signaling pathway 
decreased their expression at the end as a response to reduced hyaluronan-dependent 
pericellular matrix. 
 
  172 
 
 
Figure 59. Particle exclusion assay of MG63 cells treated with Streptomyces 
hyaluronidase. MG63 cells were plated at a low density in 35 mm dish for 48 hours. 
Then, MG63 cells were treated with Streptomyces hyaluronidase for either 24 or 48 
hours. The particle exclusion assay showed that Streptomyces hyaluronidase treatment 
removed the pericellular matrix around MG63 cells as observed by phase contrast 
microscopy. 
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Figure 60. RT-PCR analysis of anabolic factors involved in BMP7 signaling 
pathway in MG63 cells following treatment with Streptomyces hyaluronidase. 
Total RNA isolated from MG63 cells treated with Streptomyces hyaluronidase for either 
24 or 48 hours was analyzed for the expression of CD44, endogenous BMP7, follistatin, 
BMP-RII and HAS2 by conventional RT-PCR using GAPDH as a control. 24 hours 
treatment with Streptomyces hyaluronidase, CD44 expression was increased and HAS2 
expression was decreased. No difference of the expression levels of other genes 
involved in BMP7 signaling pathway (endogenous BMP7, follistatin, BMP-RII) was 
detected. However, 48 hours treatment with Streptomyces hyaluronidase, the 
expression levels of endogenous BMP7, follistatin, BMP-RII and HAS2 were reduced. 
The expression level of CD44 was decreased compared to that of CD44 in MG63 cells 
treated with Streptomyces hyaluronidase for 24 hours. 
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Human PC3 prostate cancer cells, which express CD44, have been used to study the 
biological effect of BMP7 signaling pathway in cancer (Yang et al., 2005a). 
 
PC3 cells were transfected with a ribozyme transgene targeting human BMP7 (Provided 
by Dr. Lin) (Ye et al., 2007) to decrease endogenous BMP7 mRNA and protein 
expression levels. PC3 cells were co-transfected with anti-human BMP7 ribozyme and 
eGFP. The transfection efficiency was high according to eGFP expression in PC3 
transfectants (Fig 61). 48 hours after transfection, total RNA was extracted and followed 
by reverse transcription and PCR amplification. RT-PCR results showed that with anti-
human BMP7 ribozyme transfection, the expression levels of relevant molecules in the 
BMP7 signaling pathway were decreased, namely, follistatin (BMP inhibitor), BMP-RII, 
and CD44 (Fig 62). The data suggested that endogenous BMP7 was important to 
maintain CD44 expression. 
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Figure 61. eGFP expression in PC3 cells co-transfected with anti-human BMP7 
ribozyme and eGFP. PC3 cells were co-transfected with anti-human BMP7 ribozyme 
and eGFP using Amaxa nucleofector system. The expression of eGFP was observed 
under fluorescence microscope showing a high transfection efficiency. 
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Figure 62. RT-PCR analysis of relevant molecules involved in BMP7 signaling 
pathway in PC3 cells transfected with anti-human BMP7 ribozyme. Total RNA 
isolated from PC3 cells transfected with anti-human BMP7 ribozyme or empty plasmid 
was analyzed for the expression of CD44, follistatin and BMP-RII by conventional RT-
PCR using GAPDH as a control. With anti-human BMP7 ribozyme transfection, the 
expression levels of follistatin, BMP-RII and CD44 were also decreased. 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4. DISCUSSION 
 
SMAD1, one of the down-stream components in the BMP7 signaling pathway, was 
previously found to interact with the cytoplasmic domain of full length CD44 as 
determined by yeast two-hybrid analysis (Peterson et al., 2004). This interaction was 
subsequently confirmed by co-immunoprecipitation of Smad1 and CD44 (Peterson et 
al., 2004). When hyaluronan-CD44 interactions were blocked experimentally, either 
through the use of a dominant negative CD44 plasmid transfection or with 
hyaluronidase pretreatment, a negative effect on the canonical BMP/ BMPR / SMAD1 
signaling pathway was observed (Andhare et al., 2009; Peterson et al., 2004).  This 
reduction in BMP-mediated signally could be rescued by the addition of hyaluronan or, 
transfection and overexpression of the enzyme that synthesized hyaluronan, hyaluronan 
synthase-2 (Andhare et al., 2009; Peterson et al., 2004).  One model to explain these 
results is that CD44 binds to SMAD1, and in through the interaction of CD44 with 
hyaluronan, CD44 is directed to present SMAD1 to the BMP receptor kinase facilitating 
the subsequent phosphorylation of SMAD1.  
 
Much of the knowledge about hyaluronan-CD44 signal transduction events has been 
obtained in cell models like CD44 and SMAD1-transfected COS7 cells or siRNA 
transfected primary bovine chondrocytes (Peterson et al., 2004). The disadvantage of 
the COS7 cell line is that these CD44 negative cells are SV-40 transformed African 
Green Monkey kidney cells, not chondrocytes. In addition, the overexpression of CD44 
and SMAD1 in transfected COS7 cells may suggest CD44-SMAD1 interactions that do 
  178 
not extrapolate to the levels producted in cartilage or chondrocytes. The disadvantage 
of isolated primary bovine chondrocytes is that low transfection efficiency prevents a 
100% knockdown of CD44 expression. However, the experiments performed in this 
study, a 100% knockdown of CD44 expression was obtained directly from isolated 
CD44 -/- murine chondrocytes. In addition, CD44 knockout mice share the same genetic 
background with the BALB/c wild type mice used as controls in these experiments. 
Therefore, using CD44 knockout mice the following question can be uniquely answered: 
“Is CD44 alone or is the interaction of CD44 with hyaluronan more important for BMP7-
mediated SMAD1 phosphorylation?” 
 
The first step in this study was to establish a mouse chondrocyte isolation method in our 
laboratory. At that time, only two isolation protocols related to murine chondrocytes 
were published (Argentin et al., 1993; Gosset et al., 2008). The report by Argentin et al. 
described the culture conditions that promote murine chondrocytes growth and maintain 
their differentiation in monolayer culture. The report by Gosset et al. was the only one 
that described a murine chondrocyte isolation protocol in detail. These protocols were 
modified successfully to obtain a “pure” chondrocyte preparation.  
 
Instead of using costal cartilage, in this study, murine chondrocytes were isolated from 
femoral heads and knee joints. Trypsin and collagenase D incubation times, isolation 
tools, and culture conditions were optimized in order to isolate and culture murine 
chondrocytes successfully. It was found that long time trypsinization decreased murine 
chondrocytes yield. It was also found that long time incubation with collagenase D or 
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inappropriate isolation tools will cause murine chondrocyte death. Ascorbic acid, the 
compound that promotes collagen synthesis (Murad et al., 1981), was added to culture 
medium to promote murine chondrocytes attachment to the tissue culture plates. 
Trypsinization, filtration with a 40 µm cell strainer, and wash steps were performed to 
minimize fibroblast contamination in order to obtain a pure cell suspension of 
chondrocytes.  
 
In this study, possible contamination with cigar-shaped fibroblasts from the 
perichondrium can be an issue. Consequently, the purity of our cell preparation was 
documented by observing various factors unique to chondrocytes. First, a round 
chondrocyte morphology surrounded by a pericellular matrix was observed by the 
particle exclusion assay (Fig 7 and 9). Second, expression of aggrecan and type II 
collagen, marker genes for chondrocytes, was detected by RT-PCR (Fig 10). Last, the 
presence of sulfated proteoglycans in the pericellular matrix was detected by 
cytochemical staining with toluidine blue (Fig 26 panel E and F).  In addition, to obtain 
the highest purity preparation possible, chondrocytes were plated at a high density for 
only two days to prevent fibroblast overgrowth and maintain the primary chondrocyte 
phenotype.   
 
Using this murine chondrocytes isolation protocol, about 106 chondrocytes were isolated 
per mouse. It is a low yield, which required experiments, with several treatment groups, 
to be plated in a 48-well culture plate instead of a 6-well plate, which is used typically.  
Therefore, there was significant reduction in the amount of total protein in the lysates 
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obtained from each experimental treatment group. Since no protein assay was done 
routinely due to low protein amount, normally, each treatment group has duplicates to 
ensure experiment results. Although sometimes there was a difference between 
duplicates due to some unknown factors, most of time, the results were consistent 
between duplicates. Since chondrocytes tend to become de-differentiated in monolayer 
culture, in this study, most experiments were performed with primary murine 
chondrocytes plated at high density. 
 
Adult bovine articular chondrocytes are the most common chondrocytes model being 
used in cartilage research because the bovine chondrocyte isolation technique is well-
established and large numbers of chondrocytes may be obtained from one dissection. 
Additionally, comparisons between human and bovine articular chondrocytes found a 
number of critical similarities (Hauselmann et al., 1992).  In this study, bovine articular 
chondrocytes were used to optimize experimental conditions for murine chondrocytes. 
Previous work with hyaluronan oligosaccharide treatment suggested that the 
mechanism of hyaluronan anchoring to chondrocytes may not be the same among the 
chondrocytes isolated from human, bovine and mouse cartilages. Hyaluronan 
oligosaccharides treatment displaced the pericellular matrix of human and bovine 
chondrocytes, whereas there was no effect on pericellular matrix of murine 
chondrocytes (Knudson, unpublished data). Our hypothesis is that in human and bovine 
chondrocytes, CD44-hyaluronan interaction is the key to hyaluronan/aggrecan 
anchoring to chondrocytes. However, in murine chondrocytes, other interactions, 
potentially the persistent interaction of HAS2 with hyaluronan may be most important for 
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hyaluronan/aggrecan anchoring to chondrocytes. Since HAS2-hyaluronan interaction is 
not receptor-mediated, and if this mechanism were predominant, it would be predicted 
that hyaluronan oligosaccharides treatment would have no effect on the retention of the 
pericellular matrix of mouse chondrocytes.  Nevertheless, although bovine articular 
chondrocytes and murine chondrocytes are derived from different species, of different 
ages, most of the optimized experimental conditions obtained from bovine chondrocytes 
were effective for murine chondrocytes.  
 
In our experiments comparing BALB/c wild type murine chondrocytes with CD44 -/- 
murine chondrocytes, we stimulated both groups with different concentrations of BMP7 
(0-100ng/ml range) for 1 hour, collected the protein lysate, and determined SMAD1 
phosphorylation by Western blot analysis. We found that wild type murine chondrocytes 
were more responsive to BMP7 as compared to CD44 -/- murine chondrocytes.  
Additionally, we found that wild type murine chondrocytes begin to respond with SMAD1 
phophorylation at 10ng/ml of BMP7 while CD44 -/- mouse chondrocyte begin to exhibit 
such a response at 50ng/ml BMP7 (Fig 13). 
 
Since wild type murine chondrocytes are more responsive to BMP7 than CD44 -/- 
murine chondrocytes, this suggests that the presence of CD44 promotes the cellular 
response to BMP7, perhaps by the presentation of SMAD1 by CD44 to the BMP 
receptor kinase confirming our first hypothesis. It is also interesting to note that the 
absence of CD44 (i.e., CD44 -/- murine chondrocytes) does not completely abolish 
SMAD1 presentation to or phosphorylation by the BMP receptor kinase. Previous work 
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in Dr. Knudsons’ labs found no change in the diffuse immunocytochemical staining 
pattern of SMAD1 following BMP7 stimulation compared to untreated control CD44 
negative/ COS7 cells. Moreover, expression of dominant negative CD44 (CD44Δ67) in 
bovine chondrocytes diminishes SMAD1 nuclear translocation, which suggests that 
functional CD44 promotes nuclear translocation, or even may promote phosphorylation 
of SMAD1 upon BMP7 stimulation (Peterson et al., 2004).  
 
Since wild type murine chondrocytes begin to exhibit a response at 10ng/ml of BMP7 
while CD44 -/-mouse chondrocyte begin to respond at 50ng/ml BMP7, we also conclude 
that the presence of CD44 results in a lower threshold response to BMP7 compared to 
a higher threshold response to BMP7 due to the absence of CD44. In other words, wild 
type murine chondrocytes are more sensitive to BMP7 in comparison to age-matched 
CD44 -/- murine chondrocytes.  
 
These results in murine chondrocytes may have implications to human cartilage. The 
presumed physiological range of BMPs is 1-30 nM, which equals to 17ng/ml-510ng/ml 
(Umulis et al., 2009). Moreover, the amount of BMP7 in normal human cartilage 
determined by EILSA analysis of tissues extracts is in the range of 30 ng BMP7/gram of 
cartilage (Chubinskaya et al., 2002).  However, this does not tell us the exact amount of 
BMP7 that individual human chondrocytes may be exposed to because BMP7 may be 
sequestered in the extracellular matrix, and therefore would not be available in the 
pericellular matrix. Moreover, the half-life of BMP7 is short, about 10-30 minutes (de 
Rivero Vaccari et al., 2009). In this study, we found that wild type murine chondrocytes 
  183 
in pellet culture respond less robustly to 100 ng/ml BMP7 (as determined by western 
blotting for phosphor-SMAD1) than wild type murine chondrocytes in monolayer culture 
treated with 100 ng/ml BMP7. This may be due to the fact that the actual BMP7 
concentration that a single wild type mouse chondrocyte is exposed to in a pellet culture 
is much less than 100 ng/ml. In osteoarthritis and/or old age the amount of BMP7 
present in cartilage will decrease even further (Merrihew et al., 2003). Therefore, 
functional CD44 may be needed to promote the response to the lower amounts of 
BMP7 in human cartilage. 
 
Comparing BALB/c wild type murine chondrocytes with BALB/c wild type murine 
chondrocytes transfected with mouse CD44 small interference RNA (siRNA), we found 
that treatment with siRNA to CD44 reduced the response of wild type murine 
chondrocytes to 20 ng/ml BMP7 when compared to wild type murine chondrocytes 
transfected with a control siRNA. In addition, we found that wild type murine 
chondrocytes and wild type murine chondrocytes transfected with CD44 siRNA show a 
similar response at 50 ng/ml BMP7 (Fig 15).  Since wild type murine chondrocytes are 
more responsive to 20 ng/ml BMP7 when compared to wild type murine chondrocytes 
transfected with CD44 siRNA, we conclude by this alternative approach that the 
presence of CD44 promotes SMAD1 phosphorylation by the BMP receptor kinase, 
perhaps via SMAD1 presentation, confirming our hypothesis. Consequently, this further 
supports the importance of CD44 in the BMP signaling pathway but implicates that the 
functional significance of CD44 is dependent on the apparent dose of BMP7.  
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Wild type murine chondrocytes and wild type murine chondrocytes transfected with 
CD44 siRNA showed a similar response to 50 ng/ml BMP7. This may be because 50 
ng/ml BMP7 is the threshold level for CD44 knockout mice. This means that 50 ng/ml is 
the level where a large increase in SMAD1 phosphorylation will occur in the absence of 
CD44. Moreover, the siRNA transfection does not provide a 100% knockdown of CD44 
due to transfection efficiency. The number of functional CD44 molecules per cell 
needed to promote a SMAD phosphorylation response to BMP7 is not known. For 
example, in studies using flow cytometry to detect CD44 after trypsinization, recovery of 
only 25% of the baseline expression level of cell surface CD44 on bovine articular 
chondrocytes is needed for these cells to retain a pericellular matrix (Knudson et al., 
1999). It is possible that the residual CD44 in CD44 siRNA-transfected chondrocytes is 
higher than the amount of CD44 needed to promote SMAD1 phosphorylation. If this is 
the case, SMAD phosphorylation in CD44 siRNA transfected chondrocytes could not be 
distinguished from wild type mouse chondrocyte at higher doses of BMP7.  
 
In our experiments, CD44 -/- murine chondrocytes and CD44 -/- murine chondrocytes 
transfected with human CD44 plasmid were compared to further investigate the role of 
CD44 in BMP7 signaling. In these experiments, two human CD44 plasmids [CD44 FL 
plasmid (full-length expression plasmid) and CD44 R41A plasmid (arginine 41 mutation 
to alanine in the full-length contruct)] were used.  Comparing CD44 -/- murine 
chondrocytes with CD44 -/- murine chondrocytes transfected with human CD44 FL 
plasmid, we found that CD44 -/- murine chondrocytes are less responsive to BMP7 (at 
20 and 50 ng/ml) when compared to CD44 -/- murine chondrocytes transfected with 
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human CD44 FL plasmid. In addition, we observed that the augmentation of SMAD1 
phosphorylation at 20 ng/ml BMP7 by CD44 -/- murine chondrocytes versus CD44 -/- 
murine chondrocytes transfected with human CD44 FL plasmid was more obvious than 
at 50 ng/ml BMP7 (Fig 16). 
 
Since CD44 -/- murine chondrocytes are more responsive to BMP7 following 
transfection with human CD44 FL plasmid, we conclude that the presence of CD44 
promotes SMAD1 phosphorylation by the BMP receptor kinase, perhaps via 
presentation of SMAD1, as additional support of our first hypothesis. Consequently, this 
further supports the importance of CD44 in the BMP signaling pathway by the approach 
of knocking-in CD44 expression in CD44 -/- murine chondrocytes.  
 
The augmentation of SMAD1 phosphorylation at 20 ng/ml BMP7 by in CD44 -/- murine 
chondrocytes transfected with human CD44 FL plasmid was more obvious than at 50 
ng/ml BMP7. This may be because 50 ng/ml BMP7 is the threshold level for CD44 
knockout mice, and as such 50 ng/ml would be the level where a large increase in 
SMAD1 phosphorylation will occur. Moreover, the human CD44 FL plasmid transfection 
does not provide a 100% knock in of CD44 due to modest transfection efficiency. For 
example, in Figure 19, detection of CD44 by immunofluorescence microscopy showed 
about 20% transfection efficiency. The number of functional CD44 molecules per cell 
needed to promote SMAD1 phosphorylation in response to BMP7 is not known. In 
addition, since human CD44 plasmid was transfected, there is a possibility that human 
CD44 does not function optimally in murine chondrocytes. CD44 presentation of 
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SMAD1 to the BMP7 signaling receptor would require protein-protein interaction.    
Nevertheless, following transfection of CD44 -/- mouse chondrocytes with pCD44-FL, 
these cells were more responsive to the low concentration of BMP7 than the cells 
transfected with the empty vector.   
 
The human CD44R41A plasmid codes for CD44 with a one amino acid mutation that 
completely abolishes the ability of CD44 to bind hyaluronan. However, we found that 
CD44 -/- murine chondrocytes and CD44 -/- murine chondrocytes transfected with 
human CD44 R41A plasmid show a similar response at both 20 ng/ml and 50 ng/ml 
BMP7 (Fig 18).  These results suggest that CD44 with hyaluronan binding ability is 
critically necessary to promote SMAD1 phosphorylation by the BMP receptor kinase. 
Transfection efficiency is a concern in the investigation of chondrocytes; for example, in 
Figure 19, immunofluorescence staining of CD44 shows that only about 10% murine 
chondrocytes were transfected. It is difficult to conclude that the similar response to 
BMP7 of CD44 -/- murine chondrocytes versus CD44 -/- murine chondrocytes 
transfected with human CD44 R41A plasmid is due to the lack of hyaluronan binding 
activity of CD44. Further work is necessary for clear elucidation. 
 
In primary bovine chondrocytes, the loss of hyaluronan-CD44 interactions due to 
Streptomyces hyaluronidase pretreatment exerts a negative effect on the canonical 
BMP/ BMPR/ SMAD1 signaling pathway that can be rescued by hyaluronan synthase 
transfection or the addition of hyaluronan (Andhare et al., 2009; Peterson et al., 2004). 
This suggests that hyaluronan or its interaction with CD44 may affect SMAD1 
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phosphorylation by the BMP receptor kinase.  In our experiments using BALB/c wild 
type murine chondrocytes and CD44 knockout murine chondrocytes, we found 
unexpectedly that both wild type and CD44 -/- murine chondrocytes demonstrated a 
significantly diminished response to BMP7 when pre-treated with testicular 
hyaluronidase compared to BMP7 stimulation of matrix-intact chondrocytes. In addition, 
we found that wild type murine chondrocytes demonstrated a higher sensitivity to 
testicular hyaluronidase than CD44 -/- murine chondrocytes (p<0.01 vs p< 0.05) (Fig 
27).  Since wild type and CD44 -/- murine chondrocytes demonstrated a diminished 
response to BMP7 with testicular hyaluronidase pre-treatment, we can conclude that the 
presence of the hyaluronan-dependent pericellular matrix promotes SMAD1 
phosphorylation by the BMP receptor kinase, supporting our second hypothesis.  
 
It is interesting to note that CD44 -/- murine chondrocytes respond to hyaluronidase 
treatment even though there is no CD44 present. Therefore, hyaluronan-CD44 
interaction is not required to promote SMAD1 phosphorylation by the BMP receptor 
kinase. In other words, the hyaluronan-CD44 interaction may not be the only critical 
factor in the augmentation of SMAD1 phosphorylation by hyaluronan. Consequently, it 
is reasonable to propose that hyaluronan alone or in conjunction with other factors play 
a role in SMAD1 phosphorylation. 
 
Hyaluronidase degrades hyaluronan in the pericellular matrix of wild type and CD44 -/- 
murine chondrocytes.  Wild type murine chondrocytes are more sensitive to testicular 
hyaluronidase compared to CD44 -/- murine chondrocytes with respect to diminishing 
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responsiveness to BMP7. The p value of 0.0004 was determined for wild type murine 
chondrocytes when the two groups, BMP7 treatment and BMP7 treatment following 
hyaluronidase pre-treatment were compared; whereas the p value of 0.0342 was 
determined for CD44 -/- murine chondrocytes when the two groups, BMP7 treatment 
and BMP7 treatment following hyaluronidase pre-treatment were compared. One 
explanation for this difference is that CD44 acts as an intracellular scaffold protein, 
clustering critical signaling intermediaries, as occurs in many receptor signaling systems 
(Good et al., 2011). In wild type chondrocytes, CD44 may allow the chondrocytes to 
directly sense degradative changes in the pericellular matrix and transduce those 
changes into the cell to generate a signal that results in a prominent decrease in 
SMAD1 phosphorylation, with the help of clustered critical signaling intermediaries. For 
example, if hyaluronidase produces a 90% degradation of hyaluronan, the presence of 
CD44 in wild type chondrocytes may allow the chondrocytes to sense the entire 90% 
degradation and react quickly. In CD44-/- murine chondrocytes, however, the absence 
of CD44 only allows the chondrocytes to indirectly sense degradative changes in the 
pericellular matrix and respond to the degradative changes with only a modest decrease 
in SMAD1 phosphorylation without the help of clustered critical signaling intermediaries. 
For example, if hyaluronidase produces a 90% degradation of hyaluronan, the absence 
of CD44 in CD44-/- chondrocytes may allow the chondrocytes to sense only a partial 
degradation and react slowly.  
 
By western blot analysis we found that the diminished SMAD1 phosphorylation to BMP7 
stimulation with hyaluronidase pre-treatment was neither due to the decrease of BMP7 
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receptor (ALK2) nor due to the decrease of total SMAD1 (Fig 28). This suggests that 
hyaluronan degradation causes the diminished SMAD1 phosphorylation upon BMP7 
stimulation without alterations of BMP7 receptor and total SMAD1 expression. 
Moreover, we found that both wild type and CD44 -/- murine chondrocytes regain SMAD 
phosphorylation upon BMP7 stimulation when the chondrocytes re-grow hyaluronan 
after hyaluronidase pre-treatment (Fig 29). This further confirms our hypothesis that the 
presence of hyaluronan promotes SMAD1 phosphorylation by BMP receptor kinase.  
 
In addition, we found that the effect of hyaluronan degradation cannot be compensated 
with higher concentration of BMP7 (Fig 30 and 31). Although with hyaluronidase pre-
treatment, there is an increase of SMAD1 phosphorylation when stimulated with higher 
concentrations of BMP7, SMAD1 phosphorylation expression level is still lower than 
control chondrocytes stimulated with 100 ng/ml BMP7.  It is probable that at 30 nM 
BMP7, the BMP7 receptors are saturated by BMP7. When the interaction between 
BMP7 and its receptor reaches a plateau, SMAD1 phosphorylation will be maintained at 
the maximal level no matter the presence of excess BMP7. In this condition, other BMP 
receptors may play a role for binding to BMP7, however, with much lower affinity to 
BMP7. This even further supports our hypothesis that the presence of hyaluronan 
promotes SMD1 phosphorylation by BMP receptor kinase. In addition, the presence of 
hyaluronan is indispensable to promote a robust response to BMP7.  
 
Using BALB/c wild type murine chondrocytes and CD44 -/- murine chondrocytes, we 
found that wild type murine chondrocytes and CD44 -/- murine chondrocytes 
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demonstrated a significantly diminished response to BMP7 when treated with 4-MU 
compared to BMP7 stimulation only (Fig 35). Since wild type and CD44 -/- murine 
chondrocytes demonstrated a diminished response to BMP7 with 4-MU treatment when 
compared to BMP7 stimulation only, we conclude that the presence of the hyaluronan-
dependent pericellular matrix promotes SMAD1 phosphorylation by the BMP receptor 
kinase, again supporting our hypothesis.  
 
As previously mentioned, we found that 4-MU treatment diminished SMAD1 
phosphorylation by Western blot. However, in these experiments, we found that the total 
protein isolated from murine chondrocytes treated with 4-MU was about 50% less than 
from the cultures of the vehicle control murine chondrocytes (data not shown). This 50% 
reduction in total protein may be due to 4-MU effects on cell proliferation and/or 
apoptosis, as discussed below.   
 
The effect of 4-MU, an inhibitor for hyaluronan synthase, has been studied in many 
different cells (e.g., fibroblasts, smooth muscle cells, keratinocytes, and cancer cells) 
using 4-MU concentrations ranging from 0.2mM to 1.0mM (Edward et al., 2010; 
Funahashi et al., 2009; Lokeshwar et al., 2010; Rilla et al., 2004; Vigetti et al., 2009; 
Yoshihara et al., 2005). However, there are no previous studies on the effect of 4-MU 
on chondrocytes.  Rilla et al. reported that, in rat keratinocytes, with the increase of 4-
MU concentration, the synthesis of not only hyaluronan, but also heparan sulfate 
decreased. The synthesis of chondroitin sulfate was not consistently affected by 4-MU. 
The effect of 4-MU on the synthesis of sulfated glycosaminoglycans is less prominent 
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than 4-MU effect on hyaluronan synthesis (Rilla et al., 2004). This is likely due to the 
predominant effect of 4-MU in the cytoplasm rather than in the Golgi apparatus.  In all 
reported cells, 4-MU shows a dose-dependent growth inhibition. At high concentrations 
(e.g., 1mM), 4-MU completely blocked cell proliferation in some of the reported cells, 
indicating a variability that depends on both cell type and dose. Based on Dr. Ariyoshi’s 
work on bovine articular chondrocytes (unpublished), 1mM 4-MU treatment efficiently 
decreased hyaluronan synthesis as determined by hyaluronan ELISA assay. In my 
studies, 1mM 4-MU was used for murine articular chondrocytes treatment. 
 
Data supporting a role of hyaluronan in cell proliferation comes from the experiment that 
HAS2-transfected fibrosarcoma cells show increased cell proliferation and cell migration 
(Kosaki et al, 1999). However, in rat epidermal keratinocytes, the inhibition levels of 
hyaluronan synthesis and cell proliferation are not correlated in absolute units (Rilla et 
al., 2004). In these cells, treatment with 4-MU blocked cell proliferation more strongly 
than the concomitant decrease in hyaluronan synthesis. The mechanisms of 4-MU 
inhibition of cell proliferation are not clear. It is possible that hyaluronan inhibition and 
cell proliferation inhibition are independent of each other.  
 
In addition, 4-MU has been reported to induce apoptosis in prostate cancer cells 
(Lokeshwar et al., 2010). In contrast, it has also been reported that 4-MU does not 
induce apoptosis in fibroblasts or melanoma cells (Edward et al., 2010). Based on the 
above-mentioned conflicting reports, it appears that the effect of 4-MU is variable and 
depends on cell type. Since very few floating murine chondrocytes were observed with 
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1mM concentration of 4-MU treatment, the 50% reduction in total protein in 4-MU 
treated murine chondrocytes is most likely due to the blockage of murine chondrocytes 
proliferation, not due to the induction of apoptosis. However, it is difficult to make an 
unambiguous statement whether the 4-MU effect on murine chondrocytes is due to cell 
proliferation blockage or apoptosis. Future studies are necessary to clarify this issue.   
 
4-MU may have hyaluronan-dependent and/or hyaluronan-independent effects on cell 
proliferation.  Using higher 4-MU concentrations than needed to decrease hyaluronan 
synthesis may cause other hyaluronan-independent effects that others have reported in 
other cell types (e.g. increased chondroitin sulfate and decreased heapran sulfate).  The 
4-MU concentration used in this study (1mM) was based on experiments with bovine 
articular chondrocytes and was likely not the ideal concentration for murine articular 
chondrocytes. The 4-MU dose response and effect of different incubation times on 
hyaluronan synthesis of murine chondrocytes should be done. The lowest 4-MU 
concentration and shortest treatment time that decreases hyaluronan synthesis in 
murine articular chondrocytes should be used to determine the change of cellular 
responses to BMP7. Since there was a 50% reduction in total protein in 1mM 4-MU 
treated murine chondrocytes, it is difficult to conclude the decrease of SMAD1 
phosphorylation was the direct result of 4-MU treatment, as it may be due to other 
effects of 4-MU treatment.   
 
In this model system of BMP signaling, two separate but overlapping mechanisms 
appear to play a role. The first concerns CD44 and its facilitation of BMP-mediated 
  193 
signaling in the presence or absence of CD44. The second concerns hyaluronan and 
the alteration cell signaling events due to changes in hyaluronan. These will be 
discussed below. 
 
We demonstrated in this study that CD44 stimulates BMP7-mediated signaling although 
the stimulation is subtle and more pronounced at lower concentrations of BMP. Using 
yeast two-hybrid and co-immunoprecipitation techniques, it was previously 
demonstrated that direct interactions occur between CD44 and SMAD1 (Peterson et al., 
2004). Thus, we may conclude that CD44 acts as an intracellular scaffold protein which 
clusters critical signaling intermediates in order to enhance SMAD1 phosphorylation. 
We hypothesize that CD44 binds and organizes cytoplasmic SMAD1 and perhaps 
directs SMAD1 to a unique membrane microdomain. On the one hand, knockdown of 
CD44 in mouse wild type chondrocytes reduces the stimulatory effect of BMP7 
signaling. On the other hand, over-expression of human full-length CD44 in CD44 -/- 
chondrocytes rescues the stimulatory effect of BMP signaling. In general, however, the 
effect of CD44 on BMP signaling is subtle even when a conventional experimental 
concentration of BMP7 (i.e., 100 ng/ml) is used.  
 
We also demonstrated in this study that hyaluronidase pre-treatment significantly 
decreased the activation of SMAD1 in both wild type and CD44 -/- murine chondrocytes 
as well as bovine chondrocytes. Moreover, hyaluronidase pre-treatment decreased the 
activation of SMAD1 at all BMP7 concentrations including higher doses of up to 
500ng/ml. One possible explanation is that hyaluronan facilitates BMP7 responsiveness 
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by a CD44-independent extracellular mechanism. In this regard, several studies in 
recent years have described the contribution of the extracellular matrix in the regulation 
of BMP signaling. For example, proteoglycans (particularly those containing heparan 
sulfate chains) bind BMPs and inhibit BMP signaling; whereas, heparinase treatment 
stimulates BMP signaling. However, the role of the extracellular matrix on BMP 
signaling is complex since proteoglycans also bind BMP inhibitory binding proteins (e.g., 
Noggin and Chordin) and BMP activating proteins (e.g., crossveinless2) (Umulis et al., 
2009). Consequently, one may speculate that various alterations in the extracellular 
matrix induced by either hyaluronidase, heparinase, or other agents will affect in BMP 
signaling. In our study, the removal of hyaluronan substantially decreased BMP 
responsiveness. 
 
Several explanations exist that may explain the mechanism of the hyaluronidase effect. 
First, hyaluronan may serve as a binding scaffold for BMP7 therefore facilitating BMP7 
presentation to BMPR1A. Second, hyaluronan removal may release an as yet unknown 
hyaluronan-bound co-activator. Third, hyaluronan may function as a present-and-
release platform for BMP7 since the direct BMP binding to hyaluronan is weaker than 
BMP binding to highly sulfated heparan sulfate chains. Fourth, hyaluronan removal may 
stimulate cell surface proteolytic activity and degrade a critical BMP signaling co-
activator since the loss of a hyaluronan-rich pericellular matrix induces membrane-
bound MT-MMP or ADAM10/17 – mediated cleavage (Takahashi et al., 2010). These 
possible explanations open new avenues to explore in the future. 
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To determine whether the observed promotion of BMP7 signaling by CD44 was a 
generalized effect or more specific to the BMP7 signaling pathway, another signaling 
pathway was examined.  It has been shown that CD44 interacts with other receptor 
tyrosine kinases including EGFR (Bourguignon et al., 2002; Palyi-Krekk et al., 2008; 
Wakahara et al., 2005; Yu et al., 2002).  Given that chondrocytes respond well to EGF, 
wild type and CD44 -/- murine chondrocytes were stimulated with concentrations of 
EGF between 0-50 ng/ml for 5 min and Akt and Erk phosphorylation were detected 
using anti-phosphorylated Akt and Erk antibodies in western blot analyses. We found 
that wild type and CD44 -/- murine chondrocytes had a similar Erk and Akt 
phosphorylation response to EGF. 
 
Since wild type murine chondrocytes demonstrated a similar response to EGF when 
compared to CD44 -/- murine chondrocytes, the result suggests that hyaluronan-CD44 
interaction is less specific for the EGF signaling pathway than BMP7 signaling pathway. 
Hyaluronan-CD44 interaction has been shown to have no effect on SMAD2 
phosphorylation in bovine chondrocytes upon TGFβ1 stimulation after hyaluronidase 
pre-treatment (Andhare et al., 2009). The explanation is probably because no CD44/p-
ERM interactions exist in chondrocytes, which is a precursor interaction required for 
CD44/TGFβ-R or CD44/EGFR interactions (Wang and Bourguignon, 2006).  
Alternatively, this could be because SMAD2 and CD44 do not interact.   
 
In human articular chondrocytes, IL-1 mediated MAPK-dependent phosphorylation of 
the receptor-regulated SMADs (R-SMADs) linker region alters R-SMADs activation by 
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delaying R-SMADs phosphorylation, terminating phosphorylation signals early, and 
decreasing R-SMADs phosphorylation expression levels (Elshaier et al., 2009).  We 
thus postulated that in wild type and CD44 -/- murine chondrocytes, hyaluronidase 
mediates p38 MAPK-dependent phosphorylation of the SMAD1 linker region (Ser 206) 
which decreases SMAD1 phosphorylation by BMP receptor kinase. We found that 
hyaluronidase-treated wild type and CD44 -/- murine chondrocytes demonstrated a 
significantly decreased SMAD1 phosphorylation by BMP receptor kinase compared to 
non-hyaluronidase treated chondrocytes. However, no change in p38 MAPK kinase 
expression or SMAD1 Ser 206 phosphorylation was detected in the hyaluronidase-
treated wild type and CD44 -/- murine chondrocytes.  
 
In addition, a faint signal for SMAD1 Ser206 phosphorylation was detected in both 
hyaluronidase and non-hyaluronidase treated chondrocytes stimulated with BMP7. This 
should not be the case since the current dogma is that BMP7 signaling through the 
BMPR causes phosphorylation at the C-terminal site of SMAD1 not the linker region. 
This may be due to a less than optimal specificity of the Ser 206 antibody. In this 
regard, the Ser 206 antibody might recognize phosphorylation both at the C-terminal 
serine site and at the Ser 206 site. Due to the less than optimal specificity of the Ser 
206 antibody, it is difficult to conclude that the decreased SMAD1 phosphorylation by 
BMP receptor kinase in hyaluronidase-treated chondrocytes does not occur via p38 
MAPK-dependent phosphorylation of the SMAD1 linker region (Ser 206).  Nevertheless, 
there was no change in p38 MAPK expression following hyaluronidase treatment.  
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Consequently, p38 MAPK may participate in the cross-talk of the SMAD signaling 
pathway but further work is necessary for clear elucidation. 
 
Using RT-PCR, we found that the RHAMM expression is up-regulated in primary CD44 
-/- murine chondrocytes when compared to wild type murine chondrocytes (Fig 47). This 
suggests that RHAMM may compensate for the absence of CD44 in CD44 -/- murine 
chondrocytes. In addition, we also found that mRNA levels of RHAMM decreased as the 
number of chondrocyte passages increased (Fig 48: P0, primary chondrocytes; P3, 
trypsinization and replating twice).  It is possible that this reduction of RHAMM 
correlates with the loss of pericellular matrix during passages of chondrocytes 
(Takahashi et al., 2010). So, one can postulate that after the highest number of 
passages (i.e., at P3), wild type chondrocytes would be RHAMM negative and CD44 
positive, whereas CD44 -/- chondrocytes would be RHAMM negative and CD44 
negative.  Consequently, if P3 wild type chondrocytes were pre-treated with 
hyaluronidase then one would predict a decrease in SMAD1 phosphorylation in 
response to BMP7 because RHAMM is absent and CD44 is present. However, if P3 
CD44 -/- chondrocytes were pre-treated with hyaluronidase then one would predict no 
decrease in SMAD1 phosphorylation in response to BMP7 because both the putative 
compensatory action of RHAMM and CD44 are absent.  
 
In initial experimental approaches to study this prediction, the effects of hyaluronidase 
pre-treatment on P1 (not P3) de-differentiated CD44 -/- chondrocytes were determined. 
We found that ID2 expression was decreased but the expected decrease in SMAD1 
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phosphorylation was not obvious in response to BMP7 (Fig 49).   Since ID2 is a 
downstream mediator of BMP7 signaling, this finding indicates that in P1 de-
differentiated CD44-/- chondrocytes there is still a change in the downstream signaling 
with hyaluronidase.  So, the question remains: What is responsible for this change in 
downstream molecules in BMP7 signaling with hyaluronidase treatment? 
 
On the one hand, RHAMM may be responsible for this change if there is still some 
residual RHAMM (e.g., decreased RHAMM) present in P1 de-differentiated CD44 -/- 
chondrocytes. On the other hand, if there is no residual RHAMM in P1 de-differentiated 
CD44 -/- chondrocytes, then other factors, such as HAS, may play a role. Therefore, it is 
difficult to conclude at this time whether RHAMM compensates for CD44 in CD44 -/- 
murine chondrocytes with respect to the BMP7 signaling pathway and more work needs 
to be done to elucidate this issue. The characteristics of candidate receptor(s) would 
bind to hyaluronan and interact with SMAD1, and thus probably require a 
transmembrane domain. On one hand, RHAMM might be a candidate, which binds to 
hyaluronan, but RHAMM is a peripheral membrane protein with no transmembrane 
domain. On the other hand, HAS might be another candidate, which binds to 
hyaluronan and has a transmembrane domain. However, there is no evidence of 
interaction with SMAD1 by any of these molecules. Further work is needed to elucidate 
the question.  
 
It has been reported that in collagen-induced arthritis (CIA) in the model DBA/1 mice, 
injection of hyaluronidase reduced CIA almost to the same extent in wild type and CD44 
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knockout mice. Furthermore, wild type and CD44 knockout splenocytes bind to 
immobilized hyaluronan almost to the same extent. These findings suggest that there 
are compensating receptors in CD44 knockout mice that bind hyaluronan and support 
development of CIA (Naor et al., 2007). However, the compensation for CD44 loss is 
not due to increased RHAMM expression, but rather due to the accumulation of 
hyaluronan, which causes enhanced signaling via RHAMM (Naor et al., 2007; Nedvetzki 
et al., 2004). The above findings are not compatible with our finding that RHAMM is up-
regulated CD44 knockout mice.  This may be due to a different genetic background of 
DBA/1 CD44 knockout mice and BALB/c CD44 knockout mice. It may also be due to the 
different age of knockout mice (DBA/1 CD44 knockout mice: 10-14 weeks versus 
BALB/c CD44 knockout mice: 7 days) 
 
Cartilage injury in vivo remains resistant to healing due to the lack of chondrogenic cells 
and lack of nutrition provided by the vasculature. In this regard, three-dimensional in 
vitro models of cartilage regeneration have been designed in order to study clinical 
applications of cartilage repair. The benefits of three dimensional cultures have been 
reported by other investigators indicating that three dimensional cultures more closely 
mimic the in vivo environment than two dimensional cultures (Benya and Shaffer, 1982; 
Homicz et al., 2002; Loty et al., 2000). Therefore, three-dimensional models of cartilage 
regeneration play an important role in clinical method development for cartilage repair.  
 
The ATDC5 and C3H10T1/2 cell lines are murine mesenchymal cell line and have been 
widely used in three dimensional culture as in vitro models of chondrogenesis (Altaf et 
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al., 2006; Denker et al., 1999; Lisignoli et al., 2005; Seghatoleslami et al., 2003; 
Shukunami et al., 1996; Tare et al., 2005). In this study, the specific three-dimensional 
culture method used was the pellet culture (Johnstone et al., 1998). Our results using 
pellet culture indicated that: C3H10T1/2 cells formed neo-cartilage, both wild type and 
CD44 -/- murine chondrocytes formed neo-cartilage that exhibited intense matrix 
deposition as revealed by intense staining with safranin O and fast green, and that wild 
type murine chondrocytes in pellet culture respond less robustly to 100 ng/ml BMP7 (as 
measured by SMAD1 phosphorylation) than wild type murine chondrocytes in 
monolayer culture. This may be due to the possibility that the actual BMP7 
concentration that a single wild type mouse chondrocyte is exposed to in a pellet culture 
versus a monolayer culture may be much less than 100 ng/ml. Consequently, in order to 
obtain a similar BMP7 response as observed in a monolayer culture, a much higher 
BMP7 concentration than 100ng/ml is needed in pellet culture. The above results 
indicate that pellet culture can be used as an approach for cartilage regeneration, but 
pellet culture is a more difficult system to use to study signaling pathways. 
 
Taken together, this study is the first to investigate the effect of hyaluronan-CD44 
interactions on BMP7 signaling of chondrocytes using CD44 knockout mice. We have 
proposed that hyaluronan-CD44 interactions promote BMP7 signaling in chondrocytes. 
This study has provided support for this hypothesis. The results show that due to the 
absence of CD44, CD44 -/- murine chondrocytes are less responsive to BMP7 
compared to wild type murine chondrocytes and as well, reduction of CD44 expression 
in wild type murine chondrocytes via a siRNA approach rendered those cells less 
  201 
responsive to BMP7. In addition, due to the treatment by hyaluronidase or with 4-MU, 
wild type and CD44 -/- murine chondrocytes exhibited decrease cellular responses to 
BMP7. 
 
BMP7, as an anabolic factor, which stimulates proteoglycan and type II collagen 
synthesis in the cartilage matrix, can block cartilage degradation, promote cartilage 
repair, and even rescue the early osteoarthritis changes when applied at at the optimal 
time and concentration. The role of CD44 in BMP7 signaling is subtle, with a more 
pronounced augmentation effect at lower BMP7 concentrations. It is likely that the 
importance of CD44 that we observed at low BMP7 concentrations in vitro would be 
physiologically relevant, as this is within the reported range of BMP7 found in human 
cartilage (Umulis et al., 2009; Merrihew et al., 2003). This hypothesis could be tested 
further in vitro in pellet cultures using CD44 -/- and wild type murine chondrocytes. In 
addition, since all experiments were performed with chondrocytes isolated from young, 
healthy, unstressed mice, CD44 may exert more prominent effects on BMP7 signaling 
in unhealthy, stressed conditions that would mimic early osteoarthritis. Finally, we 
observed that the hyaluronan effect on BMP7 signaling is pronounced, which suggests 
that hyaluronan may function as the major organizer for BMP7 signaling molecules to 
initiate BMP7 signaling. These data support the current clinical practice of intra-articular 
hyaluronan injection to treat osteoarthritis patients. 
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